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Thesis Abstract  
BACKGROUND 
Children with Down’s Syndrome (DS) are prone to respiratory tract infections (RTIs), yet 
there is little evidence to guide clinical practice.  
AIMS 
For children with and without DS, this thesis aims to use routinely collected data to 
identify RTI-related healthcare utilisation, those most at risk of RTI-related healthcare 
utilisation, and the effects of antibiotics in preventing RTI-related hospitalisation. 
METHODS 
A systematic review of existing interventions and a retrospective cohort study based on 
routinely collected primary and secondary care data (CALIBER). 
KEY FINDINGS 
The CALIBER cohort comprised 992 children with DS and 4874 controls. Children with DS 
consulted their GP for RTIs twice as often as controls, were prescribed antibiotics twice 
as often, and were hospitalized six times as often. In children with DS, younger age, 
congenital heart disease and asthma were risk factors for RTI-related healthcare 
utilisation. Using multivariate analysis, this study found that for infants with DS, the 
prescription of antibiotics significantly reduced subsequent RTI-related hospitalisation - 
the number needed to treat is 11.9. Separate analysis, inverse probability of treatment 
weighting, found that the protective effect for infants with DS was not significant. When 
prescriptions were analysed by type of RTI, the prescription of antibiotics for upper RTIs 
did not reduce the risk of hospitalization for children with DS or controls. This was also 
the case for lower RTIs, although with a small sample. 
CONCLUSION 
For children with DS over the age of one presenting with RTIs to primary care, antibiotic 
treatment does not prevent subsequent RTI-related hospitalisation. There is conflicting 
evidence from two separate analysis methods as to whether treating infants with DS with 
antibiotics prevents RTI-related hospitalisation, so further research is recommended. 
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Further prescribing strategies (i.e. rescue antibiotics) should be explored to broaden the 
evidence base for this at-risk group. 
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Aims and Objectives  
AIMS 
For children with and without Down’s Syndrome (DS), this thesis aims to use routinely 
collected data to identify RTI-related healthcare utilisation, those most at risk of RTI-
related healthcare utilisation, and the effects of antibiotics in preventing RTI-related 
hospitalisation. 
 
OBJECTIVES  
1. To undertake a systematic review of the literature on the effectiveness of 
preventative and therapeutic interventions for respiratory tract infections (RTIs) in 
adults and children with DS (Chapter 2); 
2. To quantify NHS healthcare utilisation attributable to RTIs in children with and 
without DS from 1997 to 2010 (Chapter 5); 
3. To ascertain which children, with and without DS, are most at risk of increased RTI-
related NHS healthcare utilisation (Chapter 5); 
4.  To assess the effects of antibiotic prescriptions in RTI-related GP consultations for 
preventing RTI-related hospitalisations, in children with and without DS (Chapter 6). 
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Chapter 1: Background 
1.1 CHAPTER OUTLINE 
In this chapter, I outline the historical context and current organisation of care of children 
with Down’s Syndrome (DS) in the UK. I subsequently give a brief overview of RTIs in 
children together with a comparison on how RTIs differ in children with DS.  
1.2 DOWN’S SYNDROME 
Historical context 
DS or trisomy 21, is a genetic condition that was first described by Sir Langdon Down in 
1866 (1).  
With an incidence of 1 in 1000 live births in 2008, DS is one of the most common genetic 
conditions in the UK (2). A recent population study conducted by the National Congenital 
Anomaly and Rare Disease Registration Service estimated the number of people living 
with DS in the UK to be almost 50,000; of which, approximately 10,500 are children 
(under the age of 18) (3). 
Despite advancements in antenatal screening (e.g. non-invasive prenatal diagnostic 
testing) from 1990 to date, the number of births of children with DS in the UK has 
remained constant (2). During the same period however, advances in medical and 
surgical treatment, social inclusion and public understanding of DS have allowed for 
significant improvement in life expectancy of these children from 30 to nearly 60 years 
(4, 5). Alongside this, there has been a corresponding improvement in quality of life (4, 
5). 
Current organisation of care 
In the UK, children with DS are provided structured child and family-centred medical care 
via multi-agency collaboration to maximise their physical, educational and health 
outcomes (6).  
This is enshrined in the Royal College of Paediatrics and Child Health (RCPCH) and Down 
Syndrome Association (DSA) Paediatric Service Specification for Children and Young 
People with DS, a non-mandatory specification designed to assist commissioners in 
service delivery to this at-risk group (6). 
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Some of the common co-morbidities that are seen in children with DS include; congenital 
heart disease (CHD), hypothyroidism, learning difficulties, sleep apnoea, 
gastroesophageal reflux disease and recurrent otitis media. Managing these particular 
conditions requires a multi-disciplinary approach led by a paediatrician (e.g. community 
paediatrician, paediatrician specialising in neurodisabilities, or a general paediatrician). 
Due to the potential frequency of multi-organ complications, specialist involvement is 
common (e.g. ENT, Cardiology, General Surgery and Gastroenterology). 
There are various models of service provision for children with DS. In some areas, there 
are dedicated unified multi-disciplinary DS clinics. In others, children with DS are seen by 
community paediatricians in generic child development centres who may then refer 
children with DS on to specialists using local care pathways based on the Service 
Specification detailed above (6).  
The RCPCH guidance states that all children with DS should be cared for and reviewed by 
a paediatrician with particular expertise in DS. Children should be reviewed once every 
three months up to the age of one, and then subsequently at least once a year. Specialist 
involvement must include Speech and Language Therapy, paediatric cardiology, 
ophthalmology, and audiology. Other services should be commissioned as and when 
required, including physiotherapy, medical specialists, sexual health services, 
occupational therapy, special needs dentistry, and Child and Adolescent Mental Health 
Services (6). 
A number of regional audits relevant to the routine care of children with DS have been 
published. A 2012 audit of the Nottingham Down Syndrome Children’s Clinic found that 
97.9% of children were visited by the Down’s Syndrome team after birth, with 87.5% 
receiving a health visitor home visit at 2 weeks of age (7). Various healthcare elements 
were audited, with some areas of good practice – for example, 94.9% received regular 
audiology assessment, and 91.9% were offered speech and language therapy; however, 
only 32.9% received regular check for symptoms of cervical spine instability (7). As with 
other studies, it appears that rates of monitoring for complications are variable (8, 9).  
A 2014 audit in Wales found that 86% of identified children with DS were followed up by 
community paediatricians, with 88% of these having regular follow up (10). However, 
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only 15% of sampled case notes included the local health board guideline for health 
surveillance, indicative of a potential difficulty with the dissemination of guidelines.   
There is little information in existing literature examining the role of General Practice for 
children with DS in the UK. A study from 1981 found that children with DS saw their GP a 
mean of 5.6 times in a year, with 4.4 visits to the GP surgery and 1.2 visits by the GP to 
patients’ homes (11). A 2007 study of adults with DS in Newcastle found that 20% had 
seen both a General Practitioner and a specialist in the previous 12 months; 18% had only 
seen their General Practitioner; and 14% had only seen a specialist physician. 48% had 
seen no medical doctor at all in the previous 12 months, and 38% had seen no doctor for 
the past 3 years (9). In contrast, an American study found that 40% and 60% of the cohort 
of 62 patients were cared by Family Physicians and medical specialists respectively (8). 
Both recent studies found that rates of monitoring for common complications of DS were 
highly variable.  
The Patient and Public Involvement (PPI) Panel for this thesis, consisting of two parents 
of children with DS and a representative from the Down’s Syndrome Association, 
reflected on the role of the GP for children with DS. They reported that interactions with 
GPs are mostly good for most parents, who may frequently attend for home visits if a 
child is unwell or prescribe antibiotics without consultations.  
The full recommended specifications for surveillance and management of specific 
medical problems associated with DS, from diagnosis to transition at 18 years of age, are 
listed below in Table 1. 
Table 1. Service standards for specific medical problems associated with children with 
DS from diagnosis to transition. 
Adapted with permission from RCPCH Paediatric Service Specification: Services for Children and Young 
People with Down Syndrome (6) 
System First year of life Early years / pre-school School Age 
Thyroid All children with DS must 
undergo the routine 
newborn blood spot 
screening test to exclude 
congenital 
hypothyroidism. 
Thyroid function must be reviewed either:  
• Annually, on the basis of annual thyroid stimulating 
hormone blood spot test; or  
• Biennial serum thyroid function and antibody tests 
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Vision All children with DS must 
undergo an examination 
for red reflex to exclude 
congenital cataract, as 
part of the routine 
newborn examination. 
By 2 years of age, 
children with DS must 
undergo a formal eye 
and vision test, including 
squint assessment. All 
children must also 
undergo a detailed visual 
assessment before 
school age (4 years), to 
include squint 
assessment, refraction 
and acuity. 
School aged children with DS 
must undergo a detailed 
ophthalmological/optometric 
assessment a minimum of 
once every two years. 
Hearing All children with DS must 
undergo the routine 
newborn hearing 
screening test to exclude 
hearing impairment. 
Before the child’s first 
birthday, children with 
DS must undergo a 
formal audiological 
review, including hearing 
assessment and 
impedance check. 
Between one and four 
years of age, children 
with DS will undergo an 
annual audiological 
review, including hearing 
assessment and 
impedance check. 
School age children with DS 
will undergo an audiological 
review, including hearing 
assessment and impedance 
check, a minimum of once 
every two years. 
Breathing Children with DS must be assessed for symptoms of 
sleep-related breathing disorder annually until 
commencing school, with further assessment 
(including overnight pulse oximetry) arranged where 
clinically indicated. 
School-age children with DS 
who develop symptoms of 
sleep-related breathing 
disorders must be 
investigated (including 
overnight pulse oximetry) 
and managed promptly, 
including referral to ENT if 
appropriate. 
Heart By 6 weeks of age, all 
children with DS must 
have a formal 
cardiological assessment 
(including 
echocardiography) to 
exclude congenital heart 
disease. 
Children with DS must be reviewed annually for signs and 
symptoms of acquired valvular heart disease, with 
further assessment (including echocardiography and 
specialist cardiology referral arranged where clinically 
indicated). 
Growth Children with DS will undergo monitoring of height and weight (plotted on a UK DS-
specific growth chart) on an annual basis. 
Haematology All children with DS will 
have a blood film 
assessment in the 
neonatal period to 
exclude related blood 
disorders. 
N/A 
Gastrointestinal Assessment (and investigation as required) of common gastrointestinal problems, 
such as constipation, feeding difficulties and coeliac disease, must take place during 
each regular medical review. 
Spinal Assessment (and investigation as required) of developing disorders of the cervical 
spine must take place during each regular medical review. 
 25 
1.3 RESPIRATORY TRACT INFECTIONS  
1.3.1 Overview 
RTIs are infections of the respiratory system which can occur at any point along the 
respiratory tract (12). They can be split into upper respiratory tract infections (URTIs), and 
lower respiratory tract infections (LRTIs). URTIs include; rhinitis (common cold), sinusitis, 
otitis media, tonsillitis, pharyngitis, tracheitis and laryngitis; and LRTIs include bronchitis, 
bronchiolitis and pneumonia. These can be bacterial, viral or fungal in pathogenic origin. 
This is illustrated in Figure 1 below (13). 
 
Figure 1. Respiratory tract infections. 
Adapted with permission from Patient.info (13) 
 
There are numerous risk factors for RTIs as illustrated in Figure 2. These include; young 
age, environmental tobacco smoke, home-dampness, attending day-care centres, atopy, 
genetic predisposition, seasonality and exposure to others with RTIs (such as having 
siblings) (14).  
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Figure 2. Risk factors for RTIs. 
Adapted with permission from The Lancet (15). 
 
Most URTIs are viral in origin and are commonly due to Rhinoviruses, Coronaviruses, 
Parainfluenza viruses, Respiratory Syncytial Virus (RSV), Adenoviruses and Influenza 
viruses. In a US study, the annual isolation rates per 1000 person-years was 113.2 for 
Rhinoviruses, 53.8 for Parainfluenza viruses, 55.7 for RSV, 33.4 for Adenoviruses and 
between 16.7 and 3.7 across different Influenza sub-types (16). URTIs which are 
commonly non-viral include epiglottitis, laryngotracheitis and pharyngitis; these are 
commonly caused by bacteria such as Haemophilus influenzae type b., Streptococcus 
pyogenes or Streptococcus pneumoniae. In contrast, the aetiology of LRTIs is more mixed 
with a study of hospitalised children noting a bacterial (25%), viral (25%) or mixed (20%) 
cause for RTIs (17). Incidence of Haemophilus influenza type b. ranges from 0.02 to 0.74 
per 100,000 in children 0-19, and for Streptococcus pyogenes the range is from 0.5-5 per 
100,000 across the same age group (18, 19). Incidence of Streptococcus pneumoniae 
infection per 100,000 ranges from 59.7 per 100,000 for neonates to 0.8 for children aged 
10-14 (20). With the higher relative incidences of viral relative to bacterial pathogens 
observed, continued high rates of antibiotic prescriptions for RTIs are therefore 
unwarranted (21). 
According to a 2007 study utilising the General Practice Research database, the overall 
risk of complications is low following acute respiratory tract infections (22). In children 0-
4 and 5-15, when antibiotics were not prescribed, the risk of pneumonia after URTI when 
was low at 10.74 and 4.45 per 10,000 cases respectively; the risk of quinsy after sore 
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throat was 1.57 and 5.99 per 10,000 respectively; and mastoiditis after otitis media was 
1.33 and 2.39 per 10,000 respectively. The most common investigated complication was 
pneumonia after a chest infection with a risk of 125.92 and 127.31 per 10,000 in the 
respective age categories, when antibiotics were not prescribed (22).  
Interventions to prevent RTIs 
Interventions targeted at preventing RTIs are focused on reducing transmission of 
pathogens between individuals (e.g. infection control measures), stimulating immune 
response (e.g. immunostimulants, passive and active immunisation) and antibiotic 
prophylaxis for individuals. 
Infection control measures such as hand and respiratory hygiene, cough etiquette, and 
personal protective equipment (e.g. gloves, apron and eye protection) are proven to 
reduce the transmission of RTIs. For example, in a 2006 systematic review, pooled results 
noted that hand washing could reduce the risk of RTIs by 16% (95% Confidence Interval 
(CI) 11–21%) (23). In another 2009 systematic review, physical measures were noted to 
be highly effective in reducing the risk of RTIs (24). These include handwashing more than 
ten times daily (Odds Ratio (OR) 0.45; 95% CI 0.36-0.57), masks (OR 0.32; 95% CI 0.25-
0.40) and gloves (OR 0.43;  95% CI 0.29-0.65) (24). 
Immunostimulants are drugs whose mechanism is primarily to stimulate the immune 
system. Although there are many different types, in general their mechanisms of action 
remain poorly understood (25). An example of an immunostimulant is pidotimod, which 
works by stimulating Tumour Necrosis Factor α, a signalling protein that regulates cells 
of the immune system (25). Another example is Isoprinosine, which stimulates the 
immune system by mimicking hormones of the thymus gland. There is published evidence 
on the use of immunostimulants for children at risk of RTIs. For example, in a 2012 
Cochrane systematic review, non-specific immunostimulants were noted to reduce RTI 
incidence by 40% on average in susceptible children (i.e. children who are known and/or 
expected to suffer from at least three RTIs per winter season) (25). In a 2010 systematic 
review, a specific bacterial immunostimulant was noted to reduce the risk of recurrent 
RTIs (i.e. at least three RTIs per winter season) by 26.2% in at-risk children (26). However, 
safety profile concerns (i.e. risk of agranulocytosis) of immunostimulants have thus far 
precluded their use in routine clinical practice (25).  
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In contrast, vaccinations are of considerable importance in preventing RTIs. There are 
vaccines developed to prevent both bacterial (e.g. Streptococcus pneumoniae, H. 
influenzae type b, and more recently nontypeable H. influenza) and viral (e.g. Influenza 
or RSV) causes of RTIs. Vaccinations are active – they stimulate a host immune response 
leading to long-lasting protection. This compares to passive immunity, such as by 
providing IgG antibodies, which leads to immediate, but short-lived protection. 
Numerous systematic reviews have been published on the effectiveness of these 
vaccines. For example, a 2012 systematic review noted the effectiveness of live 
attenuated influenza vaccines in reducing the risk of influenza-related illness in children 
by 83% (95% CI 69–91%) (27). Similar findings were observed in a 2014 systematic review 
of the pneumococcal conjugate vaccine (PCV), which reduced the risk of invasive 
pneumococcal disease by 88% (95% CI 83- 94%) (28).  
Specific to RSV, palivizumab is a monoclonal antibody designed to provide RSV-specific 
passive immunity. There have been several published systematic reviews noting its 
effectiveness in reducing the risk of severe RSV infections in high-risk children by 55% 
(95% CI 38-72%) (29, 30). However, a 2011 systematic review demonstrated that, unlike 
other devices for generating immunity that are administered population-wide (such as 
PCV and influenza vaccines), palivizumab was not considered good value for money in 
the UK when used non-selectively. This review suggests its use should be restricted to at-
risk subgroups such as those with chronic lung disease (CLD) and CHD (30).   
Finally, antibiotic prophylaxis aims to achieve sufficient blood concentrations of 
antibacterial agents to prevent bacterial infection and their subsequent growth. Whilst 
its use is commonly seen in high-risk groups, a recent 2015 systematic review noted 
inconclusive evidence that antibiotic prophylaxis in certain high-risk groups can reduce 
the rates of pneumonia, disease exacerbations, hospital admissions and mortality (31). 
Interventions to treat RTIs 
Interventions targeted at treating RTIs are predominantly focused on antivirals and 
antibiotics that aim to reduce either illness duration and/or severity.  
In the UK, the National Institute for Health and Care Excellence (NICE) produces clinical 
practice guidelines (CPGs) on the use of such interventions. These are developed through 
an extensive review of the literature and where evidence is lacking, by consensus 
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methodology (32). In 2008, a NICE CPG on antibiotics to treat upper and lower RTIs in 
children was produced. It recommended that antibiotics should be prescribed in children 
who are; (a) unwell, (b) have signs/symptoms suggestive of LRTIs or RTI-related 
complications such as mastoiditis or (c) at high risk of RTI-related complications (e.g. 
children with CHD) (33). This was updated in 2014 with the same recommendations in 
place (33).  
For antivirals, a NICE CPG, produced in 2009 and updated in 2014, recommends that 
antivirals should be prescribed in children at high risk of RTI-related complications within 
48 hours of onset of an influenza-like illness (34). 
1.3.2 Antimicrobial Resistance 
The increasing prevalence of antimicrobial resistance is a global problem. With a 
diminishing number of new antimicrobials available to use, antimicrobial resistance is 
now widely recognised as a major public health threat (35).  
In the UK, despite the Chief Medical Officer’s 2011 report and NICE CPGs advocating 
antimicrobial stewardship, recommendations are often not followed. This is reflected by 
a continuing high rate of RTI-related antibiotic prescribing, particularly in children (36).  
This is despite evidence noting the marginal benefit of prescribing antibiotics for RTIs to 
children in primary care (37). For example, in a large retrospective cohort study using 
CPRD, it was estimated that to prevent one case of pneumonia, 4,400 episodes of URTIs 
in primary care would have to be treated with antibiotics (38).  
The reasons for these high rates of antimicrobial prescribing are explored in several 
systematic reviews. For example, a 2011 systematic review of GP views determined 
uncertainty and previous experience of RTI management significantly influenced the 
decision to prescribe (39). Similar findings were seen in a 2013 systematic review 
exploring parental, physician and healthcare provider perceptions of factors influencing 
antibiotic prescribing decision making (40). More recently, in a 2015 systematic review of 
parents’ and clinicians’ views, prescribing using a “just-in-case” approach was common, 
even when neither group believed that antibiotics were clinically indicated (41, 42).   
When faced with at-risk children with recurrent RTIs such as children with co-morbidities, 
antibiotic stewardship is arguably even more challenging (36).  
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1.4 RESPIRATORY TRACT INFECTIONS IN DOWN'S SYNDROME 
The relationship between DS and RTIs is complex. Whilst structural variations of the 
respiratory, cardiovascular and gastrointestinal system may play a role in making them 
more susceptible to recurrent RTIs, immune system immaturity in children with DS may 
also contribute to different responses to treatments, such as antibiotics, when compared 
to children without DS (43). In the remainder of the chapter, what is known about the 
factors that influence the risk of RTIs in children with DS, epidemiology of RTIs in children 
with DS, and prevention and treatment options for RTIs in children with DS are discussed. 
1.4.1 Impact of anatomical variation, immune system immaturity and co-morbidities 
on risk of RTIs 
Respiratory system  
The upper airway is often narrower in children with DS compared to controls without DS. 
This may result from a range of phenotypic variations, such as midfacial hypoplasia, that 
may cause a child with DS to have recurrent RTIs even in the presence of normal sized 
tonsils and adenoids (similar to a child without DS with enlarged tonsils and adenoids) 
(43). Other associated phenotypic features or associated conditions include 
macroglossia, midface hypoplasia, choanal stenosis, narrow nasopharynx, enlarged 
tonsils and adenoids, lingual tonsils and shortening of the palate (44). 
Congenital anomalies such as tracheal bronchus are often common in DS; this is an 
aberrant or accessory bronchus arising from the trachea with an incidence of between 2 
to 5%, which is often associated with recurrent right upper lobe pneumonia (43, 45).  
A unique pattern of pathological and histological abnormalities has been demonstrated 
in children with DS. This includes a double capillary network, porous appearance and 
enlargement of the alveolar ducts and alveoli macroscopically, and reduced numbers of 
alveoli and acinar microscopic complexity (43). The effect of these abnormalities on lung 
function has not been clearly established. 
In addition to the general porosity of the lungs, DS has been associated with subpleural 
cysts. However, these are often not recognised since they are not normally apparent on 
a plain chest radiograph and are generally thought to have limited or no clinical 
significance (46). 
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Laryngomalacia, namely a soft and immature laryngeal cartilage, is the commonest cause 
of airway obstruction in children with DS under the age of two years (43, 47) with a 
prevalence of 5-10% (48). Laryngomalacia, together with tracheomalacia, are common in 
DS due to a combination of hypotonia, gastroesophageal reflux disease and lack of 
coordination, and may first be recognised after presentation with stridor (49).  
In addition, due to the smaller trachea seen in children with DS, there is an increased 
incidence of subglottic stenosis and a corresponding increased susceptibility to 
intubation trauma (43, 47). Finally, children with DS have been noted to have increased 
mucus secretions and reduced ciliary beat frequency when compared with controls 
without DS (43, 47).  
Immune system 
Variations in immunological parameters in children with DS have been well described, 
with both the increased severity and frequency of RTIs postulated to be partially due to 
immune system immaturity. These include reduced T and B cell subpopulations, 
decreased neutrophil chemotaxis, thymic abnormalities, and altered of levels of 
immunoglobulin sub-classes (50-53).  
T cells are white blood cells that are involved in regulating and signalling in the immune 
system, as well as killing infected cells. For children with DS, T cells are particularly 
reduced in the first two years of life relative to children without DS (54). A number of 
other differences have been observed, including significantly higher numbers of IFN-
gamma producing CD4+ T cells (involved in regulation) and CD8+ T-cells (involved in killing 
infected or damaged cells) (55). The thymus gland, the site of the maturation of T cells, is 
typically smaller and of an abnormal shape relative to children without DS, and 
thymocytes, the cells of the thymus, have been found to have altered receptor expression 
which could affect functionality (52).  
B cells are white blood cells that secrete antibodies or immunoglobulins. In children with 
DS they do not undergo the typical rapid expansion in numbers of infancy that occurs in 
children without DS, with one study finding that 61% of observed B cell numbers in 
children with DS were in the 5th percentile relative to the general population (54). It has 
been hypothesised that the reduced numbers of B cells occurs primarily due to the 
reduction in T helper cells, rather than due to additional factors (56). 
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There are inconsistent results regarding immunoglobulin levels in children with DS, with 
some studies reporting that levels of immunoglobulins such as IgA, IgG and IgM in 
children with DS are not significantly different from children without DS, and other 
studies reporting that IgA, IgD and IgG levels are elevated (57, 58).  
Neutrophils, white blood cells that can ingest and kill foreign microbes, are reportedly 
affected with a reduced level of overall functioning (59), reduced levels of chemotaxis 
(directed movement around the body), increased levels of chemokinesis (random 
movement) (60), and altered oxidative metabolism (61). 
Additionally, it has been suggested that there is accelerated progression to senescence 
in the immune systems of adults and children with DS, given that many of the 
haematological parameters found in DS are also observed in ageing (62). 
All of these abnormalities are thought to be linked to differing frequency and severity of 
infections in children with DS. In a recent study comparing respiratory infections and 
corresponding immune parameters in children with DS and their siblings, children with 
DS were noted to have a significantly higher frequency of LRTIs compared to their siblings 
alongside observed immune parameter differences (63). 
Cardiac system 
CHDs are present in just over 40% of children with DS. Airway and respiratory function 
may be affected by CHD surgical complications. For example, as part of surgical 
corrections of Atrio Ventricular Septal Defects (AVSDs), a CHD commonly seen in children 
with DS, surgical trauma may lead to chylothorax, injury to the recurrent laryngeal nerve, 
diaphragmatic paralysis, and subglottic stenosis (64). These complications may result in 
less compliant lungs (restrictive defects) which reduces oxygen intake and leads to 
hypoxaemia. Cardiac problems have been linked to worsening of other symptoms, such 
as obstructive sleep apnoea, in children with DS (65). 
Finally, children with DS are more susceptible to pulmonary vascular problems compared 
to children from the general population with CHD (66, 67).  
Cardiac problems, especially haemodynamically significant AVSDs, are associated with 
increased hospitalisations and chest infection rates due to left to right shunting leading 
to pulmonary oedema and subsequently increasing the risk of infections (68). 
Furthermore, in the presence of pulmonary oedema, a mild infection may result in 
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tachypnoea in contrast to a child with DS unaffected by CHD. Physiologically, this effect 
may be more evident in younger children with immature immune systems and narrower 
airways. 
A large Australian population-level study, including 1282 children and 871 adults with DS, 
compared the risk of cardiovascular events in hospitalised patients with and without DS. 
Significantly higher rates of CHD were detected in children with DS, at 35.2%, compared 
to 0.8% in those without DS (69). Rates of other cardiovascular diseases were also 
examined, with 41.7% of children with DS possessing at least one cardiovascular risk 
factor (such as high blood pressure, diabetes, sleep apnoea) compared to 5.6% of those 
without DS; additionally 4.7% of children with DS had pulmonary hypertension, 0.8% a 
cardiac arrhythmia, and 1.4% high blood pressure specifically (69). 
Gastrointestinal system 
Congenital defects of the gastrointestinal system in DS include oesophageal atresia, 
duodenal atresia, ano-rectal malformations and Hirschsprung’s disease. Of these, surgical 
repair of oesophageal atresia may lead to surgical complications that impact upon 
pulmonary function, such as post-surgery bronchitis that occurs with an incidence of 0.5-
0.9% (70).  
Children with DS may have swallowing abnormalities, oesophageal dysmotility or gastro-
oesophageal reflux. With a combined prevalence of 75% in these three conditions, any of 
which giving rise to aspiration in children with DS, the inhalation of foreign material is 
common – particularly the inhalation of liquids into the lower airway (49).  
This may lead to chronic recurrent aspiration, causing children with DS to present with 
wheeze, chronic cough, recurrent pneumonia, pulmonary scarring or impaired lung 
function (49).  It is therefore a diagnosis to be considered when a child with DS encounters 
significant or recurrent respiratory problems.  
Others 
The intrinsic structural problems described above may be exacerbated by hypotonia and 
obesity, which affect the size and shape of the pharyngeal airway. This consequently 
increases the risk of aspiration (43, 47). As a higher proportion of children with DS are 
overweight when compared with the general population, obesity is another important 
factor to consider (43). 
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1.4.2 What is known on the epidemiology of RTIs in Down’s Syndrome 
To date, there has been no epidemiological study of RTIs in children with DS in the UK. 
However, there have been several studies abroad on RTI-related secondary healthcare 
utilisation in children with DS.  
For example, in an Australian study of 3,786 hospitalisations in 405 children with DS, it 
was noted that almost one third of admissions were for respiratory tract infections, 
affecting 52.6% of all children with DS hospitalised for any reason, with an admission rate 
of 11.4 per 1,000 person-years at risk (71). When compared to published admission rates 
for the paediatric population in Western Australia, significant differences were noted - 
hospitalisations with respiratory system related diagnoses in children with DS were 17.9 
times higher. 
In a USA study of hospitalisations in 217 children with DS, 64.9% of admissions were due 
to RTIs such as pneumonia, acute bronchitis or bronchiolitis (72). Furthermore, in children 
with CHD, higher rates of RTI-related hospitalisations were observed (72). 
RSV is the most common cause of childhood LRTI. It is also a major cause of hospital 
admissions in children with co-morbidities, likely due to both the variations in innate and 
adaptive immune systems and differences in respiratory function in terms of anatomical, 
histological and physiological factors (73, 74). In a population-based cohort study 
investigating RSV related hospitalisations, children with DS were noted to have a 5.5-fold 
(95% CI 2.5-12.3) increased risk of hospitalisation due to RSV LRTIs in their first two years 
of life in the absence of other co-morbidities, such as CHD (75).   
A prospective multicentre Spanish study published in 2017 compared hospitalisation 
rates due to RSV infection and the corresponding severity of disease. A total of 93 infants 
with DS and 68 controls matched by sex and age were followed up to one year and during 
a complete RSV season (76). It was found that respiratory-related hospitalisations were 
significantly higher in the DS cohort, at rates of 44.1% compared to 7.7%. RSV-related 
hospitalisations were also significantly higher in children with DS, at rates of 9.7% 
compared to 1.5% (76).  
With a focus on hospitalisations, the epidemiology of RTIs in DS in the UK has not been 
studied thoroughly nor compared with children without DS. Therefore, uncertainty about 
the burden of RTIs to children with DS, their families and the NHS in both primary and 
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secondary care remains. It is also unclear whether the incidence of RTIs are higher in 
children with DS, or whether they have a larger proportion of serious complications (i.e. 
hospitalisations) from RTIs compared to children without DS.  
1.4.3 Prevention and Treatment: Comparison with the general population 
In contrast to the numerous systematic reviews on interventions to prevent RTIs in 
children from the general population, there appears to be little published evidence 
specifically on children with DS. Moreover, in CPGs produced by NICE on interventions to 
treat RTIs, there is little by way of evidence based recommendations for at-risk children.  
Since most research on such infections has excluded children with DS, clinicians are 
therefore unsure how best to prevent and treat them. 
For example, in a 2006 systematic review and meta-analysis of all quantitative studies on 
antibiotics for RTIs, it was noted that there was no published evidence on the use of 
antibiotics for children with DS, despite the evident clinical need for it (77). 
This is further compounded by the uncertainty of extrapolating effects of treatments 
from published studies in other at-risk children with a single co-morbidity to children with 
DS. Children with DS are known to have multiple anatomical and immunological 
variations and therefore may respond differently to interventions, such as vaccines and 
antibiotics (43). 
Additionally, there have been several published clinical opinions recommending an 
aggressive antimicrobial prescribing approach, such as prophylactic antibiotics over the 
winter months, stronger antibiotics (e.g. Co-Amoxiclav rather than Amoxicillin), and 
rescue packs of antibiotics to be kept at home (43, 78). Whilst this may be indicative of 
how the effects of antibiotics are different in children with DS in clinical practice, this has 
not been substantiated by research to date (43, 78). 
Similarly, interventions to prevent RTIs, such as vaccines, are known to produce different 
results in children with DS. For example, poor responses to vaccines have been noted in 
children with DS, such as to influenza A and Hepatitis B vaccines (79, 80). These have 
largely been attributed to reduced immunoglobulin A and G levels (50-52). In recent 
years, it has been recommended that children with DS undergo regular serological testing 
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to assess vaccine responses (e.g., antibody functionality) and repeat vaccinations 
accordingly (81). 
Whilst RSV is a prominent cause of severe RTIs in children with DS, studies of Palivizumab 
have thus far been restricted to healthy and other at-risk children (e.g. CHD) with limited 
evidence of its use in children with DS (30).  
A need for research to improve the evidence base for prevention and treatments for RTIs 
in children with DS therefore remains. This forms the basis of the subsequent chapters of 
this thesis.  
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Chapter 2: Interventions to Prevent or Treat RTIs in Down’s 
Syndrome: A Systematic Review 
ABSTRACT 
Background 
Despite a high frequency and severity of RTIs observed in children with DS, an absence 
of evidence based recommendations for optimal management of RTIs is noted. It has 
been presumed that this is due to limited research into preventative and therapeutic 
interventions for RTIs in this at-risk group, but this has not been formally assessed in a 
systematic review of the literature.  
Methods 
PubMed, Embase.com, Cochrane Library and CINAHL were searched from the time of 
inception until February 2015 using a broad strategy combining the terms “Down’s 
syndrome”, “Respiratory Tract Infections”, and relevant synonyms. The initial search 
was updated in October 2017. Studies were considered eligible if they were 
randomised controlled trials (RCTs), non-randomised controlled trials (non-RCTs), 
controlled before-after studies (CBAs), or cohort studies assessing any intervention to 
prevent or treat RTIs in individuals with DS irrespective of age.  
The bibliographies of eligible included studies were then hand searched for other 
potentially relevant studies. ClinicalTrials.gov and the World Health Organization ICTRP 
were searched for ongoing studies. 
Data extraction was completed using a customised data extraction sheet and relevant 
Cochrane 'Risk of Bias' tools were utilised to assess the risk of bias within eligible 
studies. Studies with a critical risk of bias were subsequently excluded from the 
analyses. 
Results  
A total of 17,731 records were identified from which seven studies fulfilled the 
eligibility criteria. All seven studies focused on preventative strategies for RTIs in 
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children with DS. No RCTs, non-RCTs, CBAs or cohort studies on therapeutic 
interventions were identified.  
One RCT of moderate risk of bias compared prophylactic zinc therapy with placebo. 
Outcome data were reported for 50 (78%) children who presented with extreme 
symptoms: no benefit of prophylactic zinc therapy was found on URTI episodes, doctor 
visits, antibiotic use, and school absence.  
One non-RCT with serious risk of bias included 26 children and compared prophylactic 
treatment with pidotimod, an immunostimulant, with no treatment. Treatment with 
pidotimod was associated with fewer URTI recurrences compared with no treatment 
(1.43 vs. 3.82 parent-reported episodes).  
A prospective cohort study with serious risk of bias compared a cohort of 532 Canadian 
children with DS treated prophylactically with palivizumab with a cohort of 233 Dutch 
children with DS who did not receive this intervention. The cohort treated with 
palivizumab was found to have fewer RSV-related hospitalisation (23 untreated, 8 
treated) but the same number of overall RTI-related hospitalisations (73 untreated, 74 
treated) in the first two years of life.  
The four further studies, one on a school-based infection control programme, one on 
prophylactic zinc therapy, and two on prophylactic palivizumab therapy, were 
subsequently excluded due to critical risk of bias.  
Discussion 
The evidence base for the management of RTIs in people with DS is incomplete. 
Methodologically rigorous studies are warranted to guide clinicians in how best to 
prevent and treat RTIs in both children and adults with DS. 
2.1 CHAPTER OUTLINE 
In this chapter, I review the literature on preventative and therapeutic interventions for 
RTIs in adults and children with DS. This work was published in Paediatric Infectious 
Diseases Journal in 2016 (82). 
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2.2 BACKGROUND 
One in three of all hospitalisations of children with DS below the age of three years are 
due to RTIs (71, 72). When admitted for RTIs, children with DS spend two to three times 
more time in hospital, on average, than those without DS  (43, 47). In children with DS up 
to the age of 18 years, pneumonia and other RTIs are the leading cause of death (83). 
Despite this, key clinical trials of preventative and therapeutic interventions for RTIs have 
excluded adults and children with DS. The absence of evidence based recommendations 
for the management of RTIs in DS, and the diversity of expert based prescribing 
strategies, paves the way for mixed patient information and variation in the management 
of RTIs. 
In this chapter, I provide a thorough overview of the evidence base for the management 
of RTIs in this at risk-group by systematically reviewing the literature on the effectiveness 
of interventions to prevent or treat RTIs in adults and children with DS. 
2.3 AIMS & OBJECTIVES 
2.3.1 Aims 
To undertake a systematic review of the literature on the effectiveness of preventative 
and therapeutic interventions for RTIs in adults and children with DS. 
2.3.2 Objectives 
1) To design and perform systematic searches to identify original studies on 
preventative and therapeutic interventions for RTIs in adults and children with 
DS; 
2) To extract data from studies meeting inclusion criteria using a purpose-designed 
data extraction tool; 
3) To synthesise findings by study design; 
4) To perform a meta-analysis of data by study design (where able); 
5) To critically appraise quality of evidence. 
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2.4 METHODS 
2.4.1 Data sources and searches 
The effectiveness of preventative and therapeutic interventions for RTIs in children with 
DS were systematically reviewed using a broad search strategy combining the terms 
“Down’s syndrome”, “Respiratory Tract Infections”, and relevant synonyms (82). DS-
related co morbidities such as Sleep-Disordered Breathing, CLD and CHD were also 
included in the syntax. This broad strategy ensured that all studies on management of 
RTIs in children with DS with and without these co-morbidities were captured (e.g. 
antibiotic prophylaxis in CHD and CLD).  
The following electronic databases were searched for published, unpublished and 
ongoing studies: PubMed, Embase, Cochrane Library, CINAHL. Trial registries (WHO ICTRP 
and ClinicalTrials.gov) were also searched.  
To identify any additional relevant studies, reference lists of all included articles were 
screened together with targeted searches of the grey literature using Google Scholar, 
SIGLE, and official research websites (NIHR, Wellcome Trust, NIH, NHMRC, Medical 
Research Council, Down Syndrome Association, and National Down Syndrome 
Association). Additionally, I liaised with research networks and charities, such as Trisomy 
21 Research Society, Down Syndrome International, Down’s Heart Group, Mosaic Down’s 
Group, and Down’s Syndrome Medical Interest Group (84-87).  
All searches were conducted from the time of inception of that particular information 
source, up until February 2015.  
An update of the initial search was conducted in  October 2017, searching the same 
electronic databases (PubMed, Embase, Cochrane Library, CINAHL) and trial registries 
(WHO ICTRP and ClinicalTrials.gov) for published, unpublished and ongoing studies. 
2.4.2 Study selection  
The inclusion criteria for considering studies for this review consisted of: 
2.4.2.1 Types of studies 
Randomised controlled trials (RCTs), non-randomised controlled trials (non-RCTs), 
controlled before after studies (CBAs) and cohort studies. Non-RCTs were defined as 
 41 
studies that involved allocation to different interventions using methods that are not 
random.  
2.4.2.2 Population 
All children and adults with DS irrespective of age. 
2.4.2.3 Intervention  
Any intervention (medical and surgical) for the prevention or treatment of RTIs. This 
included active observation and supportive care. 
2.4.2.4 Comparison 
Any comparator group (or none) was considered for inclusion.  
2.4.2.5 Outcomes 
Outcome measures were not pre-specified. This was chosen as articles were expected to 
cover a broad range of interventions and therefore encompass a broad range of outcome 
measures. 
I excluded studies not published in English (unless a translation was available). No limits 
on the publication year or status restrictions were set.  
2.4.3 Data extraction 
I screened titles and abstracts retrieved from the database searches along with the 
reference lists of the included studies and relevant systematic reviews, alongside a 
second independent reviewer (Kate Reed; KR). We both independently reviewed the full 
text of potentially relevant studies against the pre-defined eligibility criteria. A third 
review author (Roderick Venekamp; RV) reviewed any discrepancies and the differences 
were resolved by consensus.  
Data extraction was performed by myself and was independently checked by KR and RV. 
Quality assessment of included studies was performed by myself and RV independently. 
In the 2017 update, screening of titles and abstracts was done by myself and a second 
independent reviewer (Kunjshri Kumari Singh; KKS). A third review author (Emma 
Alexander; EA) reviewed any discrepancies. Data extraction was performed by myself and 
checked by EA. Quality assessment of included studies was performed by myself and EA 
independently.  
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For data collection, I used a standardised data extraction form including information on 
study characteristics, setting, design, randomisation, inclusion and exclusion criteria, 
data-analysis methods, interventions, outcomes, and results. 
2.4.4 Assessment of heterogeneity 
I assessed clinical heterogeneity across the included studies by reviewing differences in 
populations, interventions, and outcomes measured. In view of the marked differences 
in the interventions and study types used in the individual studies, I did not perform a 
meta-analysis.  
2.4.5 Assessment of Risk of Bias  
I assessed risk of bias in RCTs using the ‘Risk of Bias’ tool described in Chapter 8 of the 
Cochrane Handbook of Systematic Reviews and Interventions (88). Six components were 
classified as either high, moderate, low or unclear risk of bias: (i) Random sequence 
generation, (ii) Concealment of allocation, (iii) Blinding, (iv) Incomplete outcome data, (v) 
Selective outcome reporting and (vi) Additional sources of bias. Components (i) and (ii) 
accounted for sequence bias, (iii) encompassed performance and detection bias, (iv) 
attrition bias, and finally (v) covered reporting bias. Any study with a high risk of bias in 
multiple domains was classified as having a High Overall Risk of Bias and was excluded 
from the data synthesis. 
For non-randomised studies, I used the Cochrane Risk Of Bias assessment tool for non-
randomized studies of interventions (ACROBAT-NRSI) and looked at bias due to (i) 
Confounding, (ii) Participant selection, (iii) Intervention measurement, (iv) Departures 
from intended interventions (v) Missing Data, (vi) Outcome measurements and (vii) 
Reporting of study results (89). These were classified as critical, serious, moderate, low 
or unclear risk of bias. Any study with a critical risk of bias in any domain was judged to 
have a critical Overall Risk of Bias, and thus was excluded from the data synthesis.  
2.5 RESULTS 
2.5.1 Study selection  
Database searches in 2015 identified 13,575 articles. After screening of titles and 
abstracts, 157 potentially relevant published articles were identified. This substantial 
drop was due to a significant number of studies identified with no interventions 
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described. After reviewing the full texts, five published studies were considered eligible 
for inclusion (90-94).  
The 2017 update identified a further 3,302 abstracts from database searching. After initial 
title and abstract screening, 3,250 abstracts were excluded. A total of 52 full text articles 
were reviewed. Of these, 50 were excluded. This left a further two studies eligible for 
inclusion. 
Figure 3 reflects the number of records identified, included, and excluded with reasons. 
The number of records incorporates results from both the 2015 review and the 2017 
update. 
Figure 3. Systematic literature searches for inclusion in review. 
 
2.5.2 Description of included studies 
Table 2 shows the main characteristics of the seven eligible published studies (five from 
the 2015 review and two from the 2017 update). All seven studies evaluated preventative 
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(i.e. prophylactic) interventions against RTI in children with DS; none focused on 
therapeutic interventions. Three studies focused on palivizumab, a human monoclonal 
antibody. For two of these studies, the primary outcome was RTI-related hospitalisation 
(76, 90). The third study was a post-marketing observational study assessing the 
effectiveness of palivizumab in preventing LRTIs caused by RSV in children who had DS or 
were otherwise immunocompromised (95).  
Two studies assessed the effectiveness of prophylactic treatment with an oral zinc 
supplement (92, 94) on number of URTIs. One study focused on the effectiveness of 
pidotimod, an immunostimulant, on number of URTIs (91). Finally, one assessed the 
effectiveness of a school-based infection-control programme on rates of RTIs (93).  
All studies exclusively studied individuals with DS under the age of 19 years. The seven 
studies varied in terms of design (one RCT, one non-RCT, three cohort studies, and two 
CBA studies), age range of included participants, and duration of follow-up. Two studies 
were conducted in Italy (91, 94), one in Canada (92), one in Canada and the Netherlands 
(90), one in the USA (93), one in Japan (95), and one in Spain (76). 
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Table 2. Characteristic of studies included in review. 
Study Study Design 
Population 
Characteristics 
Intervention Control Outcome Measures Risk of bias 
Lockitch 
1989 (92) 
RCT 
64 children with DS 
(1-19yr) 
Zinc Sulphate 
supplements 25 
mg/day for 1–9 yrs 
and 50 mg/day for 
older children for 6 
months 
Placebo 
(identical 
lactose 
pills) 
Number of children with 
URTI (days and episodes), 
doctor visits, antibiotic use, 
and school absence 
Moderate 
Yi 2014 
(90) 
Prospective 
cohort study 
765 children with DS 
(2-18m) 
Palivizumab for 9 
months 
No 
treatment 
RSV-related hospitalisation 
Serious 
Respiratory infection-
related hospitalisation 
La Mantia 
1999 (91) 
Non-RCT 
26 children with DS 
who had at least 6 
URTIs in preceding 6 
months (3-13y) 
Pidotimod 400 
mg/day for 3 months 
No 
treatment 
Number of URTI episodes 
(‘relapses’) and days with 
fever 
Serious 
Sanchéz-
Luna 2016 
(76)  
Prospective 
cohort study 
97 children with DS 
and 70 without DS (0-
1y) 
Between 1 and 6 
doses of palivizumab 
No 
treatment 
Hospitalisations due to 
acute respiratory tract 
infections and RSV  
Critical 
Kashiwagi 
2017 (95) 
Prospective 
cohort study 
138 infants with DS 
and 167 
immunocompromised 
infants (0-2y) 
 
Palivizumab 15mg/kg 
once per month 
during RSV season 
n/a 
RSV infections and 
hospitalisations 
Critical 
Krilov 
1996 (93) 
CBA study 
71 children with DS 
(0–5y) 
Infection Control 
Programme over 1 
year 
n/a 
Respiratory illness rate, 
doctor visits, antibiotic use, 
and school absence 
Critical 
Licastro 
1994 (94) 
CBA study 
21 children with DS 
(7–15y) 
Zinc Sulphate 
supplements 1 
mg/kg/day for 4 
months 
n/a 
Infection rate (mainly URTI) 
and days with fever 
Critical 
2.5.3 Risk of bias across studies 
Table 3 shows the Risk of Bias for Lockitch’s RCT (1989) using the Cochrane Risk of Bias 
tool (92). The overall risk of bias was moderate with incomplete outcome data in 14/64 
children (22%) and insufficient information on co-interventions, allocation and analyses 
(e.g. whether intention-to-treat analyses were undertaken). Reasons given for failure to 
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complete the study included major illness, moving to other cities, and intolerance of the 
supplements. 
Table 3. Risk of bias assessment for Lockitch’s RCT (1989) using the Cochrane Risk of 
Bias tool. 
 
Table 4 shows the Risk of Bias for the non-randomised studies using the ACROBAT-NSRI 
tool (89).  
Table 4. Risk of bias assessment for non-randomised studies using the ACROBAT-NSRI. 
Domain Judgement 
Random sequence generation (selection bias) Unclear risk 
Allocation concealment (selection bias) Unclear risk 
Blinding of participants and personnel (performance bias) Low risk 
Blinding of outcome assessment (detection bias)  Low risk 
Incomplete outcome data addressed (attrition bias)  High risk 
Selective reporting (reporting bias) Unclear risk 
Other bias Unclear risk 
Overall Moderate risk 
Domain  Yi 2014 
La Mantia 
1999 
Sanchéz-
Luna 2016 
Kashiwagi 
2017 
Krilov 1996 
Licastro 
1994 
Bias due to confounding  Moderate Serious Serious Critical Serious Moderate 
Bias in selection of participants 
into the study 
Serious Moderate Critical Moderate Critical Serious 
Bias in measurement of 
interventions 
Moderate Moderate Moderate Moderate Moderate Moderate 
Bias due to departures from 
intended interventions 
Moderate Moderate Moderate Moderate 
No 
Information 
Moderate 
Bias due to missing data  Moderate Low Moderate Moderate Moderate Critical 
Bias in measurement of 
outcomes  
Moderate Serious Low Critical Moderate Serious 
Bias in selection of the reported 
result  
Low Low Moderate Serious Moderate Low 
 47 
 
The overall risk of bias for Yi et al. (90) was serious with the absence of a true internal 
comparator (i.e. control population with a similar demographic profile in the same 
geographic area). This made it impossible to assess whether the differences in RSV-
related hospitalisations were due to palivizumab or due to unmeasured differences in 
baseline risk and exposure to RSV in different countries (e.g. differences in participant 
characteristics, healthcare system or seasonality). 
The overall risk of bias for La Mantia et al. (91) was judged as serious due to subjective 
outcome measurement (e.g. parent reported URTI episodes), imbalanced baseline 
characteristics between the intervention and control groups and no adjustments for 
confounding.  
As per guidance from Cochrane, I excluded four studies with a critical risk of bias from 
the subsequent narrative.  
For the two CBA studies by Licastro et al. (94) and Krilov et al. (93), the risk of bias was 
critical. In the former, this was due to the large amount of missing data whilst in the latter 
there was no detailed information on how the school was selected for inclusion in the 
study (i.e. non-random selection of the school for the study).  
In the prospective cohort study Kashiwagi et al. the risk of bias was also critical (95). 
Although the study aimed to assess the effectiveness of palivizumab in RSV infections and 
hospitalisations, there was no control group, and thus it was not possible to judge the 
efficacy of the treatment. The study only reported the percentage of participants who 
received palivizumab and then later went on to have RSV infections or hospitalisations, 
with no statistical analysis.  
The overall risk of bias for Sanchéz-Luna et al. (76) was judged as critical due to selection 
bias. The study was observational only and there was a lack of information as to why a 
sub-sample of participants were prescribed palivizumab as RSV prophylaxis. It was stated 
that there were few differences at baseline between the groups that received 
prophylaxis, but these were not adjusted for, and residual confounding due to selection 
(by indication) cannot be excluded.  
Overall Serious Serious Critical Critical Critical Critical 
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2.5.4 Results from included studies 
2.5.4.1 Zinc  
Lockitch et al. randomised 64 children with DS to prophylactic oral zinc therapy for six 
months or placebo. However, they reported only on the 50 children (23 treated with zinc 
and 27 with placebo) who had ‘extreme’ numbers of days/episodes of illness (i.e. the 
number of days or episodes of illness exceeded the 90th percentile value for siblings and 
age-matched unrelated children). In this subset of children with DS, during six months of 
treatment, no significant differences in terms of URTI episodes, doctor consultations, and 
antibiotic use were found between those receiving zinc and children receiving placebo 
(92).  
2.5.4.2 Pidotimod 
In a non-RCT, La Mantia et al. followed 26 children with DS who had experienced at least 
six URTIs in the preceding six months; they received either the immunostimulant 
pidotimod for three months (14 children) or no treatment (12 children). While on 
pidotimod, children with DS had fewer parent-reported URTI recurrences (mean 2.7, 
standard deviation (S.D.) 1.1 vs mean 6.8, S.D. 1.3) and days with fever (mean 4.5, S.D. 
3.5 vs mean 16.9, S.D. 6.7) compared to those not receiving this treatment (91). 
2.5.4.3 Palivizumab 
In a prospective cohort study, Yi et al. followed a cohort of 532 Canadian children with 
DS treated prophylactically with palivizumab for nine months and 233 Dutch children with 
DS who did not receive this monoclonal antibody. In the first two years of life, treatment 
with palivizumab resulted in a 3·6-fold reduction in the incidence rate ratio (adjusted 
incident rate ratio (IRR) 3.63; 95% CI 1.52- 8.67) of RSV-RTI hospitalisations. Palivizumab 
however did not reduce overall hospitalisations for RTI (adjusted IRR 1.11; 95% CI 0.80 to 
1.55) (90). 
2.5.5 Results from excluded studies 
Given the minimal amount of data available in the field, the results from the excluded 
studies are presented, but should be interpreted with caution given the critical risk of 
bias for these studies.  
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2.5.5.1 Zinc 
In the CBA study using oral zinc supplementation, Licastro et al., 21 children with DS 
aged 7 to 15 were recruited. The number of RTI episodes in the past 12 months was 
assessed at baseline and a year after treatment cessation. The number of infective 
episodes significantly decreased after one year of follow up in male children (3.1±0.7 
before, 1.6±0.9 after, p<0.025) with no significant difference for female children 
observed (94).  
2.5.5.2 Infection control programme 
The CBA study Krilov et al. investigated the efficacy of a school-based infection control 
programme on the number and type of infectious illnesses experienced by its sample of 
children with DS aged 6 weeks to 5 years, with 33 baseline responders and 38 
intervention responders. At baseline it was reported that there were a median of 0.67 
respiratory infections per child per month with a non-significant reduction to 0.42 per 
child per month in the intervention year (p=0.07) (93).   
2.5.5.3 Palivizumab 
The prospective cohort study Kashiwagi et al. aimed to assess the safety and 
effectiveness of monthly doses of palivizumab during the RSV season for the prevention 
of LRTIs caused by RSV in children with DS (n=138) or other immunocompromising 
conditions (n=167). Overall, 5 patients (1.7%) across both groups had an RSV infection 
during the study period, and 2 patients (0.7%) were hospitalised (95). 
In another prospective cohort study, Sanchéz-Luna et al. followed a cohort of 161 
infants for one year, 93 of whom had DS and 68 others without DS who were age- and 
sex-matched. Of those with DS, 33 received palivizumab as RSV prophylaxis. 
Hospitalisation rates for any acute RTI and due to RSV were recorded. The rate of 
hospitalisation for any acute RTI was 3.0% (1/33) in children with DS who received 
palivizumab versus 15.0% (9/60) in those without RSV prophylaxis. However, in a 
further logistic regression analysis, adjusted by DS status, prophylaxis against RSV was 
not a predictor of subsequent hospitalisation due to RSV infection (76).  
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2.6 DISCUSSION 
2.6.1 Summary of findings 
My systematic review of the literature identified one RCT, one non-RCT, three cohort 
studies, and CBA studies on the prevention of RTIs in individuals with DS.  
Four assessed passive immunotherapies (three palivizumab, one pidotimod), two looked 
at prophylactic treatment with oral zinc supplements, and one at the effectiveness of a 
school-based infection-control programme. Due to a critical risk of bias, four studies were 
not included as part of the main results (zinc therapy, infection-control programme, and 
two palivizumab studies). 
Pidotimod, an immunostimulant, and palivizumab, a human monoclonal antibody, 
showed some benefit in individuals with DS, on URTI episodes and RTI hospitalisations 
respectively, when used prophylactically for three and nine months. They therefore may 
have a role in preventing RTIs in individuals with DS.  
Although the included RCT assessing zinc over six months showed no effect on URTI 
episodes, the excluded CBA study assessing the effects of zinc over four months showed 
a significant reduction in episodes. In view of the critical risk of bias in the latter, these 
results should be interpreted with caution. 
2.6.2 Strengths and Weaknesses 
I chose a very broad search strategy including DS-related co-morbidities such as CHD, to 
ensure a thorough and comprehensive search of all potential management options for 
RTIs in people with DS to inform clinical practice and future research. Whilst this search 
identified numerous studies (n=17,731 incorporating the 2017 update), the majority did 
not report on any interventions to prevent or treat RTIs.  
Limitations of the review are likely to stem from restricting to studies published in English 
and publication bias. The latter is owing to anecdotal evidence that most studies on 
individuals with DS involve small samples, which may limit publication potential. Whilst 
one may argue that a rigorous approach to assessment of the risk of bias is unnecessary 
in the light of limited evidence in the field, it was important to clarify both the quality and 
quantity of evidence to assist in informing current clinical practice and future directions 
for research.  
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2.6.3 Comparison with previous research   
In contrast to adults and children with DS, there is an abundance of high quality research 
into medical and surgical interventions for (recurrent) RTIs in the general population. 
With this high-level evidence, CPGs such as the NICE CPG [CG69] on prescribing 
antibiotics in RTIs in the general population have been developed (33). Similarly, 
numerous studies have highlighted the effectiveness of preventative measures for RTIs 
such as vaccination in the general population (33). However, how these 
recommendations can be translated to people with DS is unclear since their functional 
anatomy and immunity profile may both predispose them to RTIs differently and may 
make them respond differently to treatments. 
2.6.4 Implications for practice 
I found no randomised controlled trials, controlled before-after studies and cohort 
studies on therapeutic interventions for RTIs in children with DS, suggesting that there is 
no high-quality evidence to guide clinicians in managing children with DS.  
From the prophylactic treatments identified, I found some evidence for the use of 
palivizumab in preventing RSV-RTIs. Due to the absence of a true internal comparator in 
one study (e.g. comparing treated vs. untreated populations between Netherlands and 
Canada with differing healthcare practices and seasonal patterns), the causal inferences 
of palivizumab on children with DS are limited.  
Furthermore, whilst palivizumab was effective in reducing RSV related RTI 
hospitalisations, overall RTI-related hospitalisations were unaffected, except in one study 
that had a critical risk of bias where a reduction was observed. Currently, American 
Academy of Pediatrics guidance recommends palivizumab as prophylaxis in children with 
DS only when there are concurrent comorbidities (e.g. CHD, CLD, prematurity) (96). 
Pidotimod shows encouraging results in preventing RTIs, however as with most 
immunostimulants it is currently only licensed for research purposes in several European 
countries and the USA, due to a lack of high quality evidence as to its efficacy and its side 
effect profile (97). 
Finally, with a high quality RCT showing no significant effect of prophylactic zinc therapy 
in preventing RTIs, it is not recommended for clinical practice (92).  
 52 
2.6.5 Implications for research 
With no high quality, therapeutic intervention studies identified from this systematic 
review, clinicians are faced with little evidence to guide them in the treatment of RTIs in 
children with DS. A particularly relevant decision is that of prescribing antibiotics for RTIs 
where concerns about antimicrobial resistance exist. It is disappointing that, in the two 
years since the original review took place, no additional studies were identified that met 
the quality criteria for inclusion.  
Whilst randomised controlled trials remain the gold standard in providing robust clinical 
and cost-effectiveness estimates, due to the fluctuating nature of RTIs, substantial 
numbers of children with DS would need to be recruited. Cohort studies utilising 
population wide electronic health records may therefore be a viable alternative.  
This exemplifies the need for the subsequent phases of my thesis that focus on 
establishing RTI healthcare utilisation in primary and secondary care and the 
effectiveness of antibiotics in preventing hospitalisations in children with DS compared 
to children without DS using routinely collected EHRs. 
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Chapter 3: The CALIBER Database 
3.1 CHAPTER OUTLINE 
This chapter outlines the CALIBER database, including the general characteristics of its 
source datasets, the points to consider in analysing and interpreting findings from EHR 
research, and the process of identifying or “phenotyping” variables of interest in CALIBER. 
3.2 INTRODUCTION 
CALIBER (CArdiovascular disease research using LInked Bespoke studies and Electronic 
health Records) is a database of linked routinely collected electronic health records (EHR) 
from England (98), comprising data from primary care (Clinical Practice Research 
Datalink, CPRD) (98), hospital admissions (Hospital Episode Statistics, HES) (98, 99), the 
Myocardial Ischaemia National Audit Project (MINAP) (100) and the national death 
registry at the Office for National Statistics (ONS).  
It is housed at the UCL Farr Institute of Health Informatics Research and made sharable 
and research ready by defining and curating with meta-data variables (categorical, 
continuous, event) on >300 risk factors, CVDs and non-cardiovascular comorbidities.  
CALIBER also holds small-area indices of deprivation from ONS (Index Of Multiple 
Deprivation, IMD) linked by the patient’s postcode (101). The IMD is a score calculated 
for each patient’s neighbourhood based on social indices such as income, education, and 
employment. 
The data sources complement each other in providing different types of information 
about a patient’s medical history longitudinally (Figure 4) (102).  
For example, CPRD provides information on primary care encounters, encompassing 
diagnoses, observations and prescriptions. HES complements this with its stored records 
on secondary care and hospitalisations, A&E attendances, and outpatient appointments. 
MINAP stores information on all patients suspected of suffering an ischaemic cardiac 
event. ONS provides information on deprivation using the IMD score, and on date and 
cause of death if applicable. Through all these sources, researchers can learn about 
progress of illness, healthcare utilisation, interventions received and mortality and 
morbidity outcomes. 
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Figure 4. How a patient’s medical history may be recorded in the CALIBER data sources. 
 
The CALIBER dataset is pseudo-anonymised with key identifiers removed; patients’ and 
general practices’ location can only be identified at a very crude level (one of 10 regions 
in England).  
In the 2010 version of the CALIBER dataset (used for the subsequent chapters of this 
thesis), the entire cohort (100%) was linked via CPRD, HES, ONS and MINAP.  
There are several advantages to using CALIBER over a general CPRD-HES linked dataset, 
with 100% data linkage between all four data sources being one of these (102). Novel 
methods of data linkage can be error-prone, whereas CALIBER has been tried and tested 
in many other studies (103-105). Another key reason is that CALIBER allows researchers 
to use preselected and validated codelists for conditions such as diabetes, which would 
have to be created from scratch if a researcher used CPRD alone. 
3.3 SOURCE DATASETS 
3.3.1 Primary care data: Clinical Practice Research Datalink (CPRD) 
CPRD is an ongoing primary care database of anonymised medical records from general 
practitioners, with coverage of over 11.3 million patients from 674 practices in the UK 
(England, Wales, Scotland and Northern Ireland) (102). It represents one of the largest 
databases of longitudinal medical records from primary care in the world.  
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The population of active patients (alive and currently registered) on July 2013 was 4.4 
million (6.9% of the UK population) and is broadly representative in terms of age, sex and 
ethnicity of the total UK population. The CPRD is therefore a rich source of health data 
for research, including data on demographics, symptoms, tests, diagnoses, therapies, 
health-related behaviours and referrals to secondary care. 
Primary care clinical encounters are entered onto the CPRD database using Read codes. 
Read terminology is a structured hierarchy of both medical and non-medical terms 
covering categories for signs and symptoms, diagnoses, investigations, treatment and 
therapies, drugs and appliances, occupations and administrative processes. They 
therefore offer a comprehensive list of clinical terms that can be used to describe the 
care and treatment of patients.  
However, in contrast to ICD-10 codes, which are structured according to disease groups, 
Read codes encompass all clinical terminology used in primary care with approximately 
100,000 codes available to utilise. Huge variation in coding practices for the same disease 
is therefore common with detailed search strategies therefore necessary to phenotype a 
disease of interest (detailed further below). 
Information in the CPRD database is recorded in a number of tables, which can be linked 
by the pseudonymised patient identifier in order to build up a complete picture of a 
patient’s healthcare experience.  
• Patients – one row per patient, with demographic details such as year of birth, date 
of death and registration dates.  
• Practices – one row per practice, giving details such as region of the UK and the date 
when the practice achieved ‘up-to-standard data’ (see further below).  
• Consultations – each patient episode is considered a ‘consultation’ and all data are 
entered in consultations (face-to-face, telephone or administrative). This table allows 
diagnoses and prescriptions entered in the same consultation to be identified.  
• Staff – one row per staff member, with gender and role.  
• Events – there are a number of event tables with a patient having any number of 
events. Each event is linked to a single consultation and an event date, a medical 
dictionary code (Read code), product dictionary code (Multilex) and/or associated 
information in free text.  
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• Clinical – Read coded diagnoses entered by the GP with additional data such as 
observations. 
• Referrals – referrals to secondary care, with the indication recorded as a Read code. 
• Immunisations – records of immunisations. 
• Therapy – prescriptions. 
• Test – results of laboratory tests, each with a Read code. 
A screenshot illustrating how information may be entered in practice by a GP in 
consultation is denoted in Figure 5 below. This is a screenshot using the Vision clinical 
system (106).  
Figure 5. Screenshot of the Vision clinical system utilised by GPs to enter clinical 
information (e.g. Read codes). 
 
Practices participating in CPRD are assigned an “up-to-standard” date by CPRD custodians 
based on the date on which acceptable standards are met on ten practice-based 
measures of quality, completeness and representativeness. Once deemed “up-to-
standard”, their data is marked as suitable for longitudinal data research. Hence, 
conventionally, clinical data from patients are restricted from the date their practice were 
deemed “up-to-standard”.  
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Practice data are checked once delivered to CPRD for data quality issues (98). Any practice 
submitting poor data is provided feedback and if coding practices are not rectified, data 
from their practice are subsequently removed from CPRD (107).  
Despite these quality measures, data quality within CPRD is variable because data are 
entered by GPs during routine consultations and not specifically for the purposes of 
research. For example, when faced with a patient with tonsillitis, via look-up tables, 
rather than selecting the most accurate Read code, GPs may select a multitude of codes 
ranging from symptom codes such as sore throat to throat soreness and diagnostic codes 
such as throat infection, pharyngitis and/or tonsillitis. Furthermore, whilst data 
completeness within practices contributing to CPRD is better compared to those that do 
not, a lot of data is written in free-text and therefore not freely accessible. In addition, 
clinical observations such as pulse, blood pressure, and temperature are rarely recorded. 
There have been numerous CPRD studies that have undertaken validation of Read coded 
diagnoses against anonymised requested GP paper records or electronic free text. A 
systematic review of these CPRD validation studies found that diagnoses were generally 
reliable (108). Across all diseases and all validation studies, a median of 89% of records 
were validated, with a range of 24-100%. For respiratory disorders, the median was 88% 
with a range of 26-100% (108). To my knowledge, no validation study in DS has been 
conducted to date.  
Free text can no longer be requested from CPRD for validation purposes due to changes 
in information government requirements, and no free text validation was undertaken in 
the course of this thesis.  
3.3.2 Secondary care data: Hospital Episode Statistics (HES) 
Hospital Episode Statistics (HES) is a database warehouse containing details of all 
admissions, procedures, outpatient appointments and Accident & Emergency (A&E) 
attendances at NHS hospitals in England (102). It is a records-based system that covers 
all NHS trusts in England, including acute hospitals, primary care and mental health trusts 
with information on each hospitalisation stored as a large collection of separate records 
(one for each period of care) in a secure data warehouse. This data is collected during a 
patient’s time at hospital and utilised to allow hospitals to be paid for the care they 
deliver.  
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Data on diagnoses is logged using the ICD-10 coding system whilst information on 
procedures is stored using the OPCS4 coding system (102). ICD-10 is the 10th revision of 
the World Health Organizations’ medical classification system (102). It contains codes for 
diseases, signs, symptoms, abnormal findings, complaints, social circumstances, and 
external causes of injury or disease. OPCS-4 is the coding system for operations, 
procedures and interventions performed during inpatient stays, day case surgery and 
some outpatient treatments in NHS hospitals (102). Similar to CPRD, patients are 
identified by their NHS number.  
Validation studies in the field of RTIs have confirmed that HES records on RTIs appear to 
be both reliable and complete (109). However, its primary purpose is as an administrative 
dataset for financial payments. The research utility of HES is therefore limited by data 
granularity and limitations of the ICD-10 coding system. Moreover, data quality is known 
to be variable with inaccurate and/or incomplete clinical coding common due to data 
being inputted by clinical coders who have very little contact with front line clinicians and 
have to work from clinical notes which are normally inadequate and/or unstructured. 
Therefore, caution is advised when analysing and interpreting results for clinical research 
purposes. 
3.3.3 Death registry & deprivation: Office of National Statistics (ONS) 
The death registry for England and Wales curated by the Office for National Statistics 
(ONS) includes the date of death and the causes entered on the death certificate. A single 
underlying cause of death is allocated according to the WHO ICD-10 algorithm based on 
the information recorded on the death certificate, likely causal sequence and ICD 
selection rules (110).  
Deaths in England and Wales have been coded using ICD-10 since 2001 and ICD-9 in 
previous years (85). Due to a change in the rules for selecting the underlying cause from 
ICD-9 to ICD-10, the causes of deaths are not directly comparable between 2001 onwards 
and previous years (110).  
The IMD is a composite measure of deprivation calculated by ONS using indicators for 
super output areas (postcode areas). It covers the following domains; (i) Income, (ii) 
Employment, (iii) Health and disability, (iv) Education, skills and training, (v) Barriers to 
housing and services, (vi) Crime and (vii) Living environment (101).  
 59 
3.4 ACCESS TO CALIBER DATA 
Access to CALIBER data operates by a ‘safe haven’ model, where the data is stored, 
processed and managed within the security of a walled garden system, avoiding the 
complexity of assured end point encryption. A file transfer mechanism enables aggregate 
data to be transferred out of the walled garden simply and securely (86).  
CALIBER researchers are provided with pseudo-anonymised data (i.e. identifiers such as 
date of birth, name and address removed). Whilst the free text associated with coded 
data is not currently available to researchers, historically it was possible to request it (with 
a cost for manual anonymisation) and it has been used for validation studies in the past 
(111). 
3.5 ETHICAL AND SCIENTIFIC APPROVAL 
CPRD has Multi-centre Research Ethics Committee approval for all purely observational 
research using its linked EHRs (CPRD, HES, ONS) (112). The CALIBER dataset comprises 
CPRD data linked to HES, ONS and MINAP by a trusted third party with the final dataset 
held in a pseudonymised form. The CALIBER record linkage has therefore had separate 
ethical approval (09/H0810/16) for observational clinical research.  
Raw data are available for use by researchers, subject to approval of the protocol by, and 
payment to, the bodies governing access to the constituent data sets. For CPRD, this 
involves scientific approval of the protocol by the Independent Scientific Advisory 
Committee (ISAC) and a signed licence outlining scope and data confidentiality of use of 
CPRD data (113). 
Following ISAC approval, an application to the CALIBER Scientific Advisory Committee is 
made in order to use the curated CALIBER dataset. 
3.6 PHARMACOEPIDEMIOLOGY USING EHRs 
The CALIBER dataset has been developed and used for numerous studies investigating 
risk factors and the onset of cardiovascular diseases (114-118). More widely, it has been 
utilised successfully in assessing healthcare utilisation and prescribing trends for a range 
of other diseases including infections (119), mental health (e.g. depression (120)) and 
cancer (121).  
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Increasingly, EHRs such as CALIBER are being used to estimate the effects of interventions 
on outcomes in populations particularly due to its advantages in overcoming limitations 
in RCTs, such as the difficulties of including restricted patient groups (e.g. elderly, rare 
diseases), assessing intervention efficacy in real world settings, and insufficient power to 
assess rare outcomes. 
However, as EHR data is collected for reasons unrelated to research, data quality is often 
insufficiently detailed, which limits its efficacy in assessing quality of care and the 
community burden of disease. There may be missing, limited, or inaccurate information 
on exposures, outcomes and potential confounding variables such as ethnicity, body-
mass index, co-morbidities and disease severity (122, 123). These issues are discussed 
further below.  
3.6.1 Misclassification 
CALIBER researchers need to rely on Read codes that GPs have assigned to consultations, 
or ICD-10 codes that hospital coders have assigned to hospitalisations. In routine practice, 
they are unlikely to apply strict case definitions when allocating diagnostic codes. 
Misclassification can therefore occur.  
Misclassification can occur in the selection of the patient population, exposure, 
confounders and outcomes. It is commonly categorized as either non-differential or 
differential misclassification. For example, in non-differential exposure misclassification, 
the misclassification is deemed unrelated to the occurrence or presence of disease. In 
contrast, if the misclassification of exposure is different for those with and without 
disease, it is differential.  
In non-differential misclassification, this mostly produces a bias in favour of the null 
hypothesis. Differential misclassification can result in bias both for and against the null 
hypothesis (124, 125). An example of differential misclassification in routinely collected 
data would be if a clinician is more likely to spend time accurately inputting codes for a 
person with a disease than a person who is perceived as healthy.  
It is crucial therefore that phenotyping algorithms are developed rigorously with 
sensitivity analyses undertaken to assess the impact of varying codelists on findings. An 
advantage of using routinely collected data for healthcare utilisation studies is that 
coders are effectively blinded for an individual study, and this means that such studies 
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are not vulnerable to certain subtypes of bias that can secondarily cause misclassification 
bias. These other types of bias include observer bias (the knowledge of the hypothesis 
results in an interviewer emphasising certain questions), recall bias (knowledge of a 
disease state results in a participant ‘joining the dots’) and reporting bias (participants 
report certain exposures because they are aware they are of interest) (126).  
3.6.2 Missing data 
Missing data is defined as occurring when no data value is stored for the variable in the 
current observation. Occasionally, the level of missingness is so substantial that EHRs may 
not be sufficiently internally valid to undertake research (127, 128).  
For example, a patient may be White but his ethnicity may never be recorded in the EHR. 
This will lead to that patient’s ethnicity being classified as Unknown. If ethnicity is an 
important confounder in an analysis, (e.g. when analysing the impact of ethnicity on 
cardiovascular disease outcomes) but the proportion of missing or unknown ethnicity is 
high, the analyses may be compromised. 
A commonly used method to handle missing data is multiple imputation; creating 
multiple complete versions of the dataset with missing values imputed by random draws 
from distributions inferred from observed data (129). However, this is subject to 
limitations, with biased results from multiple imputation likely if significant proportions 
of the data are missing or if the recording of the variable differs between different groups 
(e.g. if BMI is more likely to be recorded in individuals who are obese rather than 
individuals who are not).   
Alternatively, in some instances, use of multiple linked data sources to cross-reference 
may increase the overall completeness of the data. For example, combining CPRD and 
HES increased completeness of ethnicity to 97%, with 85% of patients having the same 
ethnicity recorded in both databases (130). There can also be large differences in 
incidence estimates when utilising linked databases; for example community acquired 
pneumonia incidence was 39% higher when using linked databases compared to a single 
source (131). 
Data completeness is a key advantage to the use of multiple linked data sources. 
However, there are consequently effects of such an approach on sample sizes, and hence 
the ability of a study to have sufficient power to detect differences. If the aim of a study 
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is to stratify by ethnicity or some other factor that can be drawn from multiple sources, 
or if these variables are considered important confounders, then linked data may be 
considered a necessity.  
However, it should also be noted that even if linked data sources are utilised, then 
recording will remain imperfect. A total of 85% of patients having the same ethnicity 
recorded in two databases means that 15% of patients do not, and there may not be an 
easy way to adjudicate these differences without having a further negative impact on 
sample sizes. In the above study concordance of ethnicity was driven largely by patients 
who were coded as White, and minorities had reduced concordance. If the aim is to 
stratify an analysis by ethnicity, then misclassification bias may occur as a result (130). If 
data linkage means that all patients classified as having a disease state in either database 
are classified as having it overall, then incidences may be overestimated; otherwise, there 
has to be some way in which to adjudicate differences, which may be resource intensive 
and unreliable, or there will be a smaller sample size.  
3.6.3 Confounding 
A direct comparison between treatment groups will likely be affected by inaccuracies 
caused by confounding (132-134), namely a factor that varies between two groups in 
addition to those under investigation. In clinical practice, treatment assignment is 
generally based on the physician’s perception of a patient’s risk of a particular outcome 
(132, 133) and prognostic patient characteristics that are typically unevenly distributed 
among the treatment groups. When applied to treatment, this sort of confounding is 
often known as confounding by indication. 
Whilst there are numerous methods known to detect or control for measured 
confounding, there may also be unmeasured or poorly measured risk factors (e.g. 
patient’s clinical observations) of the outcome that are also associated with the exposure 
(134). These are referred to as unmeasured, unobserved, or residual confounders. 
Confounding by indication is particularly hard to address and arises from the fact that 
individuals who are prescribed a medication or who take a given medication are 
inherently different from those who do not take the drug, because they are taking the 
drug for a reason (e.g. individuals prescribed an antidepressant). 
A recently developed method that aims to address confounding is propensity score 
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methods (134). This aims to weight or match treated and untreated patients in such a 
way as to make results more comparable to a randomised controlled trial. 
The propensity score (PS) is a score applied to every person within the dataset. In the 
context of studies aiming to understand the effect of treatment, the PS is applied to each 
person in the dataset and represents their probability of receiving treatment.  
For example, in a RCT, everyone gets an equal chance of being allocated the treatment 
and therefore has a PS of 0.5. In contrast, in non-randomised studies, if a particular group 
of patients were more likely to receive treatment than healthier patients with little/no 
co-morbidities then they are likely to have a higher PS. 
The score is based on knowledge of factors that predict treatment and can therefore be 
utilised in a number of ways to tackle confounding (134, 135).  
There are four ways that PS can be utilised to reduce the effects of confounding when 
estimating the effects of treatment on outcomes: matching, inverse probability of 
treatment weighting (IPTW), stratification, and co-variate adjustment (136).  
IPTW using the PS uses weights based on the PS to create a synthetic sample in which the 
distribution of measured baseline co-variates is independent of treatment assignment. 
This analysis approach is utilised in Chapter 6 of my thesis; “Effects of Antibiotics in 
Preventing Hospitalisations in Children with Down’s Syndrome” and discussed in more 
detail in the methods section of the same Chapter. 
There is a lack of consensus in the applied literature as to which variables to include in 
the PS model. Possible sets of variables for inclusion in the PS model include the 
following: all measured baseline co-variates, all baseline co-variates that are associated 
with treatment assignment, all co-variates that affect the outcome (i.e. the potential 
confounders), and all co-variates that affect both treatment assignment and the outcome 
(i.e. the true confounders). 
In a recent review, IPTW and matching was deemed equivalent with minimal bias noted 
when both were utilised with a correctly specified PS model (135).  
However, it is important to note that despite its advantages as an analytical technique 
for EHR research, the usefulness of PS is limited by EHR data quality. For example, in acute 
events, GPs do not code signs and symptoms that may be indicators of illness severity 
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(e.g. shortness of breath). Whilst PS may take account of the fact that some patients may 
be generally sicker, because of absent information on illness severity on the day of 
treatment allocation, it may not adequately predict treatment probability.  
3.7 PHENOTYPING ALGORITHMS 
The phenotype of an individual in the context of EHR research is the set of observable 
characteristics as recorded in EHR about that person. This may include clinical 
measurements such as pulse or blood pressure, or diagnoses such as acute myocardial 
infarction. It is therefore crucial to understand the process by which information about a 
subject enters the record, in order to be able to interpret and infer the phenotype 
correctly (137).  
Frequently, it is necessary to make assumptions based on clinical knowledge and develop 
a strategy for allocating a diagnostic label to the patient (e.g. probable angina, possible 
angina). This is called a phenotyping algorithm.   
There are few diseases or conditions for which it is possible to create a ‘perfect’ 
phenotype (i.e. identifying all disease cases with perfect accuracy), because it relies on 
having accurate information in the GP/hospital and for it to be entered consistently and 
accurately in the EHR.  
Instead, a phenotyping algorithm may choose to maximise either diagnostic specificity or 
sensitivity. EHR based studies therefore typically include sensitivity analyses using 
different phenotyping algorithms (e.g. using different data sources, or using restricted or 
expanded sets of diagnoses codes). This can be used to show that the limitations of the 
phenotyping process have not introduced bias into the results.   
The use of CALIBER to cross-reference between linked data sources therefore provides 
an inherent advantage rather than utilising a single data source to be able to look at other 
information, which might give clues (e.g. primary care or medication in linked data) (138). 
3.8 CODE LISTS 
As part of the phenotyping process, codes of interest (e.g. diagnostic, symptom, 
medications) need to be identified and listed according to the relevant source dataset 
terminology (e.g. selecting all ICD-10 terms for RTIs to assess RTI-related 
hospitalisations). There are thousands of potential terms per terminology, with a varying 
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number of terms (ranging from a handful to hundreds) required depending on what the 
disease state is, and how specific a researcher is aiming to be.   
Codelists are created using an iterative process; terms are searched for in dictionaries, 
and then combined to produce an optimal set which is then categorised or labelled.  
In CALIBER, the production of code lists is assisted by the use of; (1) the CALIBER Data 
Portal, a web portal for researchers to access descriptions of contributed CALIBER clinical 
phenotypes (phenotypes), the underlying development process and codelists of Read, 
ICD-10 or OPCS codes used to define them and (2) R packages created by Dr Anoop Shah; 
the R CALIBERcodelist package (139, 140). The process of code list production is 
illustrated in Figure 6, which is followed by an explanation of each of the labelled steps. 
Figure 6. Process for generating a codelist using the R CALIBER codelists package. 
 
1) Review source dictionaries and decide which ones to use, e.g. READ, ICD-10 and/or 
OPCS dictionaries. 
2) Use these source dictionaries to create a selection of terms relevant to the individual 
query (e.g. by selecting all terms containing the word ‘infections’ or all ICD-10 codes 
beginning with ‘I10’). Combine selections using Boolean operators such as AND, OR 
or NOT to identify exactly which terms are of interest, or to exclude confounding 
terms. For example, if investigating respiratory tract infections, ‘urinary tract 
infections’ would be excluded.  
Chapter 4. Methods development of the CALIBER resource
Figure 4.4: Process for generating a codelist using the R CALIBERcodelists package
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1. Decide which source dictionaries to use, e.g. Read, ICD-10 and/or OPCS.
2. Create a selection of terms from the source dictionaries. e.g. all terms containing the word ‘angina’,
or all ICD-10 codes beginning with ‘I20’. Combine selections using Boolean operators such as AND,
OR or NOT to identify exactly which terms are of interest.
3. Allocate a category to terms in a particular selection, e.g. ‘history of angina’.
4. Set the metadata for the codelists under construction (version number, category descriptions, author
name, date). Extract the Read, ICD-10 and OPCS codelists and save them in a standard ﬁle format.
5. Ask clinicians and epidemiologists to review the codelists and suggest any changes. Also it may
be useful to validate the codelist by exploring CALIBER data, e.g. comparing myocardial infarction
records extracted using a Read codelist versus records in MINAP. The algorithm can be changed and
the results compared with the previous version if necessary.
6. Approved codelists with documentation can be shared on the CALIBER data portal (section 3.7 on
page 61) for use in subsequent studies.
developed by the CALIBER data manager to automatically extract records of interest
from the CALIBER master database. All codelists stored on the data portal have a version
number in order to track which versions of each codelist were used for a particular project.
4.3.6 Phenotyping algorithms
The phenotype of an individual is the set of observable characteristics about that person,
which may include clinical measurements such as height and blood pressure, or disease
states such as diabetes or coronary artery disease. In electronic health record research,
one is interested in studying the phenotype but the information about the phenotype is
what is recorded in the electronic health record. It is crucial to understand the process by
which information about a subject enters the record in order to be able to interpret it and
infer the phenotype correctly [178].
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3) Create a category name for terms in a particular selection, e.g. ‘URTIs’ or ‘Down’s 
Syndrome’ 
4) Set the metadata for the codelists under construction (version number, category 
descriptions, author name, date). Extract the READ, ICD-10 and OPCS codelists and 
save in a standard format. 
5) Undertake a consensus meeting with clinicians and epidemiologists who have 
expertise in the relevant field in order to review the codelists and suggest any 
changes. The algorithm may be iteratively changed with results compared with 
previous versions if necessary, which may prompt a return to Step 2 of the codelist 
generation process. 
6) Approved codelists with documentation can be shared on the CALIBER data portal for 
use in subsequent studies. 
Chapter 4 describes the codelist generation process for the relevant codelists for the 
remainder of this thesis. 
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Chapter 4: Down’s Syndrome and RTIs in CALIBER 
4.1 CHAPTER OUTLINE 
In preparation for the remainder of the next chapters of this thesis, which assess RTI-
related healthcare utilisation and effects of antibiotics on reducing RTI-related 
complications, this chapter describes the process of defining clinical phenotypes for RTIs, 
Down’s Syndrome and other variables of interest (e.g. co-morbidities), the selection of 
the study population (i.e. children with Down’s Syndrome and controls), exposures (e.g. 
consultations, antibiotic prescriptions) and outcomes (e.g. hospitalisations).  
4.2 PHENOTYPING RESPIRATORY TRACT INFECTIONS 
In this section, I detail the process of developing the phenotyping algorithm for RTIs used 
for the next chapters in this thesis.  
In cases of cardiovascular disease, MINAP, the gold standard in recording acute coronary 
events, is utilised alongside CPRD and HES within CALIBER. In contrast, for RTIs, only CPRD 
and HES data sources are available to classify whether a patient has an RTI at a particular 
point in time and attempts to identify the type of RTI.  
RTIs can be classified using either diagnostic or symptom codes or both, each of which 
has potential limitations:  
Diagnosis codes: Assuming the patient and/or healthcare professional know what type 
of RTI the patient has, it can theoretically be coded using the specific Read or ICD-10 code. 
However, some codes are still non-specific, for example ‘respiratory tract infection’ could 
either mean URTI or LRTI. In addition, some patients may have conflicting diagnostic 
codes issued on the same day.  
Symptom codes: In contrast to diagnostic codes, these do not clearly identify the clinical 
diagnoses and may range from ‘cough’ to ‘fever’. For example, based on clinical 
knowledge, blocked nose can be a symptom of seasonal rhinitis or URTI and may be 
classed as either. Similarly, fever, a sensitive but non-specific marker for an infection, may 
be a possible RTI.   
In developing the algorithm, I reviewed previously published code lists for identifying RTIs 
in UK primary and secondary care datasets. Where code lists were unpublished, authors 
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(26 in total) were contacted to provide code lists (16 provided). After merging duplicate 
code lists, a unique code list was compiled. 
Concurrently, diagnostic and symptom codes were searched through the Read and ICD-
10 dictionaries using the R CALIBERcode package using the search terms listed in the 
Appendix. Codes identified were marked as “definite exclude”, “definite include” and 
“unsure”. Codes from the latter two categories were subsequently merged with the 
unique code list compiled above. 
All Read and ICD-10 codes ever recorded in the cohort of adults and children with DS and 
controls in CALIBER were then sourced, collated and merged with the unique code list 
derived above. Any matches were deemed as “marked”. 
All unmarked Read and ICD-10 codes (i.e. codes that were being recorded in the 
population of interest in the CALIBER dataset but not identified to be of interest in the 
earlier steps) were then reviewed by myself and Dr Nischchay Mehta, an ENT Registrar 
and Wellcome Trust Fellow to identify codes that may have been missed. These were 
again marked as “definite exclude”, “definite include” and “unsure”.  
Codes that both reviewers marked as “definite exclude” were dropped. Any discrepancies 
between codes marked as “definite exclude” by one reviewer but not by another were 
discussed and resolved. These codes were subsequently reviewed by an academic GP, Dr 
Mark Ashworth, at King’s College London Department of Primary Care and Public Health 
Sciences. 
At a consensus meeting that included my academic supervisors; an ENT surgeon (Prof. 
Anne Schilder), paediatrician (Prof. Monica Lakhanpaul) and an infectious diseases 
epidemiologist (Prof. Andrew Hayward), these codelists were discussed and finalised.  
Codes were classified as either “URTI”, “LRTI” or “Unclassified RTI” (i.e. Uncertainty on 
whether it was a URTI or LRTI) and then sub-categorised as either “Probable” or 
“Possible”. 
I performed a sensitivity analysis by different levels of certainty of RTIs (i.e. “Probable” 
vs. “Possible”) and in view of similar findings, a sensitive code list incorporating both 
categories were utilised for subsequent chapters of this thesis. This is detailed in the 
Appendix. 
 69 
4.3 DOWN’S SYNDROME & CO-MORBIDITIES 
A similar process was undertaken to phenotype DS and co-morbidities. In the latter, a 
review of publications on respiratory disorders in DS was undertaken to compile a list of 
co-variates that could influence either the frequency or severity of RTIs (43, 47, 141). 
This is detailed in Table A 1. The codelist for Down’s Syndrome is included in Table A 2. 
4.4 ANTIBIOTICS 
I identified antibacterial agents listed in any chapter of the British National Formulary 
(BNF) using Multilex codes described above (142). Analyses were subsequently restricted 
to antibacterial agents listed in chapter 5.1 of the BNF excluding antituberculous and 
antileprotic drugs (BNF chapters 5.1.9 and 5.1.10). The class of a given antibacterial 
prescription is based on subchapters of BNF Chapter 5.1, the titles of which I have used 
in subsequent chapters of this thesis. All antibiotics were considered, in line with the 
approach of previous CPRD studies of antibiotic prescribing, and it was assumed there 
were no a priori differences in prescribing trends and patterns for children with DS (21).  
4.5 STUDY POPULATION 
The selection process of children with DS and controls from the CALIBER dataset 
alongside GP consultations, hospitalisations and primary care prescriptions is described 
in Figure 7 below.  
Figure 7. Overarching Diagram of Cohort, Consultation, Hospitalisations and Therapy. 
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This cohort is utilised as the basis for all subsequent analyses with all baseline 
characteristics (e.g. Date of Birth, Cause of Death, Date of GP registration, IMD) of both 
children with DS and controls incorporated in a CALIBER data file labelled 
“DENOMINATOR”. 
4.5.1 Down’s Syndrome 
Figure 8 denotes the selection process of adults and children with DS from CALIBER. 
Figure 8. Selection process of children with DS from the CALIBER dataset. 
 
Adults and children with DS were identified in any of the CALIBER data sources between 
1st January 1997 to 25th March 2010 by searching for any of the Read codes for DS in CPRD 
and by ICD-10 codes in HES recorded as either the primary or secondary discharge 
diagnosis.  
Patients started contributing study data from either the latest date of: (i) 1 January 1997, 
(ii) the date at which the GP practice provided “up-to-standard” data, (iii) the date the 
patient registered with the GP practice or (iv) their date of birth. 
This was deemed their date of entry into the cohort (i.e. entry date). 
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Patients were followed up while registered at the practice until the earliest date of: (i) 25 
March 2010, (ii) the last date of data collection from the GP, (iii) the date the patient 
transferred out of the database (i.e. leaves the GP practice) or (iv) their date of death. 
This was deemed their date of exit from the cohort (i.e. exit date). Individuals with an exit 
date prior to their entry date (i.e. patient records with data quality issues) were removed 
(n=324). A total of 2,876 adults and children with DS remained. Those who were more 
than 18 years old at the entry date were subsequently excluded from the study. A total 
of 992 children with DS remained. 
4.5.2 Controls 
For each of 2,876 adults and children with DS, five controls were frequency matched by 
GP, gender, birth year (±5y) and starting date of follow-up totalling to 14,380 controls.  
In frequency matching, matching is done by groups of subjects rather than individually. 
For example, if there are 50 children with DS, a control population with the same age 
distribution is selected. Whilst both individual and frequency matching have their relative 
advantage and disadvantages, the latter was chosen as it was easier to perform than 
individual matching and it allowed subsequent analysis of the effects of matching 
variables on the outcomes. 
Similar to adults and children with DS, only individuals with an exit date after their entry 
date were selected. Individuals older than 18 years old at the entry date were 
subsequently excluded from the study. A total of 4,874 controls remained.  
The flow diagram of the selection process of controls is shown in Figure 9. 
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Figure 9. Selection process of controls from the CALIBER dataset. 
 
4.5.3 Clinical and Demographic Characteristics of the Cohort 
Age 
I categorised age at entry into the cohort into four age-bands based on clinical consensus 
of the impact RTIs may have on different age groups; infants (0 to 1-year-old), toddlers 
(1 to 5 years old), juniors (5 to 10 years old) and young persons’ (10 to 18 years old).  
This stratification was chosen in order to group by known risk of RTIs across age groups. 
Children are at the highest risk for RTIs in the first year of life, with respiratory infections 
being the greatest cause of morbidity and mortality in this age group, hence the 0-1 
category. Risk is also increased, although less so, in the 1-5 year old category relative to 
older children (143). There is less evidence of varying risk between the 5-10 and 10-18 
years old age categories, so these divides were chosen because of the behavioural and 
educational changes relevant to these age groups. From 5 to 10, most children will have 
commenced regular education. Between the ages of 10 to 18, children go through 
adolescence and may commence secondary education.  
Due to the length of follow-up in this longitudinal cohort, these children may have 
participated in several age groups over time. For example, a child who entered the cohort 
at age three and was followed up for ten years in CALIBER would have his or her follow-
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up time segregated across the 1-5 (toddlers), 5-10 (juniors) and 10-18 years (young 
persons) age groups.  
To prepare for analyses, a separate patient record with unique identifiers was created for 
each age category with entry and exit dates corresponding to when the child entered and 
exited the age group.  
Using the example above, three patient records would be created corresponding to age 
3-5, 5-10 and 10-13. Patient records with a follow up time of less than 30 days were not 
included in subsequent analyses. 
In Figure 10 two examples are illustrated. I created a total of 1,711 patient records for 
the 992 children with DS and 8,435 patient records for the 4,874 controls for analyses in 
the subsequent chapters of my thesis.  
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Figure 10. Process for creating patient records for subsequent 
consultation/hospitalisation rates calculations. 
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Co-morbidities 
I deemed study participants to have a co-morbidity of interest (e.g. CHD) if a relevant 
READ (i.e. GP consultation) or ICD-10 (i.e. hospitalisation) code was recorded at any point 
between their entry and exit dates. Details of how each condition was phenotyped and 
subsequently selected is described above. 
IMD quintile 
In CALIBER, Index of Multiple Deprivation (IMD) information is supplied by the ONS. 
IMD scores are calculated using a number of indicators; (i) Income, (ii) Employment, (iii) 
Health and disability, (iv) Education, skills and training, (v) Barriers to housing and 
services, (vi) Crime and (vii) Living environment (101). These then produce an overall 
score for an individual postcode which represents the level of deprivation in that area. 
IMD scores are commonly stratified into quintiles, with Quintile 1, a score of ≤ 8.49, 
representing the least deprived quintile, and Quintile 5, a score of ≥ 34.18, representing 
the most deprived quintile. I established the IMD quintile of children with DS and their 
controls by separating them out according to their IMD scores into an individual 
Quintile. 
Ethnicity 
I established the ethnicity of adults and children with DS and their controls using the 
method described by Jensen, et al. (141) which assessed the completeness and 
consistency of ethnicity recording in the CALIBER dataset.  
In CALIBER, ethnicity data is provided in the HES dataset under 16 ethnic categories and 
in CPRD as Read codes. Relying on HES data alone, the 56.4% of individuals (3264 out of 
5783) with Unknown ethnicity recorded consisted of 60.0%) of controls and 39.0% of 
children with Down’s Syndrome.  
Using the process illustrated in Table 5, this was reduced to five categories consisting of; 
(1) White, (2) Black or Black British (i.e. Bl_Afric, Bl_Other, Bl_Carib), (3) Mixed (4) Asian 
or Asian British (i.e. Pakistani, Bangladeshi, Indian, Oth_Asian) and (5) Chinese or Other 
Group (i.e. Chinese and Other). 
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Table 5. The 16 groups of the 2001 Census for England and Wales mapped to the 5 
collapsed categories. 
16 groups 5 Categories 
1 British 1.White 
2 Irish  
3 Any other White background (write in)  
4 White and Black Caribbean 2. Mixed 
5 White and Black African  
6 White and Asian  
7 Any other mixed background (write in)  
8 Indian 3. Asian or Asian British 
9 Pakistani  
10 Bangladeshi  
11 Any other Asian background (write in)  
12 Caribbean 4. Black or Black British 
13 African  
14 Any other Black background (write in)  
15 Chinese 5. Chinese or Other Group 
16 Any other ethnic group (write in)  
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4.6 STUDY EXPOSURES AND OUTCOMES  
All GP consultations, hospitalisations and primary care prescriptions on the cohort were 
extracted from the CALIBER database as separate data files. The steps below detail the 
process of preparing these data files for analyses in the next chapters of my thesis into a 
single CALIBER data file. 
4.6.1 Primary care 
In total, there were 1,507,367 entries in primary care within the CALIBER dataset, of 
which 340,712 were from children with DS and 1,166,655 were from controls. The 
process of curating these data is illustrated in Figure 11. Table 6 shows the consultation 
IDs used in selecting relevant consultations of interest. 
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Figure 11. Selection process of GP consultations of RTIs and co-morbidities of interest in 
children with DS and controls within the CALIBER dataset. 
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Table 6. Consultation IDs utilised in selecting relevant GP consultations of interest (e.g. 
Inputted by a clinician rather than administrative staff). 
Clinical episode constype 
Clinic 1 
Night visit, Deputising service 2 
Follow-up/routine visit 3 
Night visit, Local rota 4 
Night visit, practice 6 
Out of hours, Practice 7 
Out of hours, Non-Practice 8 
Surgery consultation 9 
Acute visit 11 
Emergency Consultation 18 
Casualty Attendance 20 
Hospital Admission 23 
Children's Home Visit 24 
Home Visit 27 
Hotel Visit 28 
Nursing Home Visit 30 
Residential Home Visit 31 
Twilight Visit 32 
Triage 33 
Walk-in Centre 34 
Co-op Surgery Consultation 36 
Co-op Home Visit 37 
Minor Injury Service 38 
Community Clinic 40 
Initial Post Discharge Review 48 
Night Visit 50 
4.6.2 Secondary care 
There was a total of 36,534 hospitalisations in children with DS and 77,401 from controls. 
The process of curating these data is denoted in Figure 12.  
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Figure 12. Selection process of hospitalisations due to RTIs and co-morbidities of 
interest in children with DS and controls within the CALIBER dataset. 
 
4.6.3 Respiratory Tract Infections 
A proportion of RTI events were noted to have been recorded on the same date for the 
same patient. For example, a probable URTI consultation and a possible LRTI 
hospitalisation could be recorded in the same data for the same patient.   
RTIs were therefore categorised following a ranking system based on RTI-type, setting 
and whether it was probable or possible (based on codelists developed earlier). This is 
illustrated in Table 7 below. For example, based on the previous example of a probable 
URTI consultation and possible LRTI hospitalisation on the same day, the latter would 
prevail.  
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This led to a reduction in the total number of RTI-related GP consultations analysed from 
20,889 to 19,970 (-4.4%) and RTI-related hospitalisations from 826 to 800 (-3.1%), a total 
of 945 events, of which 83 were LRTIs, 373 were URTIs, and 489 were unclassified RTIs.  
Table 7. RTI ranking system utilised in prioritising RTI types and settings where conflict 
arose. 
 Disease Probable/Possible Dataset 
1 LRTI Probable SECONDARY CARE 
2 LRTI Possible SECONDARY CARE 
3 URTI Probable SECONDARY CARE 
4 URTI Possible SECONDARY CARE 
5 Unclassified RTI Probable SECONDARY CARE 
6 Unclassified RTI Possible SECONDARY CARE 
7 LRTI Probable PRIMARY CARE 
8 LRTI Possible PRIMARY CARE 
9 URTI Probable PRIMARY CARE 
10 URTI Possible PRIMARY CARE 
11 Unclassified RTI Probable PRIMARY CARE 
12 Unclassified RTI Possible PRIMARY CARE 
 
4.6.4 Prescriptions 
There was a total of 458,793 prescriptions in children with DS and 966,468 prescriptions 
in controls issued in primary care. The process of curating these data is denoted in Figure 
13. 
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Figure 13. Selection process of all prescriptions of interest (e.g. Systemic) in children 
with DS and controls within the CALIBER dataset. 
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Chapter 5: RTI-Related Healthcare Utilisation in UK Children with 
Down’s Syndrome   
ABSTRACT 
Background 
Children with RTIs present often to GP services in the UK, particularly in the winter 
months when there are higher levels of circulating respiratory tract viruses. For most 
children, RTIs are commonly a mild and relatively short viral illness. In some children, 
particularly ‘at-risk’ children such as those with DS, RTIs can quickly become more 
serious and result in hospital admissions.  
This retrospective cohort study aims to quantify RTI-related primary and secondary 
healthcare utilisation and treatments (e.g. antibiotics) in children with DS and 
controls alongside the risk of RTI-related hospitalisation, time to RTI-related 
hospitalisation, and re-consultation with their GP. 
Methods 
I used a longitudinally linked primary care, hospital admission, disease registry, and 
mortality dataset for England (the CALIBER programme). The study population 
comprised children aged 0-18 with at least one record of DS matched with five 
controls from the same GP, gender, birth year, and date of entry into CALIBER.  
I followed up individuals for occurrences of RTIs and antibiotic prescriptions recorded 
in either the primary or secondary care dataset between 1997 and 2010. I used 
Poisson regression to calculate consultation, hospitalisation, and antibiotic 
prescription rates. I used the Wilcoxon test to compare hospitalisation length of stay. 
I stratified analyses according to year, age, gender, RTI type (e.g. URTI, LRTI, and 
unclassified RTI), season (e.g. seasonal influenza/RSV), and co-morbidities (e.g. CHD). 
I assessed the proportion of RTI-related consultations leading to an RTI-related 
hospitalisation in children with DS and controls, the time to hospitalisation following 
an RTI-related GP consultation, proportion of RTI-related hospitalisations occurring 
without a prior RTI-related GP consultation and proportion of RTI-related 
consultations with a subsequent GP re-consultation.  
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Results 
RTI-related healthcare utilisation (i.e. GP consultations, hospitalisations) is 
significantly higher in children with DS compared to controls for both GP 
consultations (Adjusted RR 1.73; 95% CI 1.62-1.84) and hospitalisations (Adjusted RR 
5.70; 95% CI 4.82-6.71). This was consistent throughout the study period (1997-2010) 
and was most pronounced for LRTI-related GP consultations (Adjusted RR 3.59; 95% 
CI 3.19-4.04) and hospitalisations (Adjusted RR 11.30; 95% CI 8.45-15.10). Overall, the 
length of stay in hospital due to RTIs was longer for children with DS (Mean 5.2; 95% 
CI 5.0-5.4 days per admission) compared to controls (Mean 2.4; 95% CI 2.2-2.6).  
Children with congenital heart disease (CHD) and DS had higher rates of RTI-related 
hospitalisations compared to children with CHD and without DS (Adjusted RR 3.15; 
95% CI 1.02-9.68), but there was no difference in RTI-related GP consultations. 
Children with asthma and DS had higher rates of RTI-related hospitalisations 
(Adjusted RR 4.03; 95% CI 2.79-5.83) and RTI-related GP consultations (Adjusted RR 
2.11; 95% CI 1.78-2.51) compared to children with asthma and without DS. 
The risk of an RTI-related hospitalisation following an RTI-related GP consultation was 
higher in children with DS compared to controls (Adjusted RR 3.15; 95% CI 2.35 – 
4.24). In those hospitalised, the time to hospitalisation was similar in children with DS 
(median of 8.0 days; 95% CI 3.0-19.0) and in controls (median of 8.0 days; 95% CI 2.0-
18.0).   
The odds of re-consultation with a GP for an RTI following an initial RTI-related GP 
consultation was higher in children with DS with 24.3% re-consulting compared to 
16.0% of matched controls (OR 1.69; 95% CI 1.57-1.82).   
A high proportion of RTI-related hospitalisations were not preceded by a RTI-related 
GP consultation in both children with DS (74.1%; 95% CI 68.9-78.5%) and matched 
controls (73.4%; 95% CI 67.0-78.8%). 
Antibiotic prescribing was markedly higher in children with DS compared to controls 
over the entire study period (Adjusted RR 2.34; 95% CI 2.19-2.5). When restricted to 
antibiotics prescribed on the same day as an RTI-related GP consultation, this 
relationship persisted (Adjusted RR 2.26; 95% CI 2.1 – 2.43).   
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Differences in RTI-related antibiotic prescriptions were more apparent in LRTIs 
(Adjusted RR 3.74; 95% CI 3.3-4.25) compared to other RTIs. Infants with DS were 
prescribed the most antibiotics for RTIs compared to all other age groups.  
Discussion 
This is the first study of RTI healthcare utilisation in children with DS compared to 
controls utilising linked primary and secondary care data. Children with DS have 
higher rates of primary care consultations, antibiotic prescribing, hospitalisations, 
and longer hospital stays compared to controls.  
Children with DS are also more likely to be hospitalised following an RTI-related GP 
consultation and to re-consult with their GP for an RTI compared to controls. 
In the next chapter, I will build on this to assess the effects of antibiotic prescribing in 
reducing the risk of RTI-related hospitalisation in children with DS compared to 
controls.   
5.1 CHAPTER OUTLINE 
This chapter aims to establish RTI-related healthcare utilisation in children with DS and 
compares this to controls. I have applied a retrospective cohort study design using 
CALIBER. Details of this data source, together with phenotyping algorithms for RTIs, 
Down’s Syndrome, co-variates and selection of the study population and exposures (i.e. 
consultations, hospitalisations and prescriptions), are reported in Chapter 4. 
5.2 BACKGROUND 
Thus far, only international studies of RTI-related hospitalisations in children with DS have 
been undertaken, with no comparisons to controls and no epidemiological studies of RTIs 
in children with DS in the UK published.  
Uncertainty therefore remains around the burden of RTIs on children with DS in both 
primary and secondary care. Moreover, in the absence of comparisons to controls, 
clinicians and healthcare professionals are unable to quantify the relative risk of RTI-
related hospitalisation and re-consultation in children with DS to families and carers, or 
which children with DS are most at-risk. 
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This chapter aims to address the evidence gap by utilising the longitudinally linked 
CALIBER dataset, encompassing records of over 10 million individuals across both primary 
and secondary care, to undertake a retrospective cohort study of children with DS 
compared to controls. 
5.3 AIMS & OBJECTIVES 
5.3.1 Aim 
To quantify NHS healthcare utilisation attributable to RTIs in children with and without 
DS from 1997 to 2010 and to ascertain which children, with and without DS, are most at 
risk of increased RTI-related NHS healthcare utilisation. 
5.3.2 Objectives 
1. To investigate whether RTI-related GP consultations and hospitalisations differed 
in children with DS and controls; 
2. To investigate whether RTI-related GP consultations and hospitalisations varied by 
gender and co-morbidities that influence RTI-related healthcare utilisation; 
3. To assess whether RTI-related GP consultations and hospitalisations varied 
between and across age groups in children with DS and controls; 
4. To explore whether hospital length of stay differed between children with DS and 
controls; 
5. To investigate whether children with DS were more likely to be hospitalised 
following an RTI-related GP consultation compared to controls; 
6. To establish how soon after a RTI-related GP consultation were children with DS 
and controls hospitalised for an RTI; 
7. To examine the proportion of children with DS and controls who attended their 
GP for an RTI-related consultation preceding a RTI-related hospitalisation; 
8. To identify what proportion of children with DS and controls re-consult with their 
GP following an initial consultation for an RTI; 
9. To examine whether antibiotic prescribing and RTI-related antibiotic prescribing 
differed between children with DS and controls; 
 87 
5.4 METHODS 
5.4.1 Data Management 
5.4.1.1 Participants 
I described the selection of the study population together with assessment of the clinical 
and demographic characteristics of the cohort in the previous chapter, Chapter 4, 
“Down’s Syndrome and RTIs in CALIBER”.  
5.4.1.2 Sample size 
An Australian study of hospitalisations noted an average of 0.8 and 0.1 RTI-attributable 
hospital admissions in individuals with and without DS, respectively (71). To identify a 
difference in hospitalisation rates as large as this between the two groups at 80% power 
using a 5% significance level, 20 individuals per group with the hospitalisation rates above 
would be required. If confounding and effect modification are accounted for in this 
analysis, the sample size required to detect this difference increases by 10% for each 
variable considered and is increased four-fold if an effect modifier is included using an 
interaction term. There are approximately 992 children with DS in the CALIBER linked 
dataset to account for this.  
5.4.1.3 Respiratory Tract Infections 
Read and ICD-10 codes used to select RTIs are listed in Table A 2 and Table A 3 
(Appendix), respectively. The processes for selecting RTI-related GP consultations and 
hospitalisations are described in further detail in the previous chapter. 
5.4.1.4 Antibiotic treatment 
I selected and categorised antibiotic prescriptions into nine classes as detailed in the 
BNF; Benzylpenicillin & Phenoxymethylpenicillin, Broad-Spectrum Penicillins, 
Cephalosporins and Other Beta-Lactams, Macrolides, Metronidazole & Tinidazole, 
Penicillinase Resistant Penicillins, Quinolones, Sulphonamides & Trimethoprim and 
Tetracyclines.  
I linked these nine classes with all GP consultations irrespective of Read codes (i.e. 
reason for prescribing an antibiotic). This therefore included consultations with no 
relevant Read codes for RTIs and was utilised to ascertain differential coding behaviour 
for the two groups in general.  
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Identified consultations with same-day antibiotic prescriptions were subsequently 
linked with GP consultations corresponding with Read codes for RTIs to determine RTI 
specific prescribing rates.  
This approach matched that of other papers investigating RTI-related antibiotic 
prescribing, which also matched relevant RTI codes with antibiotic prescriptions 
occurring on the same day (21, 144). An alternative approach could have been to also 
consider Co-Amoxiclav and Amoxicillin prescriptions without Read codes, as these 
antibiotics are most commonly prescribed to treat RTIs; however, due to the possibility 
that such prescriptions were prophylactic or rescue prescriptions, this was not done 
(145).  
5.4.2 Data Analyses 
All data management and analysis was performed using STATA statistical software 
version 13 (146) and R version 3.2.3 (147) via the UCL Data Safe Haven (148). 
5.4.2.1 Consultation, Hospitalisation and Prescription Rates 
I used Poisson regression to calculate consultation, hospitalisation and prescription rates 
and rate ratios and their corresponding 95% confidence intervals. Within CALIBER, 
consultation and prescription rates were sourced from CPRD, and hospitalisation rates 
were sourced from HES. I computed rates by dividing the number of episodes during the 
active period in the database by the total number of active person years (pyr) for both 
the children with DS and the matched control groups. Persons who are active in the 
database are those who are alive and currently registered.  
5.4.2.2 Hospital length of stay 
For admissions lasting greater than one day, the length of stay was calculated as 
“discharge date – admission date”. For admissions occurring solely over the course of one 
day, I calculated the length of stay as the “discharge date – admission date + 1 day” in 
order to avoid the implication that a zero-day admission meant children were not 
admitted to hospital at all. Since 2010, the numbers of zero day admissions have risen by 
over 90% so it was important to capture this group (149). 
I reported the length of hospitalisation in both means and medians due to the highly 
skewed distribution of hospitalisation lengths. The Wilcoxon non-parametric test was 
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used to compare length of stay by RTI type due to the skewed distribution. This test 
determines if there is a difference in the variance (or location/central tendency of the 
data) in two groups – in this case the DS and control groups.  
5.4.2.3 Subgroup Analyses – Year, Age Group, Gender, IMD quintile, RTI type,  
I conducted analyses across years, age groups, gender, IMD quintile and by RTI type (i.e. 
URTI/LRTI/unclassified RTI, with the unclassified RTI label indicating uncertainty as to 
whether it was a URTI or LRTI). Since different distributions in co-morbidities that are part 
of DS could drive major differences in healthcare utilisation, the prevalence of co-
morbidities was established using the code lists described in Chapter 3. This was done 
with the intention to analyse by co-morbidities which may influence RTI-related 
healthcare utilisation. Analyses by age and IMD quintile were undertaken between 
children with DS and controls in the same age group, and across ages and IMD quintiles 
within children with DS and controls. 
5.4.2.4 Subgroup Analyses - Seasonality 
I visualised the seasonal trend of RTIs in children with DS and controls through a week-
by-week histogram graph.  
In the UK, RSV season occurs during October (week 40) to March (week 19) each year 
(150). The influenza season typically lasts from November to March. I calculated the rate 
of RTI events during the Influenza/RSV season using RTIs events between the 40th week 
of the year and the 19th week of the subsequent year and compared this to the rate of 
RTI events occurring in the rest of the year. 
5.4.2.5 Baseline risk of hospitalisation following a consultation  
All GP consultations for RTIs, irrespective of type (i.e. URTI/LRTI/unclassified RTI), were 
defined as the exposure; whilst all RTI-related hospitalisations were considered as the 
outcome or complication.  
A systematic review which determined the duration of symptoms of earache, sore throat, 
cough, bronchiolitis, croup and common cold in children was identified (151).   
This review found that in 90% of children, earache was resolved by seven to eight days, 
sore throat between two and seven days, croup by two days, bronchiolitis by 21 days, 
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acute cough by 25 days, common cold by 15 days, and non-specific respiratory tract 
infections symptoms by 16 days.  
A 28-day window was therefore utilised as the at-risk period for an RTI-related 
complication/hospitalisation. Each consultation for an RTI was followed up for up to 28 
days or the first hospitalisation for an RTI within 28 days.  
An illustration of this process is provided in Figure 14. Events (A) to (D) all are linked to 
the same patient, X12345. 
Figure 14. Process for identifying RTI-related hospitalisations following RTI-related GP 
consultations. 
 
A GP consultation for an RTI would be considered a new exposure if it occurred more 
than 28 days after the previous event. For example, Event (D) is considered a new event 
as it occurred after 28 days from Event (C). However, Event (B) is not considered a new 
event as it occurred less than 28 days after Event (A), and it is thus flagged as an excluded 
value.  
A distribution of time-to-hospitalisation is displayed and compared using the Wilcoxon 
non-parametric test due to the highly-skewed distribution. By completing this analysis, 
hospitalisations linked to a prior GP consultation could be identified, which then allowed 
analysis in Chapter 6 of the effect of antibiotic prescriptions in primary care on the rate 
of subsequent hospitalisation.  
RTIs were given a hierarchical rank with secondary care superseding primary care 
irrespective of whether it involved an upper or lower respiratory tract infection (e.g. 
  Event (A)                     X12345                     YES  
  Event (B)                     X12345              excluded value 
  Event (C)                     X12345                       NO 
  Event (D)                     X12345                     YES
   event ID               patient number               ﬂag
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Primary care consultation for LRTI on D1 followed by a URTI hospitalisation on day 4 was 
classified as a URTI). This strategy was chosen because it was assumed that diagnoses in 
secondary care would be more accurate, given the wider array of diagnostic tools 
available to clinicians in these settings. A systematic review comparing hospital discharge 
coding against medical records found that UK hospital diagnostic coding is 91% accurate 
(152).  
5.4.2.6 Hospitalisations preceded by consultations 
All RTI-related hospitalisations in the cohort were identified with a 28-day “look-back” 
undertaken to identify the proportion of hospitalisations preceded by a GP consultation 
for an RTI, shown in Figure 15. Events (A) to (D) all are linked to the same patient, X12345. 
Events (A) and (B) are flagged because in the 28-day “look back” period, a URTI, LRTI or 
unspecified RTI consultations in primary care was identified (denoted by an arrow). For 
Events (C) and (D), no RTI consultation was identified, so they are not flagged as 
hospitalisations preceded by consultations.  
Figure 15. Process for identifying RTI-related consultations preceding RTI-related 
hospitalisations. 
 
5.4.3 Scientific Approval  
I obtained scientific approval for the study from the CPRD ISAC under the remit of ISAC 
protocol 15_041R: ‘Respiratory tract infections in Down’s Syndrome’.  
 
 
 
 
  Event (A)                     X12345                     YES  
  Event (B)                     X12345                      YES 
  Event (C)                     X12345                       NO 
  Event (D)                     X12345                      NO
   event ID               patient number               ﬂag
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5.5 RESULTS 
5.5.1 Cohort size, demographics and co-morbidities 
I identified 992 children with DS. They were followed up for a total of 4,681 person-years 
at risk, a mean of 4.72 years per child. Their 4,874 frequency controls were followed up 
for a total of 22,837 person-years at risk, a mean of 4.69 years per child. The 
demographics of the study populations are shown in Table 8. 
The children were similarly distributed among the four age categories (25.6% infants, 
23.2% toddlers, 21.3% juniors and 29.8% young persons). As ethnicity was not used in 
subsequent analyses, I did not seek to address missing data by use of methods such as 
multiple imputation. 
The unadjusted prevalence of CHD and hypothyroidism were higher in children with DS 
compared with controls, whilst asthma was similarly common in both groups. CHD and 
asthma were both analysed in subgroup analyses. 
Table 8. Demographic characteristics of the cohort. 
  Control Children with DS 
Patient 4874 (100.0%) 992 (100.0%) 
Gender   
   Male 2626 (53.9%) 528 (53.2%) 
   Female 2248 (46.1%) 464 (46.8%) 
Age at Entry into Cohort   
   Infants (0-1 year) 1247 (25.6%) 252 (25.4%) 
   Toddlers (1-5 years) 1133 (23.2%) 224 (22.6%) 
   Juniors (5-10 years) 1044 (21.3%) 208 (21.0%) 
   Young Persons (10-18 
years) 
1454 (29.8%) 308 (29.8%) 
Ethnicity   
   Asian or Asian British 211 (2.5%) 56 (3.3%) 
   Black or Black British 189 (2.4%) 48 (2.8%) 
   Chinese or ‘Other’ Group 114 (1.35%) 30 (1.7%) 
   Mixed 393 (4.7%) 72 (4.2%) 
   Unknown 4005 (47.5%) 504 (29.5%) 
   White 3523 (41.8%) 1001 (58.5%) 
Co-morbidities   
   Asthma 618 (12.7%) 136 (13.7%) 
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   CHD 48 (1.0%) 393 (39.6%) 
   Diabetes 20 (0.4%) 11 (1.1%) 
   Epilepsy 34 (0.7%) 18 (1.8%) 
   Thyroid 11 (0.2%) 103 (10.4%) 
5.5.2 Comparison with known prevalence rates for children with DS 
The calculated prevalence of DS within the CALIBER cohort is 0.034%. This compares to 
an estimated prevalence of DS in England and Wales of 0.066% when a meta-analysis of 
papers assessing survival rates for DS was applied to data from the National Down 
Syndrome Cytogenetic Register, which produces annual reports on the number of babies 
born with DS each year (3).  
When comparing the prevalence of comorbidities in DS, prevalence figures in this study 
are similar to those reported in existing literature. The calculated prevalence of CHD in 
DS of 39.6% compares to rates of 33.7% to 58.2% in other studies (153-156). A prevalence 
of 13.7% for asthma compares to rates of 3.1% to 19.4% (81, 157). Calculated prevalence 
figures of 1.1% for diabetes, 1.8% for epilepsy, and 10.4% for thyroid dysfunction in this 
study compare to prevalence figures of 0.3% (158), 1-13% (159), and 25-30% (160) 
reported by other studies and reviews.  
For the control group, the prevalence of comorbidities was mostly similar to other 
studies. A prevalence of CHD of 1.0% compares to a prevalence of 0.6-0.8% in other 
studies (161, 162). The prevalence of asthma of 12.7% was slightly higher than the 
reported prevalence of 9% from Asthma UK (163). Calculated prevalence figures of 0.4% 
for diabetes, 0.7% for epilepsy and 0.2% for thyroid dysfunction compare to prevalence 
figures of 0.2% (164), 0.5% (165), and 0.1% (166) reported elsewhere. 
5.5.3 Consultation and hospitalisation rates 
5.5.3.1 Across the cohort 
Over the study period between 1997 and 2010, RTI-related GP consultation and 
hospitalisation rates were consistently higher in children with DS compared to controls. 
The disparities increased over time from a 0.1 rate difference in RTI-related consultations 
in 1999 to a 0.3 rate difference in 2009, and a 0.04 rate difference in RTI-related 
hospitalisations in 1997 to a 0.07 rate difference in RTI-related hospitalisations in 2009. 
This is illustrated in Figure 16 below.  
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Figure 16. Annual RTI-related GP consultation and hospitalisation rates in children with 
DS compared to controls. 
 
5.5.3.2 Differences between consultations and hospitalisations 
Table 9 illustrates that across all RTI types (i.e. LRTI, URTI, and unclassified RTI), children 
with DS consistently experience consultations and hospitalisations for RTIs more 
frequently compared to controls.  
When adjusted for age group, children with DS are nearly twice as likely (Adjusted RR 
1.73; 95% CI 1.62-1.84) as matched controls to present to their GP with an RTI and six 
times more likely (Adjusted RR 5.70; 95% CI 4.82-6.71) to be admitted to hospital with an 
RTI.  
The differences between children with DS and controls were most pronounced for LRTIs 
in GP consultations (RR 3.59; 95% CI 3.19-4.04) and hospitalisations (RR 11.30; 95% CI 
8.45-15.10).  
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Table 9. RTI-related GP consultation (top) and hospitalisation (bottom) rates by RTI type 
in children with DS and controls. 
 
5.5.3.3 By age and gender 
Across all age groups, children with DS consult with their GP and are hospitalised for RTIs 
more commonly than controls. This is illustrated in Figure 17 below. 
For example, across 100 infants with DS (0-1 years old), there will be 150 RTI-related GP 
consultations and 52 hospitalisations. This is in contrast to 124 GP consultations and 8 
hospitalisations in matched controls.  
The differences between children with DS and controls are more pronounced in RTI-
related hospitalisations. For example, juniors with DS (5-10 years) are seven times more 
likely to be hospitalised compared to controls (Adjusted RR 7.33; 95% CI 5.08- 10.58). This 
is in contrast to RTI-related GP consultations where the rate ratio is 2.21 (95% CI 1.95-
2.50). 
 
 
 
 96 
Figure 17. RTI-related GP consultation and hospitalisation rates stratified by age group 
in children with DS and controls. 
 
 
Table 10. RTI-related GP consultation (top) and hospitalisation (bottom) rates stratified 
by age groups and compared between children with DS and controls. 
 
Similar to the pattern seen in Table 10, both children with DS and controls experience 
fewer consultations and hospitalisations due to RTIs as they get older. This is in keeping 
with existing literature that RTI healthcare utilisation is higher in infants compared to 
their older peers (167). This is illustrated in Table 11 below. The relative risk was 
calculated separately for children with DS and controls by using the age band ‘infants’ as 
a comparator. 
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Table 11. RTI-related GP consultation (top) and hospitalisation (bottom) rates stratified 
by age group and compared within children with DS and controls. 
 
 
As denoted in Table 12, females have lower RTI-related hospitalisation rates compared 
to males in both children with DS (Adjusted RR 0.70; 95% CI 0.55-0.89) and matched 
controls (Adjusted RR 0.69; 95% CI 0.54-0.88). There is no significant gender difference 
for RTI-related GP consultation rates for children with DS (Adjusted RR 1.08; 95% CI 0.96-
1.21) and matched controls (Adjusted RR 0.99; 95% CI 0.93-1.05). 
Table 12. RTI-related GP consultation (top) and hospitalisation (bottom) rates between 
gender stratified by children with DS and controls. 
 
5.5.3.4 By IMD 
There was no significant difference in RTI-related GP consultation and hospitalisation 
rates when stratified by IMD quintile, as illustrated by Table 13. For children with DS, the 
rates of GP consultations and hospitalisations in the least deprived quintile (Quintile 1) 
was 0.642 and 0.051, lower than rates of 0.765 and 0.079 in the most deprived quintile 
(Quintile 5) but the confidence intervals overlapped. Across each quintile, there was a 
pattern of children with DS engaging in more healthcare utilisation than controls, as 
described elsewhere in the thesis. 
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Table 13. RTI-related GP consultation (top) and hospitalisation (bottom) rates stratified 
IMD quintile and compared between children with DS and controls. 
 
 
 
The relative risk was also calculated separately for children with DS and controls by using 
the IMD Quintile 1 as a comparator, shown in Table 14. This quintile reflects the least 
deprived quintile of individuals. When this analysis was done, a significantly greater 
relative risk of GP consultations and hospitalisations were evident in children with DS 
living in Quintile 5 compared to children with DS living in Quintile 1. This was also the case 
for controls living in Quintiles 5, 2 and 4 relative to Quintile 1.  
Table 14. RTI-related GP consultation (top) and hospitalisation (bottom) rates stratified 
by IMD quintile and compared within children with DS and controls. 
 
5.5.3.5 By season 
The incidence of RSV, influenza and other respiratory infections varies by season. This is 
likely to influence healthcare utilisation in both children with DS and controls (168).  
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I analysed the weekly trends of RTI-related consultation and hospitalisation rates in 
children with DS and controls. The relative risk of consultations and hospitals, adjusted 
for age group, in the RSV-influenza season (Autumn and Winter) was compared against 
the same adjusted risk for the summer season, with results denoted in Figure 18 and 
Table 15. 
A significant difference in consultations and hospitalisations (Adjusted RR 1.17; 95% CI 
1.10-1.26) was noted in controls but not in children with DS. 
Figure 18. RTI-related consultations and hospitalisations in children with DS and 
controls by week. 
 
Table 15. RTI-related consultations and hospitalisations in children with DS and controls 
by season. 
 
5.5.3.6 RTI-related consultations and hospitalisations by co-morbidities 
Co-morbidities such as CHD and asthma may account for differences in healthcare 
utilisation between children with DS and controls. I therefore analysed RTI-related 
consultation and hospitalisation, first comparing those with DS and a particular 
comorbidity to those with DS who lack the comorbidity, and controls with to those 
without the comorbidity. Secondly, I compared children with DS and a comorbidity to 
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controls with same comorbidity, and then children with DS without the comorbidity to 
controls without the comorbidity.  
Congenital Heart Disease 
Children with DS and CHD have increased RTI-related consultation (Adjusted RR 1.21; 
95% CI 1.04-1.40) and hospitalisation rates (Adjusted RR 3.07; 95% CI 2.38-3.95) 
compared to children with DS without CHD. A similar pattern is observed in controls. 
These are illustrated in Figure 19 and Table 16 below. 
Figure 19. RTI-related consultations (left) and hospitalisations (right) in children with DS 
and controls with and without CHD. 
 
Table 16. RTI-related GP Consultation (top) and hospitalisation (bottom) rates between 
children with and without CHD stratified by DS. 
 
In those with CHD, children with DS and CHD have higher rates of RTI-related 
hospitalisation (Adjusted RR 3.15; 95% CI 1.02-9.68) but similar RTI-related GP 
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consultations compared to controls with CHD. In those without CHD, children with DS 
have both higher RTI-related GP consultations (Adjusted RR 1.70; 95% CI 1.58-1.82) and 
hospitalisations (Adjusted RR 4.17; 95% CI 3.42-5.08) compared to controls. This is 
illustrated in Table 17 below.  
Table 17. RTI-related GP Consultation (top) and hospitalisation (bottom) rates between 
children with DS and controls stratified by CHD status. 
 
Asthma 
Children with DS with asthma have increased RTI-related GP consultations (Adjusted RR 
2.06; 95% CI 1.74-2.44) compared to those without asthma, but not increased RTI-related 
hospitalisations. Controls with asthma have increased RTI-related GP consultations 
(Adjusted RR 1.75; 95% CI 1.61-1.90) and also RTI-related hospitalisations (Adjusted RR 
2.65; 95% CI 2.01-3.50) relative to controls without asthma. These results suggest that 
asthma may increase the risk of RTI-related healthcare utilisation for both groups. This is 
detailed in Figure 20 and Table 18 below. 
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Figure 20. RTI-related GP consultations and hospitalisations in children with DS (left) 
and controls (right) with and without asthma. 
 
 
Table 18. RTI-related GP Consultation (top) and hospitalisation (bottom) rates between 
children with and without asthma stratified by DS. 
 
Amongst children with asthma, children with DS and asthma have significantly more RTI-
related GP consultations (Adjusted RR 2.11; 95% CI 1.78-2.51) and hospitalisations 
(Adjusted RR 4.03; 95% CI 2.79-5.83) compared to controls with asthma. Amongst 
children without asthma, children with DS still have higher RTI-related GP consultations 
(Adjusted RR 1.70; 95% CI 1.58-1.82) and hospitalisations (Adjusted RR 6.21; 95% CI 5.15-
7.50) than controls. This is illustrated in Table 19 below.  
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Table 19. RTI-related GP Consultation (top) and hospitalisation (bottom) rates between 
children with DS and controls stratified by presence of asthma. 
 
5.5.4 Length of stay in hospital 
Overall, the length of stay in hospital due to RTIs is longer for children with DS (Mean 5.2; 
95% CI 5.0-5.4 days per admission) compared to controls (Mean 2.4; 95% CI 2.2-2.6), as 
shown in Table 20. 
For each RTI type, a significantly longer hospitalisation stay was noted in children with DS 
compared to controls. In keeping with LRTIs being more severe than URTIs or unclassified 
RTIs, the longest hospitalisation time was noted in LRTI-related hospitalisations in both 
Children with DS and controls. 
Table 20. Length of stay in hospital for LRTI, URTI, and unclassified RTI in days in 
children with DS and controls. 
 
This is illustrated in Figure 21 below, which consist of 473 hospitalisations (205 URTI, 213 
LRTI, and 55 unclassified RTI) in 220 children with DS and 327 hospitalisations (187 URTI, 
73 LRTI and 67 unclassified RTI) in 266 controls, respectively. 
 
 
 
 104 
Figure 21. Distribution of RTI-related hospitalisation length of stay in children with DS 
and controls. 
 
 
5.5.5 Baseline risk of RTI-related hospitalisation following a RTI-related GP consultation  
Table 21 denotes the number and proportions of consultations for RTIs followed by a 
hospitalisation within 28 days. Across all RTI types (i.e. URTI, LRTI, or unclassified RTI), 
children with DS were three times (RR 3.15; 95% CI 2.35–4.24) more likely to be admitted 
for an RTI-related hospitalisation following a RTI-related GP consultation compared to 
controls.  
With a baseline risk of 2.1% (95% CI 1.7-2.5%), this translates to two in 100 children with 
DS being admitted for an RTI-related hospitalisation following an RTI-related GP 
consultation compared to 0.7 controls.   
Table 21. Risk of RTI-related hospitalisation following an RTI-related GP consultation 
within 28 days in children with DS and controls. 
 
5.5.6 Time to RTI-related hospitalisation following a RTI-related GP consultation 
It was hypothesised that, in addition to varying healthcare utilisation, children and 
families with DS may behave differently in the lead up to an episode of healthcare 
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utilisation, and may be more or less likely to seek help after the beginning of symptoms. 
Many factors can affect healthcare-seeking behaviour (169, 170). Building on the initial 
analyses undertaken above, Figure 22 and Table 22 denote the time-to-hospitalisation 
from an initial presentation to the GP for an RTI in children with DS and controls. The 
percentages indicate the percentage of consultations which are followed by a 
hospitalisation occurring at each time period out of all total consultations. No statistically 
significant differences were noted between both groups, with a median of 8.0 days (95% 
CI 3.0-19.0) in children with DS and 8.0 days (95% CI 2.0-18.0) in matched controls.  
Figure 22. Time to hospitalisation in children with DS and controls following an RTI-
related GP consultation. 
 
 
Table 22. Time to hospitalisation following an RTI-related GP consultation in children 
with DS and controls. 
 
5.5.7 Re-consultation with a GP following an initial GP consultation for an RTI  
Children with DS are more likely (OR 1.69; 95% CI 1.57-1.82) to re-consult with their GP 
for an RTI within 28 days of a prior RTI-related consultation compared to matched 
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controls, with a total of 24.3% children with DS re-consulting compared to 16.0% 
amongst matched controls. Full figures are available in Table 23.  
Table 23. Re-consultation with GP following an initial RTI-related GP consultation in 
children with DS and controls. 
 
5.5.8 Hospitalisations preceded by consultations 
Table 24 denotes the number and proportion of hospitalisations preceded by a RTI-
related GP consultation. No significant differences were noted between children with DS 
and controls, with 74.1% and 73.4% of RTI-related hospitalisations occurring without any 
prior GP consultation in for children with DS and controls, respectively.  
Table 24. RTI-related hospitalisations preceded by a RTI-related consultation in children 
with DS and controls. 
 
5.5.9 Antibiotic prescriptions 
5.5.9.1 Prescribing Trends 
The number of prescriptions for the whole study period varied considerably by 
antibacterial class, illustrated in Figure 23 and Table 25.  
Children with DS were prescribed at least twice as many antibiotics compared to matched 
controls over the entire study period, with a rate per person year (PPY) of 0.774 (95% CI 
0.709-0.844), compared to 0.324 (95% CI 0.311-0.337) for controls (Adjusted RR 2.34; 
95% CI 2.19-2.49). This relationship was consistent across all drug classes except for 
“Metronidazole and tinidazole” and “Tetracyclines”, classes that are rarely prescribed for 
RTIs, where there was no significant difference. 
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Broad-spectrum penicillins were the most commonly prescribed drugs in both children 
with DS and controls.  
Figure 23. Trends in antibiotic prescription rates by drug class in children with DS (left) 
and controls (right). 
 
Table 25. Antibiotic prescriptions in children with DS compared to matched controls. 
 
The highest rates of antibiotic prescribing were noted in infants and toddlers, with 
marked variations in antibiotic prescription rates by age groups. This trend is illustrated 
in Figure 24, where it is also notable that prescribing patterns in infants fluctuate by as 
much as 0.6 per person year on year, such as between 2002-2003 and 2008-2009.  
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Figure 24. Trends in antibiotic prescription rates by age group in children with DS (left) 
and controls (right). 
 
5.5.9.2 RTI-related GP consultations with antibiotics prescribed on the same day 
Over the study period, a reduction in RTI-related GP consultations with antibiotics 
prescribed on the same day was noted in children with DS (67.0% in 1997 to 57.8% in 
2010), shown in Figure 25. There was a slight reduction for controls (53.1% to 51.7%, 
respectively). 
Figure 25. Trends in percent of RTI-related GP consultations with a same day antibiotic 
prescription. 
 
When findings were stratified by RTI-type in Table 26, significant differences were 
observed in the percentage of RTI-related GP consultations with an antibiotic prescribed 
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on the same day, with more URTIs (57.0%; 95% CI 55.3-58.6% vs 47.9%; 95% CI 46.9-
49.0%) and unclassified-RTIs (52.9%; 95% CI 50.5-55.3% vs 32.0%; 95% CI 30.5-33.5%) in 
children with DS being prescribed antibiotics compared to controls. There was no 
significant difference in the high proportion of LRTIs that were prescribed antibiotics in 
children with DS compared with controls (87.0% vs. 82.5%).  
Table 26. Percentage of RTI-related GP consultations with an antibiotic prescribed on 
the same day, stratified by RTI type. 
 
When stratified by age group in Error! Reference source not found., significant d
ifferences were noted between all age-groups in the percentage of RTI-related GP 
consultations prescribed an antibiotic, with children with DS consistently prescribed 
more antibiotics for RTIs compared to controls. 
Table 27. Percentage of RTI-related GP consultations prescribed an antibiotic on the 
same day, stratified by age. 
 
Similar to findings described above (Chapter 5.5.9.1), when restricted to antibiotic 
prescriptions prescribed on the same day as an RTI-related GP consultation, children with 
DS were twice as likely to be prescribed an antibiotic for an RTI compared to matched 
controls (Adjusted RR 2.26; 95% CI 2.10–2.43), with a rate per person-year of 0.424 for 
children with DS compared to 0.188 for controls. This is shown in Table 28. The greatest 
Adjusted RR was for the Penicillinase-resistant penicillins, Quinolones, and 
Sulphonamides & trimethoprim, all of which had an Adjusted RR for children with DS 
compared to controls of greater than 5. 
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Table 28. RTI-related GP consultations with a same day antibiotic prescription sorted  by 
antibiotic class in children with DS and controls. 
 
When antibiotic prescriptions issued on the same day as a RTI-related GP consultations 
were stratified by RTI type in Table 29 below, antibiotic prescriptions for LRTIs were noted 
to be markedly higher in children with DS compared to matched controls (Adjusted RR 
3.79; 95% CI 3.34-4.30), with a rate per person-year of 0.108 for children with DS 
compared to 0.029 for controls. Prescriptions for unclassified RTIs (Adjusted RR 2.90; 95% 
CI 2.59-3.25) and URTIs (Adjusted RR 1.99; 95% CI 1.83-2.16) were also significantly 
higher. 
Table 29. Rate of RTI-related GP consultations with a same day antibiotic prescription by 
RTI type in children with DS and controls. 
 
When stratified by age group in Table 30 below, it was noted that infants with DS had the 
highest rate of RTI-related antibiotic prescribing compared to all other groups including 
controls, with rates of 0.80 (95% CI 0.65-0.99) per person-year.  
Table 30. Rate of RTI-related GP consultations with a same day antibiotic prescription by 
age group in children with DS and controls. 
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5.5.9.3 Antibiotic prescriptions linked with any (not restricted to RTI) same day 
consultation code 
To assess whether these trends may be due to variation in consultation recording 
behaviour, an analysis of antibiotic prescriptions linked to any (not restricted to RTI) same 
day consultation codes was undertaken. Figure 26 shows a high but increasing trend of 
antibiotics prescriptions recorded with consultation codes on the same day in controls 
but not children with DS. This factor may mean there is an underestimation of the 
difference in RTI-related antibiotic prescribing in children with DS compared to controls. 
Figure 26. Percentages of antibiotics prescribed with any same day consultation code in 
children with DS and controls. 
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5.6 DISCUSSION 
5.6.1 Summary of main results 
The aim of this retrospective cohort study was to quantify RTI-related primary and 
secondary healthcare utilisation and antibiotic treatment in children with DS compared 
to age matched children without DS, and also to assess risk of RTI-related hospitalisation, 
time to RTI-related hospitalisation and re-consultation with their GP. I utilised a linked 
primary and secondary care longitudinal dataset which allowed the quantification of 
differences between RTI-related consultation, hospitalisation, and antibiotic prescribing 
rates in children with DS and controls for the first time. 
This study demonstrated that children with DS attend GP consultations more often, are 
hospitalised more often, stay in hospital longer, and are prescribed antibiotics more 
frequently for RTIs compared to controls. These findings were shown to be individually 
independent of age, gender, and co-morbidities that may influence RTI-related 
healthcare utilisation, such as CHD and asthma. Among subgroups, male children with DS 
had higher RTI-related hospitalisation rates compared to females, with a rate of 7.7% for 
males compared to 5.6% for females. This relationship was also present in female 
controls. Children with DS and controls were hospitalised less often as they aged, and 
children with DS and CHD had RTI-related hospitalisations more often than controls with 
CHD and without DS. 
Children with DS were three times more likely to be admitted to hospital for an RTI 
following an RTI-related GP consultation than controls, with a risk of 2.1%, compared to 
0.7% amongst controls. However, it was also notable that a significant proportion of 
these RTI-related hospitalisations (74% in children with DS and 73% in controls) were not 
preceded by a recorded GP consultation. 
In this study, children with DS were prescribed over twice as many antibiotics for RTIs 
(0.774 PPY) compared to controls (0.324 PPY). These differences were seen in all 
antibiotic classes commonly prescribed for RTIs.  
Differences in prescribing were apparent when stratified by RTI-type, with the highest 
difference observed in prescribing for LRTIs, which was nearly four-fold greater for 
children with DS (0.108 PPY) compared to controls (0.029 PPY). Children with DS were 
also prescribed almost three times as many antibiotics for unclassified RTIs, and twice as 
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many for URTIs, compared to controls. Infants with DS (0-1 years) were prescribed the 
most antibiotics for RTIs compared to all other age groups (0.795 PPY).  
Children with DS receive more antibiotics for RTIs; firstly, because they consult their GPs 
for RTIs more often, and secondly because they are more likely to be prescribed an 
antibiotic when they do so. 
5.6.2 Comparison with existing literature 
This is the largest study of RTI-related healthcare utilisation in children with DS worldwide 
(n=992). Additionally, this is the first study known to me which compares healthcare 
utilisation in children with DS with internal controls and the first to assess healthcare 
utilisation and antibiotic prescribing in primary care for children with DS.  
The calculated prevalence of DS in the CALIBER cohort from this study is 0.034%, which 
compares to an estimated prevalence of DS in England and Wales of 0.066% using other 
methods (3). This may be due to a number of factors. The key reason for the reduced 
prevalence in this cohort may be because patients are simply not being identified in their 
GP patient records as having a DS diagnosis, which may lead to misclassification bias. The 
calculated prevalence of comorbidities within the DS cohort was consistent with existing 
studies, which implies that although the calculated prevalence was lower than other 
studies, our findings remain representative of the wider DS population.  
In keeping with studies of hospitalisations in children with DS in Australia (n=405), the 
USA (n=217), and Spain (n=93), children with DS have more hospitalisations and longer 
hospital stays compared to the general population (71, 72, 76).  These differences are 
more pronounced in LRTIs. To my knowledge, no studies have been conducted in 
developing countries.  
Existing literature shows that younger children with DS have an increased risk of RTIs with 
markedly significant differences in infants compared to controls (167). In this study, I 
found that the risk of hospitalisations consistently decreased with age, and hence infants 
were at highest risk.  
I found that male children with DS have higher RTI-related hospitalisation rates compared 
to matched controls. This is in keeping with a 2007 systematic review that identified 
84 eligible studies describing differences in incidence of infections between genders and 
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discovered that males are more likely to develop LRTIs, an RTI-type more likely to 
predispose to RTI-related hospitalisation. However, the aetiology is not yet understood 
(171).  
Existing literature on CHD and asthma notes that both CHD and asthma appear to be risk 
factors for increased RTI-related healthcare use (43, 172). In this study, increased RTI-
related GP consultations were observed amongst children with DS and asthma, relative 
to children with DS without asthma (Adjusted RR 2.06). Amongst children with DS and 
CHD, there was an increased risk of RTI-related consultation (Adjusted RR 1.28) and 
hospitalisation (Adjusted RR 3.18) relative to those with DS without CHD. Asthma and 
CHD also increased the risk of RTI-related hospitalisation and consultation amongst 
controls.  
The baseline risk of an RTI-related hospitalisation following an RTI-related GP 
consultation in our cohort was 0.7% in controls (95% CI 0.5-0.8%), a finding similar to a 
recent UK population based cohort study which noted a baseline risk of 0.9% (95% CI 0.7-
1.2%) (173). The disparity relative to children with DS, where 2.1% are admitted, is 
disappointing, but it is both notable and encouraging that the absolute numbers for both 
groups are low. 
5.6.3 Strengths and Weaknesses 
5.6.3.1 Representativeness 
As previous research has noted, the CALIBER database is broadly representative of the 
UK population as a whole. These study findings can therefore be considered nationally 
representative (98, 102, 130). Similar findings could also be expected in other 
industrialised countries with similarly structured healthcare systems. 
5.6.3.2 Misclassification 
As described in Chapter 3, by relying on READ and ICD-10 codes for diagnoses, this study 
may be subject to misclassification bias. In this study, its effects would be most 
pronounced in the selection of RTI-related consultations and hospitalisations.  
It is known that considerable inter-practice variation exists in coding certain conditions 
such as RTIs (144, 174, 175). For example, READ or ICD-10 codes for “respiratory tract 
infection” could be either an URTI or LRTI. This may lead to either over or underestimation 
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of healthcare utilisation and/or the effects of antibiotics, depending on whether the 
consultation/hospitalisation is analysed as an exposure or outcome. I aimed to address 
this by separately considering unclassified RTI-types.  
Furthermore, GPs may not use diagnostic codes to define every RTI episode, and may 
instead rely on symptom codes or free text entries (144, 174, 175). Whilst my developed 
codelists incorporated symptom codes, a proportion of RTIs are likely to be missed either 
due to free text entries or non-recording by GPs.  
Whilst antibiotic prescriptions are well coded in CPRD, it’s not possible to estimate 
whether prescriptions were dispensed, or whether a delayed prescribing strategy was 
intended. This is unlikely to be different between children with DS and controls, so it may 
lead to either over or underestimation of RTI-related antibiotic use in both groups. There 
may also be differences in the propensity of parents of children in each group to give 
antibiotics to their children. The analysis linking antibiotic prescriptions with any types of 
consultation codes noted high levels of prescribing with any code for both groups, and an 
increasing trend over time of antibiotics linked with same day consultation codes for 
controls, but not for children with DS. Children with DS seem to be receiving more 
prescriptions without consultation codes relative to controls, which may imply an analysis 
of rescue or prophylactic prescribing would be worthwhile, or that future analysis should 
consider prescriptions of relevant antibiotics without Read codes. 
Whilst a longstanding link between viral RTIs and asthma is known (172), it is possible 
that episodes of asthma exacerbation may have been misclassified as RTIs due to 
overlapping symptoms (e.g. difficulty in breathing or cough). If GPs perceive children with 
DS to be at increased risk of RTIs, they may record RTIs more carefully and accurately for 
this group compared to controls. Consequentially, some RTI-related prescribing for 
controls could have been misattributed. This may mean that the difference in prescribing 
rates could be greater than was calculated. This is differential misclassification bias (e.g. 
consultation codes better recorded in children with DS compared to controls).  
With regards to asthma, it is also important to note that formal diagnoses are not 
normally given until a child is aged over 5 years and can participate in objective testing, 
meaning information on healthcare utilisation relying on CPRD codes may be unreliable 
in the infant and toddler groups. Labels of ‘asthma’ in this group may actually relate to 
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viral induced wheeze, which is a more common symptom of a normal respiratory 
infection in younger age groups due to smaller airways (176). It is estimated that 
approximately 18-53% of infants who are hospitalised with wheezing symptoms 
subsequently have asthma when they reach preschool age (177). However, this 
misclassification most likely was not differential between the two groups. In general, 
asthma diagnoses made solely using specific asthma codes on CPRD were found to have 
a positive predictive value of 86.4% in a recent validation study (178). The approach in 
this study only used consultation codes, so future studies could consider incorporating 
information on steroid inhaler prescriptions. However, interestingly, the same validation 
study found that the addition of information on asthma-related prescribing and 
reversibility testing did not increase the positive predictive value (178). 
Finally, amongst limitations related to misclassification, it is thought that linking antibiotic 
prescriptions to RTI-related GP consultations is a sensitive marker of RTI-related 
antimicrobial prescribing in EHR research. However, antibiotic drug classes, such as 
Benzylpenicillins and Macrolides (an alternative for penicillin allergic patients), are also 
commonly prescribed for skin and soft tissue infections, which children with DS may also 
be at risk of. These antibiotic groups may therefore not be as specific markers for RTI-
related antibiotic prescribing.  
5.6.3.3 Missing data  
A proportion of medically attended RTIs in both children with DS and controls will be 
missed, as RTIs are seen not only by GPs but also at other ambulatory care centres (i.e. 
Urgent Care Centres, Out-of-Hours GP) and A&E (38). Whilst A&E attendances are 
recorded in a discharge summary, this is variably coded subsequently in the GP record 
with little information aside from recording of “OOH Visit” or “ED attendance” (38). Little 
recording of these Read codes were identified. If families of children with DS perceive an 
increased risk of severe RTIs and correspondingly attend A&E or ambulatory care centres, 
a larger proportion of RTIs will be missed in children with DS compared to controls. This 
will therefore lead to an underestimation of healthcare utilisation between children with 
DS compared to controls.  
Research has noted that most RTIs do not lead to a GP consultation (179). There is little 
qualitative evidence on healthcare seeking behaviour in families of children with DS, and 
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whether this varies from other patient groups. The data may therefore reflect a 
difference in propensity to consult when children with DS and controls have RTIs, rather 
than a true difference in RTI incidence.  
Whilst incomplete and/or poor recording of co-morbidities will be evident in CALIBER, it 
is not possible to address missingness when it is not clear whether data are missing or 
not. Amongst the included comorbidities, poor recording of asthma may be present 
particularly for under-5 year olds. The format is only to record chronic illnesses that do 
occur, not to record the fact that chronic illnesses do not occur. This is in contrast to other 
data types, such as age and gender, where it is clear whether or not data is missing. This 
can therefore lead to either an over or underestimation of the prevalence of co-
morbidities in children with DS and/or controls.  
5.6.4 Implications for practice 
5.6.4.1 Primary and secondary care 
This study demonstrates that children with DS are twice as likely to consult their GP for 
an RTI and six times more likely to be hospitalised due to RTIs compared to children 
without DS. When hospitalised, children with DS remain in hospital for twice the duration 
of controls. 
Two in 100 children with DS who attend their GP for an RTI will later be hospitalised, a 
threefold increased risk compared to controls. They are similarly more likely to re-consult 
with their GP for an RTI compared to controls. This suggests that a review of the current 
management of children with DS presenting with RTIs in primary care would be 
beneficial. It will be important to identify whether the high rates of admission are related 
to severity of the infection, time at presentation, or time and type of antibiotics 
prescribed. Healthcare professionals in primary care should be vigilant when assessing 
children with DS with the knowledge that subsequent hospital admissions are more likely. 
The PPI panel felt that symptoms in children with DS were sometimes dismissed as merely 
being part of the disorder. For example, in one case of floppiness, this was presumed to 
represent normal hypotonia and was actually a sign of meningitis. Cases such as this could 
impede early intervention in acute illness. A focus group based study reported that 
parents feel the level of their child’s functioning is sometimes related to the level of care 
that they receive (180). 
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One of the reasons for the higher rate of hospitalisation in children with DS could be 
increased uncertainty with regards to morbidity in this group, such as speed of 
deterioration or oxygen requirements, and many of the admissions may be precautionary 
rather than related to increased severity. In this context, parents have even reported that 
some doctors seem ‘afraid’ of children with DS (180). With this in mind, it is important to 
consider that an increased likelihood of hospitalisation may not be an appropriate proxy 
for an increased likelihood of severe infection. Even so, any hospitalisation can be a 
traumatic event for a child and their family, especially if such interruptions in their lives 
are common, and can be a risk in its own right for subsequent complications such as 
hospital acquired pneumonia.  
Given that a significant proportion of RTI-related hospitalisations (74% in children with 
DS and 73% in controls) are not preceded by GP consultations, it is important to direct 
any education of professionals or other interventions towards multiple points along the 
patient pathway, and to include the diverse set of professionals with whom children with 
DS come into contact. A&E, community and other general or respiratory professionals 
should receive consistent guidance on how to assess and manage children with DS and 
RTIs. In addition, it may be useful to educate parents to help them understand when it is 
most appropriate to attend a GP, A&E, or ambulatory care centre. Such education could 
be delivered by healthcare professionals at routine appointments.  
Finally, the relative difference in RTI-related healthcare utilisation was most prominent 
in infants with DS relative to controls. It could be argued that this is linked to immune 
system immaturity at this age, as discussed in Chapter 1 (181). A study of children aged 
0-24 months found a rapid increase in respiratory infections in the first two months after 
the commencement of daycare, followed by a rapid fall sustained over the following nine 
months; first socialising with other young children may begin at this stage, increasing the 
risk of RTIs (182). 
5.6.4.2 Antibiotic prescribing 
Children with DS are twice as likely as controls to be prescribed antibiotics for RTIs overall 
(0.774 PPY vs 0.324 PPY), and three times more likely to be prescribed antibiotics for LRTIs 
(0.103 PPY vs 0.028 PPY). Infants with DS (<1 years) are prescribed the most antibiotics 
across all age groups (0.795 PPY) and significantly more than control infants (0.392 PPY). 
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All antibiotic classes in section 5.1 of the BNF were included, in line with the methodology 
of previous studies investigating RTI related antibiotic prescribing (21). 
NICE do already recommend a lower threshold for prescribing antibiotics in children with 
comorbidities, which may account for the higher rates in antibiotic prescription rates (33). 
However, this study quantifies the baseline risk of RTIs in children with DS compared with 
controls and antibiotic prescribing patterns for the first time, and enables healthcare 
professionals to inform families and carers of the risks to their child accurately.  
The greater rates of prescribing may mostly be attributed to greater clinical need, which 
could be due to a more complex individual problem or multiple simultaneous problems 
requiring attention. However, a number of other factors should be considered. As 
identified by the PPI panel, rescue pack prescriptions are common for children with DS. 
Various factors have been identified as being related to prescribing decisions, such as 
parental expectation, uncertainty, and pressure from employers (41, 42). Parental 
expectation may be greater due to experience with past admissions and frequent 
complications; uncertainty may be better due to clinicians infrequently encountering 
children with DS; and employer pressure may be exacerbated given that children with DS 
are otherwise more likely to need further interventions later on (71). As shown in Figure 
24, there is a notable variation in prescribing rates year on year, especially for infants and 
the younger age categories, where uncertainty with regards to rapid deteriorations is 
likely to be more of a problem. The PPI panel also felt that children with DS “usually need 
stronger antibiotics” and may have to try several before one works, which may further 
exacerbate the higher prescribing rate.  
It will also be important to emphasise to families that, although a significant difference in 
consultation and hospitalisation rates were noted, the absolute numbers mean that 
families can expect 0.638 RTI-related GP consultations per child per year, and 0.067 RTI-
related hospitalisations per child per year. This can also be expressed by saying that the 
average child with DS can expect to have three RTI-related GP consultations every two 
years, and one RTI-related hospitalisation every 15 years, although this advice can be 
further refined by age and infants are noted to be at most risk. Regarding prescribing 
rates, this study found that children with DS are prescribed 0.774 antibiotics for RTIs per 
child per year. This means families can expect close to one episode of an RTI severe 
enough to justify receiving antibiotics in primary care, each year.  
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All children with DS should receive an annual review where health risks such as these are 
discussed (183). The RCPCH currently recommends that children with DS should be seen 
by a designated paediatrician at least yearly, so they could fulfil this role (6). Healthcare 
professionals can use the information on risk provided by this study to inform their 
management of reviews, consultations and decisions, especially considering the 
advantages and disadvantages related to antibiotic prescribing, different antibiotic 
prescribing strategies and also provision of ‘safety netting’ for the child.  
The differences between children with DS and controls are more pronounced in children 
with DS and asthma or CHD, and younger children with DS. There are therefore specific 
at-risk groups and/or periods within the whole population of children with DS (who are 
already at higher risk of RTI) that both healthcare professionals and families must be 
aware of in order to guide appropriate antibiotic management.  
5.6.5 Implications for research 
The results from this chapter provide some initial insight into the RTI risks associated with 
children with DS, but separately there is a need to explore further what contributes to 
some of the findings. It will be important to identify; whether differences in RTI-related 
healthcare utilisation in children with DS and controls correspond to true differences in 
incidence or simply a difference in the propensity to seek healthcare; why children with 
DS and controls that are hospitalised for RTIs do not utilise primary care more often 
preceding their hospitalisation; what are the mechanisms for children with DS having 
increased RTI-related healthcare use independent of co-morbidities; and why are there 
differences between RTI-related healthcare use between males and females? 
With regards to further variables, one rationale behind investigating healthcare 
utilisation in asthma and CHD was in order to separate out groups of patients who may 
be prescribed steroid inhalers or diuretics, which could affect the presentation or 
incidence of RTIs. In the case of reflux medication, there were only 10 prescriptions so 
the power was insufficient to conduct such an analysis, although this could be conducted 
in subsequent studies. Future research may also seek to analyse subgroups specifically 
with regards to these prescriptions as additional co-variates, ideally with a larger dataset.  
In addition, other studies have demonstrated a link between socioeconomic factors and 
incidence of RTIs (184, 185). Although I analysed by IMD quintile, it may have been useful 
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to analyse by some of the sub-components of the IMD score, such as Living Environment, 
or Education, skills and training. 
Only inpatient admissions were examined, rather than A&E attendances. Admission 
routes were also not examined and may provide some useful information for the design 
of future interventions. Given that 74% of admissions in children with DS were not 
preceded by an RTI-related GP consultation, and any referrals for acute RTIs would likely 
be quick, it may be expected that more admissions were acute or emergency admissions. 
Although not explored by this study, further research may also want to examine 
prescribing rates for antivirals for influenza in children with DS. These are rarely 
prescribed for children without DS, despite recommendations to do so (34, 186). It may 
be even more important to prescribe them in children with disorders such as DS which 
put them at greater risk. In the US, the Centers for Disease Control and Prevention 
recommend that all children with neurological disorders be treated with a neuraminidase 
inhibitor if they present with symptoms indicative of influenza, and DS is associated with 
many neurological complications (187). Examining rates of uptake of the influenza 
vaccine and other preventative methods will also be important; after the 2009 H1N1 
pandemic adults and children with DS in Mexico were at higher risk of severe 
complications (188). The PPI panel felt that children with DS were sometimes too ill to 
receive vaccinations, so this should be explored. 
In the next chapter, I will establish; (a) the risk of RTI-related hospitalisation following a 
RTI-related GP consultation, stratified by whether or not they were prescribed antibiotics, 
and (b) whether children with DS and controls are appropriately prescribed antibiotics in 
primary care, by assessing the impact of antibiotic prescribing on subsequent RTI-related 
hospitalisation.  
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Chapter 6: Effects of Antibiotics in Preventing Hospitalisations in 
Children with Down’s Syndrome  
ABSTRACT 
Background 
Children with DS have increased rates of consultations and hospitalisations due to RTIs 
compared to controls. Despite this, there is little evidence on interventions to prevent 
or treat RTIs in this at-risk population. This chapter aims to estimate the risk of 
hospitalisation following a GP consultation for an RTI and the effects of antibiotics in 
reducing this risk. 
Methods 
Described in the earlier chapters, the data source is the CALIBER programme and the 
study population are children aged 0-18 matched with five controls from the same GP, 
gender, birth year and date of entry into CALIBER.  
Individuals were followed up with GP consultations for RTIs with a flag variable inserted 
if an antibiotic prescription was issued on the same day. Each RTI-related GP 
consultation was followed up for the first RTI-related hospitalisation or up to 28 days, 
whichever occurred sooner.  
Univariate and multivariate logistic regression was undertaken to assess the effects of 
antibiotics on the risk of RTI-related hospitalisation in patients consulting for RTIs. These 
analyses were conducted separately in children with DS and children without DS so that 
the protective effects could be compared. Co-variates for the final model include; (1) 
age group, (2) gender, (3) CHD, (4) asthma, (5) number of prior RTI-related 
hospitalisations and (6) number of prior RTI-related GP consultations. Where significant 
protective effects were seen, the number needed to treat (NNT) to prevent one RTI-
related hospitalisation were estimated.  
In addition, an alternative analysis using inverse probability of treatment weighting 
(IPTW) using propensity scores was undertaken to estimate the effects of antibiotics in 
children with and without DS. Baseline characteristics between the weighted and 
unweighted samples were compared using standardised mean differences.  
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Results 
1.8% (95% CI 1.3%-2.3%) of children with DS consulting with an RTI who are prescribed 
an antibiotic have an RTI-related hospitalisation compared to 2.5% of those not 
prescribed an antibiotic (95% CI 1.9%-3.4%). 0.6% (95% CI 0.4%-0.8%) of children 
without DS consulting with an RTI have an RTI-related hospitalisation compared to 0.7% 
(95% CI 0.5%-1.0%) of those not prescribed an antibiotic.  
Multivariate analysis using adjusted logistic regression models found that antibiotics 
had a significant protective effect for infants (0-1 years) with DS (AOR 0.260; 95% CI 
0.077-0.876) with an NNT of 11.9. However, analysis using IPTW concluded that the 
protective effect was not significant (AOR 0.919; 95% CI 0.845-1.000). In children 
without DS there was no significant protective effect within any age group or within any 
sub-classification of RTI. 
Discussion 
Treating children with DS older than one year with antibiotics appears to make no 
difference in preventing RTI-related hospitalisations. There is conflicting evidence from 
two separate analysis methods as to whether treating infants with DS with antibiotics 
prevents RTI-related hospitalisation, so further investigation is recommended to inform 
definitive recommendations  
In children without DS, treating RTIs with antibiotics was found to have a minimal 
impact on the risk of subsequent hospital admission. This study could not provide 
information on other potential benefits of prescription such as reduced symptom 
duration and severity.  
6.1 CHAPTER OUTLINE 
This chapter aims to estimate the effects of prescribing antibiotics for an RTI in primary 
care on the risk of subsequent RTI-related hospitalisation.  
Using the same cohort of children with DS and controls described previously, RTI-related 
GP consultations were identified and flagged if a same-day antibiotic prescription was 
issued. Each consultation is subsequently followed up to 28 days to ascertain if an RTI-
related hospitalisation occurred.   
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6.2 BACKGROUND 
With findings from the previous chapter, healthcare professionals are now able to 
quantify the risk of consultation and hospitalisation in children with DS compared to 
controls alongside identifying children with DS who are at higher risk. However, as 
highlighted from my systematic review, there remains little evidence to guide them in 
management of RTIs. 
In a study on complications after common RTIs in the general UK population using the 
CPRD, the absolute risk of rare outcomes, effects of antibiotics on this risk and the 
number of antibiotic courses needed to prevent one complication was estimated (38). 
This study provided evidence on the usefulness of antibiotics to healthcare professionals, 
generalizable to UK primary care. 
Building on this methodology, and with advances in data linkage in CALIBER, more 
accurate estimates of both the absolute risk of RTI-related hospitalisations and effects of 
antibiotics on this risk is calculated in this chapter for children with DS and controls. 
6.3 AIMS & OBJECTIVES 
6.3.1 Aims 
To assess the effect of antibiotic prescriptions in RTI-related GP consultations for 
preventing RTI-related hospitalisations, in children with and without DS. 
6.3.2 Objectives 
1. To investigate if antibiotic prescription on the same day as a RTI-related GP 
consultation will reduce the risk of RTI-related hospitalisations in children with 
DS and controls; 
2. To establish the Number of children with DS and matched controls Needed to 
Treat (NNT) with antibiotics to prevent a RTI-related hospitalisation; 
3. To establish the type of antibiotics prescribed by GPs on the same day as an RTI-
related consultation. 
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6.4 METHODS 
6.4.1 Data Management 
Building on data management steps described in Chapter 5, all GP consultations for RTIs 
irrespective of type (i.e. URTI, LRTI, unclassified RTI) were defined as the exposure; whilst 
all RTI-related hospitalisations were considered as the outcome/complication.  
Each consultation for an RTI was followed up until an RTI-related hospitalisation occurred 
or for 28 days, whichever occurred sooner.  
GP consultations by RTI type were subdivided into those with and without an antibiotic 
prescription on the same day as the RTI-related GP consultation.   
Antibiotics prescribed on the same-day as an RTI-related GP consultation were then 
listed. There was no separate analysis of multiple prescriptions issued on the same day; 
the classification was binary as to whether a child received antibiotic, or whether they 
did not. However, if two or more were prescribed, then each antibiotic would be included 
in individual antibiotic-specific prescribing rate calculations. 
In preparation for the analyses stage, several new co-variates were created. These were 
used to aid adjustment and provide more precise estimates of the effects of antibiotics.  
Co-Variate 1: 6-months RTI-related hospitalisation 
The frequency of RTI-related hospitalisations in the 6 months preceding a consultation 
could influence the frequency of later RTI-related hospitalisations. This co-variate was 
created by counting the number of RTI-related hospitalisations for each patient in the 6 
months preceding a relevant RTI-related GP consultation. A unique count was therefore 
present for each relevant RTI-related GP consultation analysed. A distribution of this 
count is illustrated in Table 31 below. 
Table 31. Count of RTI-related hospitalisations 6 months preceding an analysed RTI-
related consultation in children with DS and controls. 
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Co-Variate 2: 6-months RTI-related GP consultations average 
The frequency of RTI-related GP consultations in the 6 months preceding an individual 
consultation could influence the frequency of later RTI-related hospitalisations This co-
variate was created by counting the number of RTI-related GP consultations for each 
patient in the 6 months preceding a relevant RTI-related GP consultation. A unique score 
was created for each relevant RTI. A distribution of this count is illustrated in Table 32 
below. 
Table 32. Count of RTI-related GP consultations 6 months preceding an analysed RTI-
related consultation in children with DS and controls. 
 
Figure 27 illustrates the process for creating both co-variates below. RTI events (A) to (D) 
are all linked to the same patient (71173) and occur across the age groups. For events (B) 
to (D), six months of data preceding each event is available, and for each of these at least 
one RTI-related GP consultation or hospitalisation was flagged, denoted by the small 
vertical arrows. For Event (B), there were two events; for Event (C), three events. For 
Event (A) less than six months of follow up was available because of the date the patient 
entered the dataset was less than six months before Event (A).  
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Figure 27. Process for creating Co-Variate 1 and Co-Variate 2. 
 
Two other additional co-variates were considered, but were ultimately not used because 
there was insufficient power to detect difference due to the ratio of co-variates to 
outcomes. These two co-variates were the 28-day RTI-related Consultation Average, and 
the 28-day RTI-related Hospitalisation Average. Details on the process to create these co-
variates are included in the Appendix as Figure A30 and Figure A31. The current Co-
Variates were chosen over the alternatives after an academic consensus meeting, where 
it was decided that exposure to consultations or hospitalisations over 6 months were 
more clinically meaningful for the analysis. 
6.4.2 Data Analysis 
6.4.2.1 Adjusted logistic regression 
Univariate analysis for each of the co-variates created above alongside age group, 
antibiotic treatment, CHD, asthma and gender were performed to assess whether these 
co-variates influenced RTI-related hospitalisation. All co-variates (i.e. gender, age group, 
hospitalisations 6-months before, consultation 6-months before, CHD and asthma) were 
included in the final regression model which was used to calculate adjusted odds ratios 
for the outcome of RTI-related hospitalisation following an RTI consultation comparing 
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treated and untreated patients. Separate models were calculated for children with DS 
and children without DS (Adjusted OR <1 suggests a protective effect of antibiotics after 
taking into account baseline differences in treated and untreated patients). Models 
initially examine the protective effect of antibiotics for all consultations in children with 
DS and in children without DS. Subsequent models are stratified according to age group 
and type of RTI.  
Sensitivity analyses utilising 7, 14 and 21-day at-risk periods were also undertaken and 
detailed in Appendix Table A 7 and Table A 9. Further sensitivity analyses adjusted for 
clustering, namely the effect posed by children with very high numbers of attendances 
which may skew the data, are included in Table A 8 and Table A 10. 
6.4.2.2 Number Needed to Treat (NNT) 
The NNT was calculated following methods described in Laupacis et al. (189) and 
Newcombe’s method 10 (Wilson scores), as described in Froud et al. (190), was used to 
estimate standard error, from which 95% Cis were derived for the absolute risk difference 
and inverted to obtain Cis for NNT point estimates. NNT calculation was only undertaken 
when there was evidence of a statistically significant independent protective effect of 
antibiotics. This was done to avoid the misleading conclusion that even when there is no 
significant protective effect, treating enough people may prevent a hospitalisation.  
6.4.2.3 Inverse Probability of Treatment Weighting (IPTW) using propensity scores (PS) 
As previously discussed, there are difficulties in utilising observational data to estimate 
causal treatment effects. There are several potential approaches to address this, such as 
IPTW using PS (135). The primary analysis was based on controlling for the effect of 
confounders but a secondary analysis was conducted to check the robustness of 
conclusions utilising IPTW.  
The PS is defined as a subject’s probability of treatment selection, conditional on 
observed baseline co-variates (191). Weighting subjects by the inverse probability of 
treatment received creates a synthetic sample in which treatment assignment is 
independent of measured baseline co-variates. As the goal of PS analyses should be to 
induce balance in measured and unmeasured baseline co-variates between treatment 
groups, IPTW using the PS will therefore allow one to obtain unbiased estimates of 
average treatment effects, assuming there is no unmeasured confounding (192).  
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There are various methods to utilise PS in reducing the effects of confounding, including 
PS matching, stratification on the PS, co-variate adjustment using PS, and IPTW. Several 
studies have proven PS matching to be more effective at inducing balance in baseline co-
variates between treatment groups than stratification on the PS and co-variate 
adjustment using PS, while PS matching and IPTW have been comparable in reducing 
imbalances (135). However, PS matching requires new controls to be selected while IPTW 
does not require this step. Ultimately, IPTW using PS was chosen because of its strengths 
in utilising time-dependent co-variates and the ability to estimate a single overall 
treatment effect, and also because it was not necessary to produce a new control group 
with this analysis. It is important to note that adjustment using PS and IPTW may be 
sensitive to whether or not the PS was estimated appropriately (193).  
It should be noted that PS tend to perform worse when there is confounding by 
indication, compared to multivariate outcome modelling (194). Confounding by 
indication occurs when a particular variable is both a risk factor for an outcome and is 
associated with the exposure of interest, while not acting as an intermediate step in the 
casual pathway between the exposure and outcome. Although PS is not the chief method 
to control for confounding, PS allows for special insights in nonexperimental studies since 
it places the focus on study design rather than analysis. PS allow for insights into the 
initiation of treatment and potential barriers to treatment while considering the timing 
of co-variates and treatment, giving depth to nonexperimental study designs.  
For the purposes of this study, the other methods each had their own drawbacks. PS 
matching is effective in balancing known co-variates but may result in a loss of 
observations in the treatment group. Stratification separates subjects by PS to estimate 
treatment effects individually, however this can complicate interpretation and the 
stratification process may not produce results that are clinically relevant. Although co-
variate adjustment is the simplest method to utilise PS, its accuracy relies on certain 
assumptions about the linear relationship of features distinguishing individual events 
(193).  
Unlike analyses using adjusted logistic regression, no formal data-driven selection of co-
variates was undertaken apart from a priori selection of variables into the PS model.  
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One reason for this is that the PS model is a multivariate model, in which relationships 
may be different than those found univariately. Stated differently, gender may appear to 
not be associated with the effects of antibiotics to prevent a RTI-related hospitalisation, 
but conditional on age groups, there may be a relationship with RTI-related 
hospitalisation.  
With advice against selection of confounders in the PS model based on univariate p-
values, all co-variates generated in Section 6.4.2.1 except for those included in the 
Appendix were utilised in the PS model to create a single propensity score from 0-1 that 
measures the propensity of a child with DS or matched controls to be treated with 
antibiotics or not for each exposure of “RTI-related GP consultation”. The PS was created 
separately for children with DS, and for controls.  
Each child was then weighted according to the inverse of the probability of being 
prescribed an antibiotic at an RTI-related consultation. 
Baseline characteristics of the unweighted and weighted sample were then compared to 
assess whether the weighting process balanced measured baseline co-variates between 
treatment groups using standardised differences. Absolute standardised mean 
differences (SMDs) directly quantify balance in the means (or proportions) of co-variates 
across the groups and are expressed as percentages of pooled SDs. An absolute 
standardised difference of 0.00 on a co-variate indicates no between-group imbalance 
for that co-variate, and values <0.10 indicate negligible imbalance.  
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6.5 RESULTS 
6.5.1 Risk of RTI-related hospitalisation following an RTI-related GP consultation 
categorised by antibiotic prescriptions 
Building on initial analyses undertaken in Chapter 5, the risk of RTI-related 
hospitalisations following an RTI-related GP consultation categorised by antibiotic 
prescriptions was calculated. This is displayed in Table 33, with Table 34 showing results 
stratified by RTI-type. 
The risk of RTI-related hospitalisation following RTI consultation is higher in children with 
DS with and without antibiotic treatment compared to controls. In 1000 consultations for 
an RTI in children with DS who receive an antibiotic, 18 will subsequently be hospitalised 
for an RTI. In 1000 consultations for an RTI in children with DS who do not receive an 
antibiotic 25 will subsequently be hospitalised for an RTI. The figures for children without 
DS are 6 per 1000 consultations with antibiotics and 7 per 1000 consultations without 
antibiotics.   
Table 33. Risk of RTI-related hospitalisation within 28 days in children with DS and 
controls who were/weren’t prescribed antibiotics for an RTI-related GP consultation. 
 
Table 34. Risk of RTI related hospitalisation within 28 days in children with DS and 
controls who were/weren't prescribed antibiotics for an RTI related GP consultation 
stratified by RTI type. 
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6.6.2 Effects of Antibiotics in preventing a RTI hospitalisation  
6.6.2.1 Assessing independent effect of co-variates on the outcome of RTI-related 
hospitalisation 
Table 35 denotes the univariate analyses of all the co-variates prepared. All the co-
variates are incorporated into the final logistic regression model, whether or not they 
were significant. Small numbers prevented analyses in certain subgroups. The odds ratio 
represents the odds of hospitalisation in those who received an antibiotic prescription 
versus those who did not receive an antibiotic prescription for an RTI. 
Table 35. Univariate analyses to assess which co-variates influenced the outcome: RTI-
related hospitalisations. 
 
6.6.2.2 Effects of Antibiotics: Unadjusted using Logistic Regression 
Table 36 presents the unadjusted effect of antibiotics in reducing the risk of 
hospitalisations following a RTI in primary care stratified by RTI type without 
incorporating any of the co-variates from Table 35. Unadjusted, antibiotics did not 
provide a significant protective effect for any individual subtype of RTI, either for children 
with DS or controls.  
Table 36. Unadjusted protective effect of prescribing antibiotics for an RTI-related GP 
consultation to prevent a RTI-related hospitalisation in children with DS and controls 
stratified by RTI-type 
.  
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Table 37 presents the unadjusted effect of antibiotics in reducing the risk of 
hospitalisations following an RTI in primary care stratified by age-group. This indicates 
that the protective effect of antibiotics was not significant across all age groups. 
Table 37. Unadjusted protective effect of prescribing antibiotics for an RTI-related GP 
consultation to prevent a RTI-related hospitalisation in children with DS and controls 
stratified by age-group. 
 
6.6.2.3 Effects of Antibiotics: Adjusted using Logistic Regression 
All co-variates from 6.6.2.1 were incorporated into the final adjusted logistic regression 
models (i.e. age group, gender, cardiac, asthma, RTI-hospitalisation 6-months before and 
RTI-consultation 6-months before). When stratified by RTI-type, antibiotics had no impact 
on reducing RTI-related hospitalisation for any individual classification, shown in Table 
38. 
Table 38. Adjusted protective effect of prescribing antibiotics for an RTI-related GP 
consultation to prevent a RTI-related hospitalisation in children with DS and controls 
stratified by RTI-type (adjusted for all 7 identified co-variates). 
 
When stratified by age group, shown in Table 39, antibiotics prescribed for an RTI-
related GP consultation had a significant protective effect in preventing RTI-related 
hospitalisation for infants (0-1 years) with DS. The AOR was 0.260 (95% CI 0.077-0.876). 
The NNT was 11.9 (95% CI 6.0-1708.7). No significant protective effect at other ages or 
in controls was noted.  
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Table 39. Adjusted protective effect of prescribing antibiotics for an RTI-related GP 
consultation to prevent a RTI-related hospitalisation in children with DS and controls 
stratified by age-group (adjusted for all 7 identified co-variates). 
 
6.6.2.4 Effects of Antibiotics: Adjusted using IPTW 
As described in Section 6.4.2.3, all co-variates identified in Table 35, whether or not they 
showed a significant effect on reducing RTI-related hospitalisations, were utilised in the 
PS model. These were age, gender, asthma co-morbidity, CHD comorbidity, and 6-month 
history of RTI-related consultations and hospitalisations. The PS model creates a single 
propensity score from 0-1 that measures the propensity of a child with DS, or matched 
controls, to be treated with antibiotics, or not, for each exposure of “RTI-related GP 
consultation”. 
Illustrative graphs in Figure 28 denote the distribution of propensity scores in treated and 
untreated groups in children with DS and matched controls. 
An inverse probability of treatment weighting was then calculated using the propensity 
score to weight a child with DS or matched control according to how likely at the time of 
exposure to an RTI-related GP consultation they were going to get an antibiotic 
prescription. 
This therefore aimed to create a treated/untreated group that were balanced in terms of 
measured co-variates akin to a randomised controlled trial (that also balances for 
unmeasured co-variates). As can be seen, before weighting, the PS distributions for the 
treatment and no treatment groups were relatively well matched, but after weighting 
they matched more precisely. With more similarity in PS distributions for the treatment 
and no treatment groups, it will be more likely that the effects observed are due to the 
difference in treatment rather than due to differing measured or unmeasured co-
variates.  
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Figure 28. Graph of distribution of propensity scores. 
 
Before IPTW, the standardised mean difference (SMD) in co-variates in terms of age, 
gender, cardiac disease, asthma, gender, 6 months RTI-related hospitalisations and 6 
months RTI-related GP consultations was noted below in Figure 29, both in the 
unmatched and the weighted sample. This quantifies balance in the means of co-variates 
across the groups and is expressed as percentages of pooled SMDs. An absolute 
standardised difference of 0.00 indicates no between-group imbalance for that co-
variate, and values <0.10 indicate negligible imbalance. As can be seen, after weighting 
occurred, the SMD was below 0.01 for both children with DS and for controls across all 
variables, indicating negligible imbalance across all variables. 
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Figure 29. Standardised mean difference of co-variates between treated and untreated 
groups in children with DS and controls before and after matching and weighting. 
 
 
The adjusted logistic regression model in Table 38 and Table 39 was re-run to produce 
Table 40 and Table 41 below. These were adjusted for: age, gender, asthma co-morbidity, 
CHD comorbidity, and 6-month history of RTI-related consultations and hospitalisations. 
For infants, the adjusted protective effect was not significant (AOR 0.919; 95% CI 0.845-
1.000). Results at all other ages and for all types of RTI were also not significant.  
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Table 40. Adjusted protective effect of prescribing antibiotics for an RTI-related GP 
consultation to prevent a RTI-related hospitalisation in children with DS and controls 
stratified by age-group using IPTW. 
 
 
Table 41. Adjusted protective effect of prescribing antibiotics for an RTI-related GP 
consultation to prevent a RTI-related hospitalisation in children with DS and controls 
stratified by RTI type using IPTW. 
 
6.6.3 Antibiotics prescribed for an RTI-related GP consultation 
Table 42 denotes the types of antibiotics prescribed on the same day as an RTI-related 
GP consultation in both children with DS and controls.  
Similar proportions of Broad-spectrum penicillins were prescribed for RTIs in primary care 
in children with DS and controls (62.3% vs 63.0%).  
In contrast, there are significant differences in the prescription of Macrolides, which were 
prescribed more often for children with DS (20.8% vs 12.5% in controls). Benzylpenicillins 
were prescribed less often for children with DS (7.4% in children with DS vs 18.7% in 
controls). 
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Table 42. Antibiotics prescribed on the same day as an RTI-related GP consultation in 
children with DS and controls stratified by drug class. 
 
 
A further analysis in Table 43 involves comparing and assessing whether the distribution 
of named antibiotics was different between children with DS and controls. Of particular 
relevance to RTIs, it is notable that Co-Amoxiclav (amoxicillin trihydrate/potassium 
clavulanate), Azithromycin (azithromycin dihydrate) and Clarithromycin are prescribed 
more frequently in children with DS compared to controls.  
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Table 43. Antibiotics prescribed on the same day as an RTI-related GP consultation in 
children with DS and controls stratified by drug class & antibiotic name. 
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6.7 DISCUSSION 
6.7.1 Summary of main results 
Children with DS are at higher risk of RTI-related hospitalisations than controls, with 13 
of 1000 children with DS who are prescribed antibiotics after an RTI-related GP 
consultation being admitted to hospital, along with 23 of 1000 among those without 
prescriptions. This is in contrast to 4 and 6 per 1000 controls, respectively.  
Despite current guidance that antibiotic prescriptions should be considered for ‘at risk’ 
children presenting with RTIs, which may include children with DS and comorbidities such 
as CHD, they appear to make no difference in preventing hospitalisations amongst older 
children with the DS, or when results were stratified by RTI type (33). For LRTIs it should 
be noted that the small number of subjects in this sample (15 hospitalisations in children 
with DS, and 7 in controls, shown in Table 34) may have led to the study being 
underpowered - the sample size calculation described in 5.4.1.2 advised that there should 
be at least 20 hospitalisations per group in order to detect a difference in hospitalisation 
rates. Given these results, caution is advised when prescribing; especially given concerns 
that overuse of antibiotics may lead to unnecessary side effects and promote antibiotic 
resistance.  
There was some evidence to suggest that prescribing antibiotics to infants (0-1 years) 
may reduce the risk of RTI-related hospitalisations with an AOR of 0.260 (95% CI 0.077-
0.876) and NNT of 11.9, although the NNT confidence interval was very large (95% CI 6.0-
1708.7). However, in the IPTW model using propensity scoring which produces a result 
analogous to a randomised controlled trial, the protective effect for infants was not 
significant. The potential to reduce hospitalisations is notable given that infants with DS 
are the most hospitalised age group, hospitalised at a rate per person-year of 0.515.  
It is also important to note that although the multivariate adjusted logistic regression 
analysis did show a significant effect for infants with DS, according to the sensitivity 
analysis in Table A 9, this only became significant after the 28-day at-risk period, rather 
than after the 7, 14, and 21 day risk periods. The adjusted odds ratio remained below 1 
at each time period, and dropped as more time passed, but the 95% confidence interval 
crossed 1 in each instance until 28 full days had passed, and as the sample progressively 
increased in size. The 28-day risk period was chosen because a systematic review found 
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that the duration of RTI symptoms in children commonly lingered for up to 28 days, such 
as 25 days for acute cough and 21 days for bronchiolitis, so it may well be that 
deterioration linked to these specific symptoms underpinned the significant finding 
(151). Children continued to be admitted right up until the 28-day limit, as is shown in 
Figure 22.  
6.7.2 Comparison with existing literature  
Numerous high-quality studies and Cochrane reviews have concluded that antibiotics 
have little effect in reducing complications in children from the general population with 
RTIs in general, or URTIs (195-197). This study found that antibiotics are not justified in 
order to prevent admission in older children with DS, or when prescribed by RTI-type. A 
recent study found that treatment with early azithromycin prevented progression of RTI 
symptoms to severe LRTIs in toddler-age children suffering from recurrent RTIs, but did 
not report differences in hospitalisations, although the absolute number of 
hospitalisations was low (198). 
A previously published CPRD based study identified 3.4 million episodes of RTIs and 
assessed the effects of antibiotics in preventing complications such as mastoiditis 
following otitis media, pneumonia following an URTI and quinsy following tonsillitis (38). 
In this previous study, the data were not linked to secondary care data, potentially leading 
to underestimation of complication rates and consequent overestimation of NNTs. This 
study successfully links to secondary care data, although the relatively small number of 
RTI episodes limits analysis by complications. Studies are needed using linked data to 
measure the impact of antibiotics utilising the entire data available through CPRD, 
expanding findings beyond the small number of controls used in this study. 
My systematic review of interventions to treat RTIs in adults and children with DS 
identified few relevant studies, and those identified focused on uncommon treatments. 
This study is therefore the first to assess the efficacy of a common treatment option, 
namely antibiotics, for RTIs in this at-risk group. 
6.7.3 Strengths and Weaknesses 
This is the first study that I am aware of to assess the effects of antibiotics in primary care 
in children with DS. The strengths include the use of a large sample size of children with 
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DS, internally matched controls and collation of clinical data from primary and secondary 
care data sources within CALIBER.  
There are several generic biases to observational evaluation of the effect of interventions 
using electronic health records that are described more fully in Chapters 3-5, such as 
missing data. A particular issue in the current analysis relates to the coding of RTIs. In 
particular, it may often be difficult to clinically distinguish LRTI from URTI. Consequently, 
many RTIs had nonspecific codes and there were relatively few patients with recorded 
LRTI. This limited the power to detect protective effects of antibiotics in LRTI in children 
with DS. This study aimed to address this problem by separately considering unclassified 
RTIs in its analysis.  
There are also a number of limitations associated with the coding process. GPs are not 
coding predominantly to enable research, and data quality issues relating to matching 
presentations against codes may remain. Differential misclassification bias could have 
occurred if consultation codes are better recorded in patients who are prescribed 
antibiotics compared to those who are not. Separately, the nature of RTIs as 
predominantly clinical diagnoses may mean that distinctions between LRTIs and URTIs 
are unreliable. There are many factors that could influence the choice of certain coding 
labels and variation is likely to be present. By grouping symptoms and diagnoses under 
URTI/LRTI/unclassified RTI labels, I hoped to address variation in GPs’ perceptions on 
what symptoms constitute each of these diagnoses, but the other factors cannot be 
addressed.  
It is also possible that GPs may adjust their coding behaviours to justify their decision to 
prescribe; for example, simple sinusitis for 10 days or less should not be offered 
antibiotics, but patients with respiratory symptoms who meet three or more Centor 
criteria should be considered for immediate antibiotics (33, 199, 200). GPs who choose 
to prescribe if they perceive that a child is ‘not quite right’ but does not fit the clinical 
picture for immediate prescribing may reflexively emphasise Centor symptoms, namely 
absence of cough, fever, tonsillar exudate and enlarged anterior cervical nodes. Within 
my codelist, codes such as ‘O/E (‘On Examination’) fever, Peritonsillar abscess, or Acute 
Bacterial Tonsillitis may have been chosen in such situations. In other cases, codes that 
include the label ‘Bacterial’ may have been chosen even if cultures had not been 
performed, for example if green sputum was present. The drive to prevent 
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overprescribing may mean GPs feel more under pressure to justify decision making even 
if some decisions are not quite in line with current guidelines.  
The limitations of the NNT calculation for infants (0-1 years) of 11.9, 95% CI 6.0-1708.7, 
should also be stated. The NNT was only calculated in the event of significant results in 
the multivariate analyses, to avoid the implication that for non-significant results, 
treating a certain number of children would avert later infections. NNT values can be 
unreliable in observational studies, particularly due to confounding by indication, and 
indeed it is important to note that in the PS using IPTW analysis, the effect for infants was 
not significant (201). To minimise the impact of these limitations, the maximal number of 
co-variates should ideally be accounted for, but a lack of power impeded incorporation 
of further co-variates in this thesis (202).  
All antibiotics were considered when analysing antibiotic prescriptions in primary care, 
following the approach taken by other respiratory research studies utilising CPRD and 
HES (21). An advantage of this approach is that it allows consideration of all possible 
prescribing behaviours, and there may be a minority of atypical prescribing behaviours if 
GPs are more uncertain particularly when treating children with DS. A disadvantage of 
this approach is that it does not capture the prescription of Co-Amoxiclav and Amoxicillin 
when no Read codes are used, even though these are likely to have been prescribed for 
RTIs; but since some could be rescue or prophylactic prescriptions, this may not have 
been a reliable approach (145). The PPI panel reported that their children tended to be 
prescribed Co-Amoxiclav more than Amoxicillin, the latter being the more common 
antibiotic for the general population (203). Whilst Co-Amoxiclav was not prescribed more 
commonly than Amoxicillin in this study, it was prescribed more commonly in children 
with DS than in controls.  
Finally, a further limitation relates to the fact that, after their initial presentation to their 
GP for an RTI, some untreated children may ultimately have been prescribed antibiotics 
elsewhere (e.g. A&E, OOH). It is also not possible to tell whether prescribed antibiotics 
were ultimately taken.  
6.7.4 Implications for practice 
Healthcare professionals should be aware that prescribing antibiotics for RTIs in older 
children with DS appears to make minimal difference for the prevention of subsequent 
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RTI-related hospitalisation, irrespective of RTI type. This study was underpowered to 
detect differences for LRTIs, so antibiotic prescriptions should not be ruled out for these 
patients. However, these concerns will have to be balanced with the concern of 
overprescribing and resultant antibiotic resistance (204). The absolute risk of RTI-related 
hospitalisation for children with DS after a related GP consultation is 2.1%, which could 
be considered low given the complex medical needs of this group, although any 
hospitalisation, no matter how rare, is undesirable for the child and their family. 
Regarding subgroups, there are conflicting results as to whether prescribing antibiotics 
for infants with DS presenting to primary care for RTIs averts subsequent hospitalisation. 
Consequently, no definitive recommendation can be given. Infants with DS have high 
overall RTI-related healthcare utilisation with a rate per person-year of 1.495 RTI-related 
GP consultation rates and 0.515 RTI-related hospitalisations. This are the highest rates 
amongst the age bands, although the role of GPs may be limited due to the high 
percentage (74%) of children with DS who present to hospital without a preceding RTI-
related GP consultation.  
In the absence of gold standard evidence such as a randomized controlled trial, a targeted 
approach in prescribing antibiotics in children with DS is recommended, balancing risks 
and potential benefits. Algorithms could be designed to support healthcare professionals 
in deciding when antibiotics should be prescribed for children with DS. One example 
algorithm is ‘STARWAVe’ which identifies children from the general population at risk of 
hospitalisations and informs decision making using factors such as short (≤3 days) illness; 
high temperature; age (<24 months); recession; wheeze; asthma; and vomiting (173). If 
a child has three or more of these symptoms, there is a higher risk they will be 
hospitalised for their RTI in the following 30 days (173). Such algorithms could be tailored 
for use in children with DS using data from this study, such as the indication that very 
young children may be more likely to benefit from antibiotic prescribing, and the finding 
in Chapter 5 that children with DS and asthma are more likely to be hospitalised than 
controls with asthma, but without DS.  
Qualitative data has found that GPs sometimes experience diagnostic uncertainty and 
have varied prescribing strategies for at-risk children with influenza-like illnesses, and this 
study may offer guidance for prescribing strategies going forward (205).  This is the case 
for middle-severity RTIs, where clinicians are more likely to err on the side of caution and 
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prescribe; however, this study found no particular benefit from prescribing for 
unclassified RTIs in either children with DS or controls (206).  
6.7.5 Implications for research 
It is recommended that further research is undertaken to quantify the benefit of 
antibiotic prescriptions for infants with DS in primary care to avert RTI-related 
hospitalisation. Ideally, this should be prospective research using a larger sample size. 
Further studies could also assess the benefit of antibiotics, particularly for LRTIs where 
this study was relatively underpowered. 
There is also a need for research prospectively mapping the patient journey, experience, 
and interactions/interventions with the health service across the whole health system 
from primary to secondary and, where appropriate, tertiary care. More qualitative 
research with healthcare professionals and families is required to inform the co-design of 
future interventions, such as algorithms to support the management of an RTI, and to 
inform their implementation and evaluation in community and hospital settings. These 
interventions should support clarity and collaboration in prescribing decisions so that the 
use of antibiotics to manage RTIs in children with DS is optimised.  
A prospective study with better data capture mechanisms on clinical presentations, risk 
factors, antibiotics received and pathogens responsible, such as a British Paediatric 
Surveillance Unit study, would be valuable to ascertain the impact of this increased 
antibiotic exposure on antimicrobial resistance in this at-risk group (207). A randomised 
trial, incorporating varied antibiotic prescribing strategies such as rescue treatment, 
prophylactic treatment, and the effects of delayed treatment, would be useful to further 
broaden the evidence base for treatment of children with DS. 
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Chapter 7: Key Findings, Discussion, Recommendations and 
Conclusions 
7.1 DESCRIPTION OF CHAPTER CONTENTS  
In this chapter, I summarise and draw together key findings from my thesis alongside the 
strengths and limitations of the methodology utilised. This is followed by a discussion of 
these findings placed in the context of previous literature and the implications for clinical 
and public health policy, practice and research.  
For children with and without DS, this thesis aimed to use routinely collected data to 
identify RTI-related healthcare utilisation, those most at risk of RTI-related healthcare 
utilisation, and the effects of antibiotics in preventing RTI-related hospitalisation. 
The objectives were: 
1. To undertake a systematic review of the literature on the effectiveness of 
preventative and therapeutic interventions for RTIs in adults and children with DS 
(Chapter 2) 
2. To quantify NHS healthcare utilisation attributable to RTIs in children with and 
without DS from 1997 to 2010 (Chapter 5) 
3. To ascertain which children, with and without DS, are most at risk of increased 
RTI-related NHS healthcare utilisation (Chapter 5) 
4. To assess the effect of antibiotic prescriptions in RTI-related GP consultations for 
preventing RTI-related hospitalisations, in children with and without DS (Chapter 
6) 
7.2 KEY FINDINGS  
7.2.1 Limited evidence on interventions to prevent or treat RTIs in children with DS   
In my systematic review of the literature (Chapter 2) in 2015, I reviewed a total of 13,575 
records of which I identified three studies on preventative interventions for RTIs in 
children with DS that fulfilled the inclusion, exclusion and quality criteria. No RCTs, CBAs 
or cohort studies on therapeutic interventions in this field were found in the literature.  
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Of the three studies, one RCT of moderate risk of bias compared prophylactic zinc therapy 
with placebo for 62 children with DS, and noted no benefit on URTI episodes, doctor visits, 
antibiotic use, and school absence (92).  
One non-RCT, with serious risk of bias, had a population of 26 children and compared 
prophylactic treatment with pidotimod (an immunostimulant) against no treatment and 
noted fewer parent-reported URTI recurrences (mean 2.7, S.D. 1.1 vs mean 6.8, S.D. 1.3) 
and days with fever (mean 4.5, S.D. 3.5 vs mean 16.9, S.D. 6.7) (91).  
A prospective cohort study with serious risk of bias compared a cohort of 532 Canadian 
children with DS, treated prophylactically with palivizumab, with a cohort of 233 Dutch 
children with DS who did not receive palivizumab. It noted that the treated cohort had 
fewer RSV-related hospitalisations (23 untreated, 8 treated) but the same number of 
overall RTI-related hospitalisations (73 untreated, 74 treated) in the first two years of life 
(90).  
Two further studies, one on a school based infection control programme and one on 
prophylactic zinc therapy were subsequently excluded due to critical risk of bias (93, 94).  
After the 2017 update of the systematic review which identified a further 3,302 abstracts, 
I shortlisted two additional studies investigating treatment with prophylactic 
palivizumab. Both of these were also subsequently excluded due to critical risk of bias 
(76, 95).  
My systematic review was based on a very broad search strategy that included DS-related 
co-morbidities such as CHD and adults with DS to ensure a thorough and comprehensive 
search of all relevant studies for RTIs in DS.  By restricting the inclusion criteria to high 
quality study designs (e.g. randomised controlled trials, controlled before-after studies 
and cohort studies) I excluded case reviews and case series that may be more commonly 
published on DS but are less likely to inform routine clinical practice.  
7.2.2 Children with DS have increased RTI-related healthcare utilisation compared to 
controls 
Using the CALIBER dataset, I undertook a retrospective cohort study of 992 children with 
DS and 4,874 controls matched for birth year (±5y), starting date of follow-up, gender 
and general practice. 
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Children with DS consult their GP at a rate of 0.64 per person per year (PPY) in contrast 
to controls at 0.36 PPY (Adjusted RR 1.73; 95% CI 1.62-1.84). Children with DS are 
hospitalised for all RTIs at a rate of 0.067 PPY compared to controls at 0.013 PPY (Adjusted 
RR 5.69; 95% CI 4.82-6.73).  
The differences between children with DS and controls were most pronounced for LRTIs 
(in contrast to URTIs and unclassified RTIs) with an Adjusted RR of 3.59 for LRTI-related 
GP consultations (95% CI 3.19-4.04) and 11.30 for LRTI-related hospitalisations (95% CI 
8.45- 15.10).  
Additionally, children with DS are admitted for a longer period of time in hospital due to 
RTIs (Mean 5.2 days; 95% CI 5.0-5.4) compared to controls (Mean 2.4 days; 95% CI 2.2-
2.6). 
7.2.3 Children with DS (in particular infants) are prescribed more antibiotics in primary 
care for RTIs compared to controls  
Children with DS are prescribed more antibiotics than controls, at a rate of 0.774 PPY 
compared to 0.324 for controls (Adjusted RR 2.34; 95% CI 2.19-2.49). These differences 
were significant across all antibiotic drug classes that are routinely used for RTIs. These 
prescriptions were made in consultations that were coded as being RTI-related, although 
it is conceivable that a minority were prescribed for other reasons.   
Differences in RTI-related antibiotic prescription on the same day as RTI-related 
consultations were most apparent in LRTIs (Adjusted RR 3.79; 95% CI 3.34-4.30). 
Infants with DS (0-1 years) were prescribed the most antibiotics for RTIs compared to all 
other age groups at a rate of 0.795 PPY (95% CI 0.65-0.99).  
7.2.4 Children with DS have an increased risk of hospitalisation following an RTI-related 
GP consultation 
Children with DS have an increased risk of RTI-related hospitalisation following a RTI-
related GP consultation (RR 3.15; 95% CI 2.35–4.24) compared to controls. In those 
hospitalised, the time to hospitalisation was similar with a median of 8.0 days (95% CI 
3.0-19.0) in children with DS and 8.0 days (95% CI 2.0-18.0) in matched controls. 
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The odds of re-consultation with a GP for an RTI following an initial RTI-related GP 
consultation was higher in children with DS compared to matched controls (OR 1.69; 95% 
CI 1.57-1.82). This was unrelated to any subsequent hospitalisation episodes.  
A high proportion of RTI-related hospitalisations are not preceded by a RTI-related GP 
consultation in both children with DS (74.1%; 95% CI 68.9-78.5%) and matched controls 
(73.4%; 95% CI 67.0-78.8%). 
Stratified by antibiotic prescriptions, the baseline risk of RTI-related hospitalisation in 
children with DS is significantly higher compared to matched controls with 1.8% of 
children with DS (95% CI 1.3-2.3%) prescribed antibiotics being admitted compared to 
0.6% of controls (95% CI 0.4%-0.8%). 
In those not prescribed antibiotics, the baseline risk was 2.5% in children with DS (95% CI 
1.9%-3.4%) and 0.7% in controls (95% CI 0.5-1.0%). 
7.2.5 There are conflicting results as to whether prescribing antibiotics for all RTI-types 
in primary care reduces the risk of RTI-related hospitalisation in infants with DS (0-1 
year) 
When antibiotics are prescribed for all RTI types in primary care, adjusting for CHD, 
asthma, gender, and number of RTI hospitalisations and consultations preceding a RTI-
related consultation using adjusted logistic regression, the risk of RTI-related 
hospitalisation is reduced in infants with DS (0-1 years) with an adjusted odds ratio of 
0.260 (95% CI 0.077 to 0.876, p=0.297) and an NNT of 11.9 (95% CI 6.0- 1,708.7). This was 
not significant for infant controls with an AOR of 0.409 (95% CI 0.091- 1.846). 
However, when using inverse probability of treatment weighting to calculate the 
propensity score, aiming to create treated/untreated groups that are balanced in 
measured co-variates akin to a randomised controlled trial, the effect for infants was not 
significant (AOR 0.919; 95% CI 0.845-1.000, p=0.0506). The effect for infant controls was 
also not significant (AOR 0.983; 95% CI 0.961-1.005, p=0.1237).  
7.2.6 Prescribing antibiotics by type of RTI does not reduce the risk of RTI-related 
hospitalisation  
Looking at specific RTI-types (i.e. URTI, unclassified RTI, LRTI), prescribing antibiotics had 
no significant effect for URTIs, unclassified RTIs and LRTIs in children with DS and controls. 
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However, the absolute number of LRTIs in both were small and the CIs relatively wide, so 
the study was underpowered to assess any impact in this domain.  
7.2.7 Strengths and limitations of my CALIBER dataset work 
Strengths 
To date, this is first study to quantify objectively RTI-related healthcare utilisation using 
routinely collected data from both primary and secondary care datasets with matched 
controls, and the first to assess the effects of antibiotics for RTIs in children with DS. As 
the CALIBER database is broadly representative of the UK population as a whole, and the 
prevalence of comorbidities in the CALIBER cohort matched those from other studies of 
children with DS, these study findings can therefore be considered both nationally and 
internationally representative. To my knowledge it is also the largest study of RTI-related 
healthcare utilisation in children with DS worldwide. 
Limitations 
Considerable inter-practice variation exists in coding certain conditions such as RTIs (144, 
174, 175). For example, READ or ICD-10 codes for “respiratory tract infection” may 
potentially mean that it could be either an URTI or LRTI. This may lead to either over or 
underestimation of healthcare utilisation. Separate consideration of ‘unclassified RTIs’ 
was incorporated in order to address this limitation. It could be argued that, with regards 
to subtypes of RTIs, misclassification in this domain is unimportant, because what the 
thesis is describing is whether prescribing antibiotics, when clinicians are presented with 
certain sorts of symptoms, averts subsequent hospitalisation. Whether these 
combinations neatly fit the URTI or LRTI labels may be unimportant.   
Despite the extensive effort undertaken to code for co-morbidities such as asthma and 
congenital heart disease, due to the known variation in GP coding behaviour and HES 
coding of co-morbidities, it is likely that children with DS and matched controls may be 
misclassified as either having or not having CHD/asthma. This may lead to either an 
overestimation or underestimation of healthcare utilisation in comparison between 
these groups. 
Selective recording of consultations codes by GPs when an antibiotic prescription is 
issued may lead to differential misclassification bias (e.g. consultation codes better 
recorded in children with DS compared to controls, or in treated vs untreated subjects). 
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It is also not possible to deduce whether prescriptions were ultimately dispensed, or 
dispensed but not taken.  
Despite the extensive lists of co-variates generated to capture the baseline health and 
the risk of hospitalisations in the children under study, unmeasured confounding is likely 
to remain in the analyses. A large number of other relevant factors affecting RTI risk have 
been identified by other studies; atopy status, smoking status, presence at daycare, 
sharing a bedroom with adults, sharing a bedroom with young children, and exposure to 
damp or mould have been found to increase risk, and breastfeeding status has been 
found to decrease risk (14, 208, 209). Adjustment for these factors in subsequent studies 
may be difficult, because with the exception of atopy status, smoking status and in some 
cases breastfeeding status, this information will not be routinely collected or recorded. 
Smaller survey-based studies could collect this information, but there would 
consequently be an effect on sample size, and most likely a reduction in power would 
restrict any attempt to adjust for the additional co-variates. 
Importantly, in the absence of data to assess RTI severity during consultation (e.g. clinical 
observations), confounding by indication is likely to persist in these analyses. This is likely 
to lead to an underestimation of the effects of antibiotics in both groups. 
It has been noted anecdotally that prescribing rescue courses of antibiotics (i.e. 
antibiotics to be kept at home and taken when an RTI is worsening) is common in children 
with DS, as it is in other patients with chronic respiratory problems (210). The PPI panel 
observed that it was not uncommon for parents to phone their GP, request antibiotic 
prescriptions, and collect them without consultations. These children may present to 
their GP for a worsening RTI after having started their antibiotic course at home and 
subsequently be admitted to hospital for a severe RTI. As these children would be 
classified as not receiving antibiotics, (i.e. no same day antibiotic prescription recorded 
with a Read code for a RTI-related GP consultation), this could have had a role in 
minimising any difference in effect of antibiotics in the analyses.  
Finally, it should be noted that the dataset for this thesis runs from 1997-2010. Over this 
time period, and indeed in the seven years since 2010, there has been an increased focus 
on antimicrobial resistance with various publicity campaigns designed to reduce 
prescribing rates. For example, in 2014 the UK Antibiotic Guardian Campaign was 
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launched, encouraging the public and clinicians to make pledges designed to reduce the 
use of antibiotics; in 2017 the Keep Antibiotics Working campaign aimed to encourage 
the public not to request antibiotics when visiting their GP (211, 212). Such campaigns 
could have reduced prescribing rates in children with DS, if families or clinicians are more 
concerned given their already higher prescribing rates; or they could have differentially 
affected the healthy matched controls, if they are perceived to be less in need of 
antibiotics. In the context of increasing antibiotic resistance, there will need to be a wider 
consideration of how to optimise prescribing for all children and adults in future, which 
could involve a greater use of algorithms to encourage targeted prescribing. 
I am aiming to undertake further analysis incorporating 2010-2015 after the completion 
of this thesis, which hopefully could shed some light on any effect that has occurred to 
this end. Other new analyses which I aim to complete in this work will include analysis of 
multiple prescriptions and prescription combinations on the same day; and analysing 
prescriptions commonly prescribed for RTIs but prescribed without a Read code. 
7.3 DISCUSSION 
7.3.1 Implications for clinical and public health practice  
The key message from this thesis is that parents and carers of children with DS should be 
made aware that the risk of RTIs-related healthcare in children with DS is elevated relative 
to children without DS. The average child with DS can expect to have three RTI-related 
GP consultations every two years, and one episode of an RTI severe enough to justify 
receiving antibiotics in primary care every year. The overall risk of hospitalisation is low; 
the average child with DS will have one RTI-related hospitalisation every 15 years, which 
is most likely to occur in infancy. Antibiotics prescribed in primary are not effective for 
averting subsequent hospitalisation for older children with DS. The risk of hospitalisation 
is higher in LRTIs compared to URTI and unclassified RTIs. Children with DS with 
concomitant asthma or CHD have also been identified as a high-risk population for 
increased RTI-related healthcare utilisation relative to those with DS but without asthma 
or CHD. 
This thesis has also found that research into respiratory tract infections typically excludes 
children with DS. A systematic review in 2006 found there was no published evidence on 
the use of antibiotics for children with DS, and my systematic review likewise found no 
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such studies (77). Healthcare professionals are therefore currently lacking in guidance in 
how best to manage children with DS presenting on RTIs.  
Work from this thesis has therefore contributed substantially towards addressing this 
problem by assessing the current literature on interventions to prevent or treat RTIs in 
children with DS, healthcare utilisation of children with DS, and the effects of antibiotics 
in reducing the risk of RTI-related hospitalisation in children with DS. 
From the treatments identified in the systematic review, I found some evidence for the 
use of palivizumab in preventing RSV-related hospitalisations in a population of children 
with DS under two years (90). Pidotimod reduced parent-reported URTI recurrences and 
days with fever (91), and zinc had no effect on URTI episodes (92). It is clear that current 
guidelines have little to rely on in the way of evidence, and as such clinicians need more 
support in decision making. In the two years since my initial search took place, no new 
high-quality studies were identified, and going forward more would be welcomed. 
When a child develops symptoms of a RTI, there are a number of options a parent or 
carer can take - either to watch and wait, access treatment in primary care or secondary 
care, or to start treatment themselves. The decision taken can be directed by a number 
of factors such as severity of symptoms, co morbidities, parents’ capacity to manage their 
child’s illness and also to recognise when further treatment is required. Other identified 
factors from a cross-study analysis include perceived child vulnerability, combatting 
uncertainty, and combatting social disapproval, all factors that may be felt more acutely 
in the parents of children with complex needs (169). Children who are at higher risk of 
deterioration are more likely to require prompt recognition of symptoms and access to 
primary and secondary care for assessment and effective management. The difficulty for 
health professionals is often how to identify the high-risk populations who require 
targeted, prompt assessment and treatment, which can be better achieved by building 
good relationships with parents and carers.  
Whilst GP consultations and antibiotic prescribing may be a function of health-seeking 
behaviour by parents or carers and risk-aversion by GPs who do not wish to under-treat 
children with DS, the differences in hospitalisations together with the prolonged length 
of stay observed are a sensitive marker of illness severity and provide evidence that 
future public health campaigns or education strategies to increase symptom recognition 
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for children with DS may be valuable. This will endeavour to ensure that children receive 
timely assessment and an effective management plan, whether this be antibiotic 
treatment, watch and wait policy with safety netting or referral for more intense 
intervention. Parents and carers should be informed of the high risk of RTI, but they 
should also be educated about signs and symptoms to alert them to a possible RTI, and 
provided with information on where and how to access support from the health service. 
Although the outright frequency of RTI-related hospitalisation is low, it should not be 
forgotten that families and children may experience other hospitalisation events related 
to other comorbidities, such as CHD, which may be traumatic if they involve surgery. Any 
individual hospitalisation puts a child at risk of infections such as hospital acquired 
pneumonia, and can have an effect on development, schooling and mood. Therefore, it 
cannot be said that even if the frequency of RTI-related hospitalisations is low, that it is 
acceptable.  
Regarding antibiotics, current NICE recommendations state that antibiotics should be 
prescribed immediately if the child is (1) systemically unwell or (2) at high risk of serious 
complications due to pre-existing co-morbidities such as CHD (33). Findings from my 
thesis indicate that children with DS in particular could benefit from a more targeted 
antibiotic prescribing strategy for RTIs in primary care. This is more vital for children with 
DS at high risk such as infants with DS (0-1 years), although this study provided conflicting 
results about the benefits of prescribing for this group. The existing NICE guidelines could 
be more specific as to how to manage children with DS. In addition, national best practice 
guidance disseminated by the Down Syndrome Medical Interest Group could also include 
guidance on this issue, alongside consideration of what factors can help parents (213). 
However, it should not be forgotten that there are legitimate concerns about the overuse 
of antibiotics in primary care and the development of antimicrobial resistance (214, 215). 
For example, a recent randomised controlled trial has clearly shown increased carriage in 
resistant organisms after macrolide administration but not after placebo (216). Children 
with DS may be more at risk given possible immune system immaturity (50-53) as 
discussed in Chapter 1.  
Finally, with 74% of children with DS being admitted for an RTI-related hospitalisation 
without presenting to their GP and hence accessing primary care, the impact of prompt 
antibiotic prescribing in primary care have a limited impact on overall RTI-related 
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hospitalisation rates across the cohort. The reasons why parents and carers do not readily 
access their GP remains unclear, and needs to be explored. Parents and carers of children 
with DS may have different health seeking behaviour either due to personal preferences, 
differing advice to utilise secondary care, because the child’s symptoms have 
deteriorated enough to warrant direct access to secondary care, or because of direct or 
indirect discrimination (217). Healthcare professionals should consider all these 
possibilities when treating children with DS in the context of RTI-related hospitalisations, 
and adjust their behaviour accordingly.  
As discussed in Chapter 1, children with DS often come under the care of a 
multidisciplinary team and the RCPCH recommends that children with DS should 
primarily be cared for by paediatricians with particular expertise in DS (6). It is 
recommended that they are reviewed once every three months up to the age of one, and 
subsequently yearly where an annual review could take place. At such an annual review, 
families and children could be examined and assessed as to their general health, as well 
as for identified at-risk comorbidities; families could be given the opportunity to consider 
what adaptations could be made to their care to improve the fluidity of their experiences 
through the NHS; and paediatricians could answer questions that families may have 
about events during the year, such as hospitalisations.  
A possible reason for the lack of presentation to primary care prior to hospitalisations 
may be that families of children with DS are more familiar with their paediatrician and 
the paediatrician is also relatively accessible. Of course, it is not known to what extent 
the RCPCH guidance is followed in practice. However, any intervention should certainly 
be directed towards paediatricians, especially for younger children with DS. According to 
the RCPCH guidance, children with DS should also be reviewed by at least four other 
specialists and then up to six more services; in this context, it is conceivable that families 
of children with DS experience healthcare provider ‘fatigue’ and therefore, to some 
degree, may want to minimise the number of services they see unless necessary. They 
may also be more aware about when it is appropriate to present to A&E as opposed to 
seeing a General Practitioner, given their greater experience of the NHS compared to 
families of children without DS.   
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7.3.2 Implications for research  
The overall evidence base for management of RTIs in children with DS is low. It is clear 
that research is necessary in many areas in order to optimise care. These research areas 
are as follows: a) An accurate map of the patient journey; b) Development of an algorithm 
to guide prescribing strategies; c) Examination of strategies to prevent RTIs beyond 
antibiotic prescription; d) A more detailed analysis of sub-populations of children with DS 
who are at greater risk; e) Use of laboratory data to identify certain bacteria or viruses, 
and hence certain antibiotics, linked to healthcare utilisation behaviours; f) An RCT to 
further quantify the benefit of antibiotic prescribing for RTIs in children with DS. Each of 
these research recommendations is explained in the subsequent paragraphs.  
First, this thesis has quantified RTI-related healthcare utilisation at GPs and hospitals, but 
there is now a need for a more detailed map of current services that deliver care. This 
should encompass A&E and walk-in centres, as well as social care and other potential 
contact points; the large number of comorbidities means children with DS will encounter 
a variety of specialists in different settings (141). As a result, there is a need to 
prospectively follow the patient journey when and how critical decisions are made with 
regards to management of RTIs. This could run alongside qualitative research exploring 
the patient and family experience and decision making in relation to accessing health 
services and antibiotic prescribing.  
Second, research is required to establish and co-design an algorithm to better target 
antibiotics in children with DS for RTIs. This study found that certain groups, namely 
infants, those with CHD, and with asthma, are at greater risk of hospitalisation. It may be 
that those at risk of RTI-related hospitalisation could be defined in greater detail, thus 
enabling the development of a symptoms-based scoring algorithm could optimise 
prescribing, modelled on algorithms those that already exist for many other conditions 
(173, 218, 219).  
Third, research should examine other RTI treatment strategies beyond antibiotics. 
Qualitative work and/or a scoping survey of prescribers is necessary to clarify the extent 
of rescue antibiotic prescribing which is not quantifiable in my thesis due to the absence 
of Read codes for “rescue prescribing”. Prophylactic antibiotic usage is another strategy 
to explore, as it has been successful in reducing exacerbations in chronic respiratory 
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diseases (220). The efficacy of antivirals should be quantified, which is already 
recommended for children at high risk of RTI-related complications (34). Finally, vaccine 
uptake was not assessed in this thesis and research into methods to ensure uptake 
remains high in children with DS should be encouraged. As discussed in Chapter 1, poor 
responses to certain vaccines have been noted in children with DS (79, 80) and it would 
be interesting to see whether this has resulted in a perception amongst families that 
vaccines are not always worthwhile, which could be assessed in a qualitative study 
alongside outright assessment of uptake of vaccinations such as the flu vaccine.  The 
degree to which families would be supportive of children with DS undergoing regular 
serological testing to assess vaccine responses (e.g., antibody functionality) and repeat 
vaccinations could also be assessed (81).  
Fourth, while studies in this thesis have identified children with DS as an at-risk group for 
increased healthcare utilisation and hospitalisation following an RTI, the magnitude of 
increased risk in children with DS with certain other relevant co-morbidities (e.g. chronic 
lung disease or immunosuppression due to cancer therapy) could not be assessed due to 
the small numbers identified. Adequately powered stratified analyses using larger 
datasets of children with DS (e.g. CALIBER dataset with data from more recent years) will 
be necessary to quantify this risk.  
Fifth, linking laboratory data (e.g. from the PHE’s ‘Lab base’) on positive specimens to 
general practice datasets would allow assessment of the relative effects of influenza 
versus other respiratory infections on RTI-related healthcare utilisation. The effects of 
specific antibiotics in reducing RTI-related hospitalisations linked to specific pathogens 
could also be better delineated.  
Finally, more evidence is needed, ideally from RCTs, on the effect, risks, benefits and 
impact on antimicrobial resistance of using antibiotics to treat RTIs in children with DS, 
particularly for infants with DS.  
7.4 CONCLUSION 
Work from this thesis has contributed substantially to understanding the relationship 
between respiratory tract infections and the effects of treatments such as antibiotics in 
children with and without DS with important research, clinical and public health 
implications.  
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Overall, there was good evidence suggesting a higher healthcare utilisation in both 
primary and secondary care in children with DS for RTIs compared to controls. This is 
further increased in infants (0-1 year olds) and children with asthma and CHD. 
My systematic review found that there is little existing evidence on interventions to 
prevent and treat RTIs in children with DS, and I was then able to quantify the benefit 
provided by the prescription of antibiotics in primary care for RTIs in children with DS. 
Based upon my results I recommend that prioritisation of further research into antibiotic 
treatment for infants with DS presenting to primary care with any RTI. 
For children with DS at other ages presenting with RTIs, I would not recommend antibiotic 
treatment; for lower RTIs, further investigation is recommended with a larger sample 
size. Other prescribing strategies should be explored to broaden the evidence base for 
this at-risk group.  
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Appendix 
Table A 1. Condition and co-morbidities searched using the RCALIBERcodelists 
package 
 
Sub-Category Conditions Searched Conditions Not Searched Codes Searched 
Conditions Associated with Breathing Difficulties in Down's Syndrome  
Respiratory Obstructive sleep apnoea  Sleep|Apnoe* 
 Chronic lung disease  Lung 
 Tracheostomy  Trache* 
    Subpleural cysts   
Cardiovascular Congenital heart disease  Congenital|Heart 
 Atrioventricular canal defect  Atri* 
 Atrial & ventricular septal defects  Atri*|Ventric* 
 Aortic regurgitation  Regurg* 
 Patent ductus arteriosus  Duct* 
 Tetralogy of Fallot  Fallot 
 Double outlet right ventricle  Ventric* 
 Mitral valve prolapse  Valve 
  Acquired valve disease   Valve 
Gastrointestinal Gastroesophageal reflux disease  Reflux* 
 Swallowing dysfunction  Swallow* 
 Oesophageal atresia repair  Oesophag* 
  Tracheo-oesophageal fistula   Trache* 
Anatomical Tracheal bronchus  Trache* 
 Tracheomalacia  Trache* 
  Small jaw  
  Macroglossia  
  Narrow nasopharynx  
  Adenotonsillar hypertrophy  
  Choanal stenosis  
  Laryngomalacia  
  Narrow trachea  
  Mid-face hypoplasia  
  Subglottic stenosis  
    Small upper airway   
Contributory factors  Obesity  
    Hypotonia   
Conditions Associated with Infections in Down's Syndrome 
Cancer Acute Leukaemia  Acute|Leukaemi* 
  Myeloproliferative disease   Myeloproliferative 
Misc  Increased mucus secretions  
  Reduced ciliary beat frequency  
  B-cell function abnormality  
  Decreased neutrophil chemotaxis  
  Thymic abnormalities  
  
Alteration of levels of 
immunoglobulin subclasses 
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Alterations in response to 
vaccinations 
 
  
Reduced T and B lymphocyte 
subpopulations 
 
    Ciliary dysfunction   
Population: Down's Syndrome 
Down's Syndrome Down's Syndrome   Down|Trisomy|Mongol 
Infections    
URTI Common Cold  Common|upper|infection 
 Rhinitis  Acute|rhinitis 
 Sinusitis  Sinusit*|rhinosinusitis 
  Nasopharyngitis  
  Pharyngitis  
 Epiglottits  Epiglot* 
  Laryngitis  
  Laryngotracheitis  
 Tracheitis  Trache* 
  Tonsillitis  
    Otitis Media   
LRTI Chest infection  Chest|Lower resp* 
 Bronchitis  Bronchi* 
 Bronchiolitis  Bronchi* 
 Croup |Laryngotracheobronchitis  Croup |Laryngotracheo 
  Pneumonia   Pneumon* 
SBIs Meningitis  Mening* 
 Septicaemia  Sepsis |Septic* 
 Endocarditis  Endocard* 
  Abscess   Abscess 
Other Infections Skin and soft tissue  Infect* 
 Urinary  Infect* 
 Gastro  Infect* 
 TB (All subtypes)  Infect*| Lung 
 Named organism infections w/out  site  Infect* 
 Otitis externa  Infect* 
  Bone   Infect* 
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Table A 2. List of Read codes 
Down’s 
Syndrome    
 Q909  Down’s Syndrome, unspecified 
 1543  Down’s Syndrome- trisomy  21 
 10759  Down’s Syndrome NOS 
 19062  Partial Trisomy Syndromes 
 18415  Trisomy 21 
 Q929  Trisomy and partial trisomy of autosomes, unspecified 
 Q901  Trisomy 21, mosaicism (mitotic nondisjunction) 
 Q900  Trisomy 21, meiotic nondisjunction 
LRTI       
 
22448 POSSIBLE O/E - intercostal recession 
 25722 POSSIBLE O/E - subcostal recession 
 
7092 POSSIBLE Recurrent wheezy bronchitis 
 
152 POSSIBLE Wheezy bronchitis 
 
8582 POSSIBLE O/E - chest findings 
 
5978 PROBABLE Acute wheezy bronchitis 
 
13573 PROBABLE Influenza with bronchopneumonia 
 
8539 POSSIBLE O/E - shallow breathing 
 
14976 PROBABLE Viral pneumonia NOS 
 
5202 PROBABLE Viral pneumonia 
 
44425 PROBABLE Pleural empyema 
 
7000 POSSIBLE O/E - dyspnoea 
 
1934 PROBABLE Laryngotracheobronchitis 
 
18451 PROBABLE Acute bronchiolitis due to respiratory syncytial virus 
 
17359 PROBABLE Chest infection - unspecified bronchitis 
 
10321 POSSIBLE O/E - consolidation 
 
41137 PROBABLE Acute bronchitis or bronchiolitis NOS 
 
8318 PROBABLE Lung consolidation 
 
22795 PROBABLE Chest infection - other bacterial pneumonia 
 
3683 PROBABLE Basal pneumonia due to unspecified organism 
 
23095 PROBABLE Bacterial pneumonia NOS 
 
25694 PROBABLE Pneumonia due to other specified organisms 
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1576 PROBABLE Pneumonia due to mycoplasma pneumoniae 
 
3480 PROBABLE Bronchitis NOS 
 
3163 PROBABLE Tracheobronchitis NOS 
 
10114 POSSIBLE O/E - tachypnoea 
 
9639 PROBABLE Lobar pneumonia due to unspecified organism 
 
5324 PROBABLE Atypical pneumonia 
 
25571 POSSIBLE O/E - coarse crepitations 
 
1382 PROBABLE Acute viral bronchitis unspecified 
 
10086 PROBABLE Pneumonia and influenza 
 
11101 PROBABLE Acute tracheobronchitis 
 
9062 POSSIBLE O/E - crepitations 
 
4626 POSSIBLE O/E - rhonchi present 
 
29669 PROBABLE Acute bronchitis and bronchiolitis 
 
1849 PROBABLE Lobar (pneumococcal) pneumonia 
 
6094 PROBABLE Pneumonia or influenza NOS 
 
37447 PROBABLE Acute lower respiratory tract infection 
 
886 PROBABLE Bronchopneumonia due to unspecified organism 
 
4899 PROBABLE Recurrent chest infection 
 
978 PROBABLE Pleurisy 
 
572 PROBABLE Pneumonia due to unspecified organism 
 
148 PROBABLE Bronchitis unspecified 
 
6124 PROBABLE Acute lower respiratory tract infection 
 
1019 PROBABLE Acute bronchiolitis 
 
3358 PROBABLE Lower resp tract infection 
 
312 PROBABLE Acute bronchitis 
 
2581 PROBABLE Chest infection NOS 
 
68 PROBABLE Chest infection 
 2375 PROBABLE Empyema 
    
RTI       
 
6475 POSSIBLE [D]Respiratory system and chest symptoms 
 
7118 POSSIBLE O/E - pyrexia - ? cause 
 
5892 POSSIBLE O/E - fever 
 
16660 POSSIBLE O/E - nose crusting 
 
4519 POSSIBLE H/O: bronchitis 
 163 
 
1740 POSSIBLE Night sweats 
 
2389 POSSIBLE [D]Pyrexia of unknown origin 
 
6086 POSSIBLE Pyrexia symptoms 
 
6484 POSSIBLE Temperature symptoms 
 
6065 POSSIBLE Fever symptoms 
 
5859 POSSIBLE Feels hot/feverish 
 
1020 POSSIBLE [D]Fever NOS 
 
24181 POSSIBLE Sputum: mucopurulent 
 
15430 POSSIBLE [D]Sputum abnormal - colour 
 
14804 POSSIBLE Sputum appears infected 
 
1025 POSSIBLE Bronchial cough 
 
735 POSSIBLE [D]Breathlessness 
 
7707 POSSIBLE Cough symptom NOS 
 
21113 PROBABLE Acute respiratory infection NOS 
 
9807 POSSIBLE Sputum - symptom 
 
7708 POSSIBLE Productive cough-yellow sputum 
 
550 POSSIBLE Rhinorrhoea 
 
7074 PROBABLE Respiratory infection NOS 
 
5896 POSSIBLE Dyspnoea - symptom 
 
5175 POSSIBLE Breathlessness symptom 
 
7773 POSSIBLE Productive cough -green sputum 
 
2931 POSSIBLE Difficulty breathing 
 
3628 POSSIBLE Persistent cough 
 
1234 POSSIBLE Productive cough NOS 
 
4931 POSSIBLE Dry cough 
 
1429 POSSIBLE Breathlessness 
 
1160 POSSIBLE [D]Cough 
 
4822 POSSIBLE Shortness of breath 
 
293 PROBABLE Respiratory tract infection 
 
292 POSSIBLE Chesty cough 
 
1273 POSSIBLE C/O - cough 
 
92 POSSIBLE Cough 
    
URTI       
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32802 POSSIBLE Other upper respiratory tract diseases 
 
2097 PROBABLE Nasal cavity and sinus disease NOS 
 
16986 POSSIBLE Nose running 
 
8975 POSSIBLE Catarrh unspecified 
 
11139 POSSIBLE Blocked nose 
 
1309 PROBABLE Nasal infection 
 
9483 POSSIBLE Sinus congestion 
 
1401 POSSIBLE Nasal obstruction 
 
7479 POSSIBLE Catarrh - eustachian 
 
3821 POSSIBLE Rhinitis - acute 
 
3110 POSSIBLE Nasal congestion 
 
6481 POSSIBLE Nasal symptoms 
 
5765 POSSIBLE C/O - catarrh 
 
1513 PROBABLE Infection ear 
 
5577 PROBABLE Nonsuppurative otitis media + eustachian tube disorders 
 
731 POSSIBLE Otalgia 
 
5813 POSSIBLE Earache symptoms 
 
10781 PROBABLE Acute suppurative otitis media tympanic membrane intact 
 
15774 PROBABLE Influenza with laryngitis 
 
16184 PROBABLE Streptococcal sore throat with scarlatina NOS 
 
16147 POSSIBLE O/E - purulent ear discharge 
 
22131 POSSIBLE O/E - tonsils hyperaemic 
 
20372 PROBABLE Acute suppurative otitis media NOS 
 
97279 PROBABLE [X]Influenza+other manifestations, virus not identified 
 
21012 PROBABLE Acute mucoid otitis media 
 
20669 PROBABLE 
Acute suppurative otitis media tympanic membrane 
ruptured 
 
10641 PROBABLE Acute epiglottitis (non strep) 
 
17899 PROBABLE Acute bacterial pharyngitis 
 
20618 POSSIBLE O/E - nose discharge 
 
7266 PROBABLE O/E - follicular tonsillitis 
 
14791 PROBABLE Influenza with gastrointestinal tract involvement 
 
4718 PROBABLE Pharyngolaryngitis 
 
8570 POSSIBLE O/E - rhinorrhoea 
 
3605 PROBABLE Peritonsillar abscess - quinsy 
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10087 PROBABLE Acute laryngotracheitis 
 
9973 PROBABLE Recurrent acute otitis media 
 
15287 POSSIBLE Sore throat symptom NOS 
 
4902 PROBABLE Streptococcal pharyngitis 
 
6958 POSSIBLE Otorrhagia 
 
6620 PROBABLE Febrile cold 
 
6498 POSSIBLE O/E - tonsils mod. enlarged 
 
16388 PROBABLE Influenza NOS 
 
18363 POSSIBLE O/E - tympanic membrane red 
 
5115 PROBABLE Acute viral laryngitis unspecified 
 
5102 PROBABLE Serous otitis media NOS 
 
19431 PROBABLE Croup 
 
15410 POSSIBLE Throat symptom NOS 
 
10156 PROBABLE Acute bacterial tonsillitis 
 
18371 PROBABLE Acute otitis media with effusion 
 
3260 PROBABLE Acute nasopharyngitis 
 
4221 PROBABLE Recurrent upper respiratory tract infection 
 
26010 PROBABLE Other acute upper respiratory infections 
 
7021 PROBABLE Acute maxillary sinusitis 
 
20104 PROBABLE Acute tonsillitis NOS 
 
9357 PROBABLE Acute viral tonsillitis 
 
8950 PROBABLE Feverish cold 
 
20374 PROBABLE Acute nonsuppurative otitis media NOS 
 
1285 PROBABLE Laryngotracheitis 
 
2984 PROBABLE Frontal sinusitis 
 
2476 PROBABLE Chest cold 
 
5148 PROBABLE Acute secretory otitis media 
 
5947 PROBABLE Influenza like illness 
 
911 PROBABLE Quinsy 
 
1765 PROBABLE Streptococcal sore throat 
 
1747 PROBABLE Recurrent acute tonsillitis 
 
9093 PROBABLE Pyrexial cold 
 
3624 PROBABLE Maxillary sinusitis 
 
4061 PROBABLE Acute follicular tonsillitis 
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8496 PROBABLE Streptococcal tonsillitis 
 
7730 PROBABLE Acute serous otitis media 
 
386 POSSIBLE Throat pain 
 
11499 PROBABLE Throat infection - tonsillitis 
 
5935 POSSIBLE O/E - nasal discharge 
 
6466 PROBABLE Viral sore throat NOS 
 
5390 PROBABLE Catarrhal otitis media NOS 
 
4868 PROBABLE Acute viral pharyngitis 
 
8980 POSSIBLE Influenza-like symptoms 
 
5553 POSSIBLE Has a sore throat 
 
14931 POSSIBLE Inflamed throat 
 
1134 PROBABLE Acute bilateral otitis media 
 
1390 POSSIBLE Snuffles 
 
6014 POSSIBLE Sore throat NOS 
 
5806 POSSIBLE O/E - painful ear 
 
407 PROBABLE Acute pharyngitis NOS 
 
556 PROBABLE Influenza 
 
896 PROBABLE Nasal catarrh - acute 
 
2137 PROBABLE Acute suppurative otitis media 
 
638 POSSIBLE Otorrhoea 
 
3694 PROBABLE Acute left otitis media 
 
4348 PROBABLE Acute right otitis media 
 
2125 PROBABLE Tonsillitis 
 
1257 PROBABLE Acute tracheitis 
 
6421 PROBABLE Viral upper respiratory tract infection NOS 
 
1142 PROBABLE Croup 
 
310 PROBABLE Throat infection - pharyngitis 
 
368 PROBABLE Common cold 
 
5887 PROBABLE Acute non suppurative otitis media 
 
1246 PROBABLE Coryza - acute 
 
142 PROBABLE Acute laryngitis 
 
1474 PROBABLE Suppurative and unspecified otitis media 
 
243 PROBABLE Sinusitis 
 
2157 PROBABLE Flu like illness 
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893 PROBABLE Acute pharyngitis 
 
6294 PROBABLE Acute upper respiratory tract infection 
 
980 PROBABLE Acute sinusitis 
 
267 PROBABLE Otitis media NOS 
 
404 POSSIBLE Throat soreness 
 
5755 POSSIBLE Sore throat symptom 
 
138 PROBABLE Acute tonsillitis 
 
2637 PROBABLE Upper respiratory tract infection NOS 
 
76 PROBABLE Upper respiratory infection NOS 
 
asthma       
 
39570 
 
Asthma causes night symptoms 1 to 2 times per month 
 
38145 
 
Asthma limits walking on the flat 
 
13175 
 
Asthma disturbs sleep frequently 
 
11370 
 
Asthma confirmed 
 
1555 
 
Bronchial asthma 
 
7191 
 
Asthma limiting activities 
 
3018 
 
Mild asthma 
 
4442 
 
Asthma unspecified 
 
13065 
 
Moderate asthma 
 
24884 
 
Asthma causes daytime symptoms 1 to 2 times per week 
 
7416 
 
Asthma disturbing sleep 
 
31225 
 
Asthma causes daytime symptoms 1 to 2 times per month 
 
13066 
 
Asthma - currently dormant 
 
233 
 
Severe asthma attack 
 
26504 
 
Asthma never restricts exercise 
 
16655 
 
Asthma monitoring admin. 
 
19520 
 
Asthma treatment compliance satisfactory 
 
232 
 
Asthma attack 
 
38143 
 
Asthma never disturbs sleep 
 
10274 
 
Asthma medication review 
 
19539 
 
Asthma monitoring check done 
 
5515 
 
Seen in asthma clinic 
 
13064 
 
Asthma severity 
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7378 
 
Asthma management plan given 
 
185 
 
Acute exacerbation of asthma 
 
25707 
 
Asthma monitor 1st letter 
 
13176 
 
Asthma follow-up 
 
10043 
 
Asthma annual review 
 
81 
 
Asthma monitoring 
 
78 
 
Asthma 
    
cardiac       
 
8464 
 
Acute cor pulmonale 
 
39885 
 
Revision of closure of defect of atrioventricular septum 
 
50626 
 
Close defect interventricular septum using pericardial patch 
 
12889 
 
Percut transluminal prosth occlusion patent ductus arterios 
 
12312 
 
Pulmonary valve disorders 
 
5058 
 
Mitral incompetence, non-rheumatic 
 
49551 
 
Tricuspid stenosis and regurgitation, cause unspecified 
 
3810 
 
Complete atrioventricular block 
 
35372 
 
Tricuspid regurgitation, non-rheumatic 
 
41569 
 
Other specified catheterisation of heart 
 
3169 
 
Heart valve and adjacent structures operations NOS 
 
36668 
 
Closure of patent ductus arteriosus NEC 
 
42132 
 
Ventricular septal defect, unspecified 
 
48207 
 
Other operations on heart 
 
54772 
 
Other specified ventricular septal defect 
 
89256 
 
Congenital heart disease 
 
30443 
 
Mitral valve disease NOS 
 
12844 
 
Repair of tetralogy of Fallot 
 
48331 
 
Primary closure of defect of atrioventricular septum NEC 
 
4939 
 
Bacterial endocarditis 
 
20940 
 
Repair of subaortic stenosis 
 
19188 
 
Percut translum prosth occlus patent ductus arteriosus 
(PDA) 
 
63046 
 
Tetralogy of Fallot NOS 
 
1267 
 
Mitral valve diseases 
 
30725 
 
Aortic arch anomalies 
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84407 
 
Other operations on ventricles of heart 
 
34902 
 
Closure of defect of interatrial septum 
 
10078 
 
Diseases of mitral and aortic valves 
 
1007 
 
Aortic incompetence alone, cause unspecified 
 
48205 
 
Congenital malforms of cardiac chambers+connections 
unsp 
 
6886 
 
Congenital aortic valve stenosis 
 
39810 
 
Heart wall, septum and chamber operations 
 
3301 
 
Coarctation of aorta 
 
73602 
 
Repair of atrium NEC 
 
16191 
 
Closure of defect of interatrial septum NOS 
 
9573 
 
Ligation of patent ductus arteriosus 
 
3300 
 
Bicuspid aortic valve 
 
16539 
 
Subaortic stenosis 
 
2977 
 
Mitral valve incompetence 
 
30173 
 
Valves of heart and adjacent structures operations 
 
3863 
 
Cyanotic congenital heart disease NOS 
 
12775 
 
Acute and subacute endocarditis 
 
15133 
 
Replacement of aortic valve NEC 
 
17088 
 
H/O: cardiac surgery 
 
10079 
 
Right heart failure 
 
11878 
 
Mitral and aortic regurgitation 
 
5621 
 
Other congenital heart anomalies 
 
30340 
 
Closure of defect of unspecified septum of heart 
 
17328 
 
Aorta operations 
 
38436 
 
Closure of defect of atrioventricular septum NOS 
 
36575 
 
Closure of defect of interventricular septum 
 
19019 
 
Aortic valve disorders NOS 
 
18820 
 
H/O: cardiac anomaly 
 
7342 
 
Open correction of patent ductus arteriosus (PDA) 
 
5743 
 
Valvular heart disease 
 
18785 
 
Heart septal defects 
 
7894 
 
Plastic repair of mitral valve 
 
9498 
 
Plastic repair of aortic valve 
 
4548 
 
Aortic valve disorders 
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22003 
 
Regurgitation of unspecified heart valve 
 
3418 
 
Paroxysmal ventricular tachycardia 
 
73476 
 
Repair of defect of the atrioventricular septum 
 
1005 
 
Aortic regurgitation alone, cause unspecified 
 
5477 
 
Correction of tetralogy of Fallot 
 
9450 
 
Mitral valve regurgitation 
 
2343 
 
Aortic stenosis alone, cause unspecified 
 
247 
 
Congenital heart anomaly NOS 
 
32163 
 
Closure of defect of atrioventricular septum 
 
2841 
 
Implantation of intravenous cardiac pacemaker system 
 
1294 
 
Mitral valve prolapse 
 
6401 
 
H/O: heart disorder 
 
18395 
 
Other specified atrial septal defect 
 
9286 
 
Tricuspid regurgitation, cause unspecified 
 
10187 
 
Aortic regurgitation, non-rheumatic 
 
1735 
 
Aortic aneurysm 
 
3520 
 
Catheterisation of heart NOS 
 
7474 
 
Ostium secundum atrial septal defect 
 
3625 
 
Patent foramen ovale 
 
2427 
 
Catheterisation of heart 
 
44896 
 
Common atrioventricular-type ventricular septal defect 
 
9011 
 
Eisenmenger's complex 
 
1536 
 
Supraventricular tachycardia NOS 
 
2727 
 
Patent ductus arteriosus 
 
561 
 
Mitral regurgitation 
 
3255 
 
Atrial septal defect NOS 
 
246 
 
Ventricular septal defect 
    
diabetes       
 
14803 
 
Diabetes mellitus, adult onset, no mention of complication 
 
85660 
 
Diabetes type 1 review 
 
8403 
 
Non-insulin dependent diabetes mellitus - poor control 
 
30323 
 
Type 1 diabetes mellitus with persistent proteinuria 
 
30294 
 
Type 1 diabetes mellitus with persistent microalbuminuria 
 
32359 
 
Perceived control of insulin-dependent diabetes 
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11626 
 
Diabetic retinopathy NOS 
 
26054 
 
Type 2 diabetes mellitus with persistent proteinuria 
 
2342 
 
Diabetic neuropathy 
 
5884 
 
NIDDM - Non-insulin dependent diabetes mellitus 
 
1682 
 
Diabetes mellitus with ketoacidosis 
 
55239 
 
Type 1 diabetes mellitus with gastroparesis 
 
18219 
 
Type II diabetes mellitus 
 
18390 
 
Type 2 diabetes mellitus with persistent microalbuminuria 
 
18824 
 
Diabetic foot examination declined 
 
16230 
 
Diabetes mellitus with neurological manifestation 
 
10692 
 
Type 1 diabetes mellitus with ketoacidosis 
 
18278 
 
Insulin treated Type 2 diabetes mellitus 
 
1407 
 
Insulin treated Type 2 diabetes mellitus 
 
35383 
 
Diabetic patient unsuitable for digital retinal photography 
 
17858 
 
Type 1 diabetes mellitus 
 
11047 
 
Conversion to insulin 
 
83532 
 
Diabetes type 2 review 
 
18505 
 
IDDM-Insulin dependent diabetes mellitus 
 
28769 
 
Diabetic on insulin and oral treatment 
 
22823 
 
Diabetic foot examination 
 
17859 
 
Type 2 diabetes mellitus 
 
13074 
 
Diabetic diet 
 
11471 
 
Diabetes medication review 
 
1038 
 
Insulin dependent diabetes mellitus 
 
22130 
 
Diabetes monitoring default 
 
1647 
 
Insulin dependent diabetes mellitus 
 
95994 
 
Diabetic foot screen 
 
9974 
 
Seen in diabetic eye clinic 
 
1323 
 
Diabetic retinopathy 
 
506 
 
Non-insulin dependent diabetes mellitus 
 
12675 
 
Diabetes: shared care programme 
 
7563 
 
Diabetic on diet only 
 
1549 
 
Type 1 diabetes mellitus 
 
8836 
 
Diabetes management plan given 
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4513 
 
Non-insulin dependent diabetes mellitus 
 
7069 
 
Background diabetic retinopathy 
 
13067 
 
Diabetic monitoring NOS 
 
1684 
 
Diabetic on oral treatment 
 
2378 
 
Diabetic - poor control 
 
12506 
 
Diabetes: practice programme 
 
608 
 
Follow-up diabetic assessment 
 
758 
 
Type 2 diabetes mellitus 
 
711 
 
Diabetes mellitus 
 
2379 
 
Seen in diabetic clinic 
 
6125 
 
Diabetic annual review 
 
3550 
 
Diabetic monitoring 
 
9897 
 
Diabetes monitoring admin. 
    
epilepsy       
 
9747 
 
Epilepsy NOS 
 
4093 
 
Status epilepticus 
 
5117 
 
Grand mal status 
 
46603 
 
Emergency epilepsy treatment since last appointment 
 
4801 
 
Epileptic seizures - myoclonic 
 
22341 
 
Epilepsy confirmed 
 
18471 
 
Epileptic seizures - clonic 
 
1715 
 
Epileptic absences 
 
8187 
 
Tonic-clonic epilepsy 
 
6271 
 
Status epilepticus, unspecified 
 
19550 
 
Epilepsy control good 
 
8487 
 
Myoclonic seizure 
 
5152 
 
Epileptic seizures - tonic 
 
36696 
 
Epilepsy monitoring NOS 
 
2907 
 
Petit mal (minor) epilepsy 
 
3607 
 
Fit (in known epileptic) NOS 
 
11752 
 
Patient on maximal tolerated anticonvulsant therapy 
 
6983 
 
Epilepsy monitoring 
 
9326 
 
Epilepsy medication review 
 
11015 
 
Seizure free >12 months 
 173 
 
573 
 
Epilepsy 
    
thyroid       
 
11146 
 
TSH - thyroid-stimulating hormone deficiency 
 
95885 
 
Hypothyroidism annual review 
 
718 
 
Subclinical iodine-deficiency hypothyroidism 
 
51481 
 
Congenital hypothyroidism NOS 
 
24681 
 
Thyroid dis.treatment changed 
 
10097 
 
Congenital hypothyroidism 
 
28735 
 
Hypothyroidism monitoring administration 
 
46630 
 
Hypothyroidism monitoring second letter 
 
3941 
 
Hypothyroidism NOS 
 
46057 
 
Hypothyroidism monitoring first letter 
 
14704 
 
Thyroid deficiency 
 
3290 
 
Acquired hypothyroidism 
 
8268 
 
Thyroid disease monitoring 
 
273 
 
Hypothyroidism 
    
Table A 3. List of ICD-10 codes 
LRTI       
 
B953 PROBABLE Streptococcus pneumoniae as the cause of diseases classified to other chapters 
 
J154 PROBABLE Pneumonia due to other streptococci 
 
J121 PROBABLE Respiratory syncytial virus pneumonia 
 
J152 PROBABLE Pneumonia due to staphylococcus 
 
J851 PROBABLE Abscess of lung with pneumonia 
 J14X PROBABLE Pneumonia due to Haemophilus influenzae 
 J153 PROBABLE Pneumonia due to streptococcus, group B 
 J852 PROBABLE Abscess of lung without pneumonia 
 
J158 PROBABLE Other bacterial pneumonia 
 
J168 PROBABLE Pneumonia due to other specified infectious organisms 
 
J218 PROBABLE Acute bronchiolitis due to other specified organisms 
 
J159 PROBABLE Bacterial pneumonia, unspecified 
 
J188 PROBABLE Other pneumonia, organism unspecified 
 
J151 PROBABLE Pneumonia due to Pseudomonas 
 
J129 PROBABLE Viral pneumonia, unspecified 
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J209 PROBABLE Acute bronchitis, unspecified 
 
B961 PROBABLE Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified to other chapters 
 
J157 PROBABLE Pneumonia due to Mycoplasma pneumoniae 
 
J13X PROBABLE Pneumonia due to Streptococcus pneumoniae 
 
J210 PROBABLE Acute bronchiolitis due to respiratory syncytial virus 
 
J180 PROBABLE Bronchopneumonia, unspecified 
 
J219 PROBABLE Acute bronchiolitis, unspecified 
 
J189 PROBABLE Pneumonia, unspecified 
 
J181 PROBABLE Lobar pneumonia, unspecified 
 
J22X PROBABLE Unspecified acute lower respiratory infection 
    
RTI       
 
B349 PROBABLE Viral infection, unspecified 
 
R05X POSSIBLE Cough 
 
R060 POSSIBLE Dyspnoea 
    
URTI       
 
J398 PROBABLE Other specified diseases of upper respiratory tract 
 
J038 PROBABLE Acute tonsillitis due to other specified organisms 
 
J019 PROBABLE Acute sinusitis, unspecified 
 
J041 PROBABLE Acute tracheitis 
 
J040 PROBABLE Acute laryngitis 
 
J020 PROBABLE Streptococcal pharyngitis 
 
H660 PROBABLE Acute suppurative otitis media 
 
J208 PROBABLE Acute bronchitis due to other specified organisms 
 
J030 PROBABLE Streptococcal tonsillitis 
 
H709 PROBABLE Mastoiditis, unspecified 
 
J028 PROBABLE Acute pharyngitis due to other specified organisms 
 
J101 PROBABLE Influenza with other respiratory manifestations, other influenza virus identified 
 
H650 PROBABLE Acute serous otitis media 
 
H651 PROBABLE Other acute nonsuppurative otitis media 
 
H920 POSSIBLE Otalgia 
 
J00X PROBABLE Acute nasopharyngitis [common cold] 
 
J029 PROBABLE Acute pharyngitis, unspecified 
 
H921 POSSIBLE Otorrhoea 
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H659 PROBABLE Nonsuppurative otitis media, unspecified 
 
H669 PROBABLE Otitis media, unspecified 
 
J050 PROBABLE Acute obstructive laryngitis [croup] 
 
J039 PROBABLE Acute tonsillitis, unspecified 
 
J069 PROBABLE Acute upper respiratory infection, unspecified 
 
asthma       
 
J458 
 
Mixed asthma 
 
J46X 
 
Status asthmaticus 
 
J450 
 
Predominantly allergic asthma 
 
J459 
 
Asthma, unspecified 
    
cardiac       
 
Q232 
 
Congenital mitral stenosis 
 
Q264 
 
Anomalous pulmonary venous connection, unspecified 
 
Q238 
 
Other congenital malformations of aortic and mitral valves 
 
Q228 
 
Other congenital malformations of tricuspid valve 
 
Q201 
 
Double outlet right ventricle 
 
Q262 
 
Total anomalous pulmonary venous connection 
 
Q258 
 
Other congenital malformations of great arteries 
 
Q268 
 
Other congenital malformations of great veins 
 
I052 
 
Mitral stenosis with insufficiency 
 
Q282 
 
Arteriovenous malformation of cerebral vessels 
 
I510 
 
Cardiac septal defect, acquired 
 
Q254 
 
Other congenital malformations of aorta 
 
I059 
 
Mitral valve disease, unspecified 
 
I080 
 
Disorders of both mitral and aortic valves 
 
I083 
 
Combined disorders of mitral, aortic and tricuspid valves 
 
I081 
 
Disorders of both mitral and tricuspid valves 
 
Q208 
 
Other congenital malformations of cardiac chambers and connections 
 
I330 
 
Acute and subacute infective endocarditis 
 
Q251 
 
Coarctation of aorta 
 
I071 
 
Tricuspid insufficiency 
 
Q230 
 
Congenital stenosis of aortic valve 
 176 
 
I361 
 
Nonrheumatic tricuspid (valve) insufficiency 
 
I441 
 
Atrioventricular block, second degree 
 
Q244 
 
Congenital subaortic stenosis 
 
Q231 
 
Congenital insufficiency of aortic valve 
 
Q221 
 
Congenital pulmonary valve stenosis 
 
I341 
 
Mitral (valve) prolapse 
 
I440 
 
Atrioventricular block, first degree 
 
Q256 
 
Stenosis of pulmonary artery 
 
Q213 
 
Tetralogy of Fallot 
 
T825 
 
Mechanical complication of other cardiac and vascular devices and implants 
 
Z954 
 
Presence of other heart-valve replacement 
 
Q233 
 
Congenital mitral insufficiency 
 
I38X 
 
Endocarditis, valve unspecified 
 
I350 
 
Aortic (valve) stenosis 
 
Q219 
 
Congenital malformation of cardiac septum, unspecified 
 
T828 
 
Other specified complications of cardiac and vascular prosthetic devices, 
 implants and grafts 
 
Q249 
 
Congenital malformation of heart, unspecified 
 
Q257 
 
Other congenital malformations of pulmonary artery 
 
T827 
 
Infection and inflammatory reaction due to other cardiac and  
vascular devices, implants and grafts 
 
I351 
 
Aortic (valve) insufficiency 
 
I517 
 
Cardiomegaly 
 
I340 
 
Mitral (valve) insufficiency 
 
Z952 
 
Presence of prosthetic heart valve 
 
Q250 
 
Patent ductus arteriosus 
 
I420 
 
Dilated cardiomyopathy 
 
Q218 
 
Other congenital malformations of cardiac septa 
 
Q211 
 
Atrial septal defect 
 
Q210 
 
Ventricular septal defect 
 
I270 
 
Primary pulmonary hypertension 
 
Q212 
 
Atrioventricular septal defect 
 
Z867 
 
Personal history of diseases of the circulatory system 
    
diabetes       
 177 
 
E100 
 
Insulin-dependent diabetes mellitus 
 
E105 
 
Insulin-dependent diabetes mellitus 
 
E115 
 
Non-insulin-dependent diabetes mellitus 
 
E106 
 
Insulin-dependent diabetes mellitus 
 
E143 
 
Unspecified diabetes mellitus 
 
Y423 
 
Insulin and oral hypoglycaemic [antidiabetic] drugs 
 
E116 
 
Non-insulin-dependent diabetes mellitus 
 
E112 
 
Non-insulin-dependent diabetes mellitus 
 
E114 
 
Non-insulin-dependent diabetes mellitus 
 
E111 
 
Non-insulin-dependent diabetes mellitus 
 
E113 
 
Non-insulin-dependent diabetes mellitus 
 
E108 
 
Insulin-dependent diabetes mellitus 
 
O240 
 
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent 
 
E139 
 
Other specified diabetes mellitus 
 
E101 
 
Insulin-dependent diabetes mellitus 
 
E109 
 
Insulin-dependent diabetes mellitus 
 
E119 
 
Non-insulin-dependent diabetes mellitus 
    
epilepsy       
 
Y466 
 
Other and unspecified antiepileptics 
 
G408 
 
Other epilepsy 
 
G419 
 
Status epilepticus, unspecified 
 
G406 
 
Grand mal seizures, unspecified (with or without petit mal) 
 
G403 
 
Generalized idiopathic epilepsy and epileptic syndromes 
 
G409 
 
Epilepsy, unspecified 
    
thyroid       
 
E02X 
 
Subclinical iodine-deficiency hypothyroidism 
 
E038 
 
Other specified hypothyroidism 
 
E890 
 
Postprocedural hypothyroidism 
 
E031 
 
Congenital hypothyroidism without goitre 
 
E039 
 
Hypothyroidism, unspecified 
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Table A 4. Selection process of ethnicity codes from the CALIBER dataset 
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Table A 5. RTI-related GP consultation (top) and hospitalisation (bottom) rates 
between gender stratified by children with DS and controls – adjusted by cardiac 
co-morbidities 
 
 
 
 
 
 
Table A 6. RTI-related GP consultation (top) and hospitalisation (bottom) rates 
between gender stratified by children with DS and controls – adjusted by asthma 
co-morbidities 
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Table A 7. Sensitivity analyses: Adjusted effects of antibiotics stratified by RTI-
type using 7, 14, 21 and 28 day at-risk periods for RTI-related hospitalisation 
(adjusted by the 7 identified co-variates) 
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Table A 8. Sensitivity analyses: Adjusted effects of antibiotics stratified by RTI-
type using 7, 14, 21 and 28 day at-risk periods for RTI-related hospitalisation 
(adjusted for clustering and by the 7 identified co-variates) 
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Table A 9. Sensitivity analyses: Adjusted effects of antibiotics stratified by age-
group using 7, 14, 21 and 28 day at-risk periods for RTI-related hospitalisation 
(adjusted by the 7 identified co-variates) 
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Table A 10. Sensitivity analyses: Adjusted effects of antibiotics stratified by age-
group using 7, 14, 21 and 28 day at-risk periods for RTI-related hospitalisation 
(adjusted for clustering and the 7 identified co-variates) 
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Additional Co-Variates – Figures A30 and A31 
RTI Level Co-Variate 3: 28-day RTI Consultation Average 
This co-variate was created by counting the number of RTI related GP consultations for 
each virtual patient in the 28 days preceding a relevant RTI-related GP consultation. A 
unique score was created for each relevant RTI. No score was generated if less than 28 
days follow up time present. 
 
Figure A30. Process for creating RTI Level Co-Variate 3. 
 
 
 
RTI Level Co-Variate 4: 28-day RTI Hospitalisation Average 
This co-variate was created by counting the number of RTI related hospitalisations for 
each virtual patient in the 28 days preceding a relevant RTI-related GP consultation. A 
unique score was created for each relevant RTI. No score was generated if less than 28 
days follow up time present. 
 
Figure A31. Process for creating RTI Level Co-Variate 4. 
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